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Summary
Cancer - this one word stands for a vast variety of complex diseases. Cancers are named
according to the organ they originate from, like breast cancer, colon cancer or brain
cancer. However, when analyzing the molecular phenotype of the cells of theses different
cancer types one can observe that each type itself consists of many different diseases.
The genetic aberrations leading to malignant growth can vary from case to case and
so can the molecular mechanisms that a tumour cell uses to facilitate de-differentiation
and progression. To the eye of a molecular biologist, cancers are very heterogeneous.
Modern treatment strategies target specific oncogenic mechanisms, like the specific
inhibition of a signaling pathway. In view of the molecular heterogeneity of cancers,
it cannot be expected that all patients will benefit from this treatment. Some cancers
depend on the activity of a pathway and will hence respond to its inhibition, while
others might not. To use targeted therapies effectively, we must first understand the
heterogeneity of tumours.
A modern genomics based approach to classify cancers is gene expression profiling
using microarrays or high throughput sequencing. Expression profiles monitor the
expression of virtually all genes in a tumour simultaneously. They thus characterize
its molecular phenotype at a high resolution. Importantly, the oncogenic events, like
aberrations in the genome and associated perturbations of signaling pathways, shape
these profiles. Hence, classifying tumours by expression profiles means classifying them
by the underlying mutational changes that distinguishes them from healthy tissue.
The tumour profiling projects, covered in my thesis, are carried out in close collab-
oration with various experimental groups: Cell of origin expression signatures were
developed in collaboration with the group of Christoph Beier from the Department of
Neurology, University of Regensburg. The finding that specific genetic perturbations
direct the development of different brain tumour types was discovered in collabora-
tion with the group of Ulrike Nuber from the Department of Laboratory Medicine of
Lund Strategic Research Center for Stem Cell Biology. The characterization of sig-
naling pathways in human transformed GC B cells and their activity in lymphomas
was conducted in collaboration with the group of Dieter Kube from the Department of
Haematology and Oncology, University Medical Center Go¨ttingen.
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Summary
My contribution was the statistical analysis of the expression profiles. I designed exper-
iments, analyzed the quality of expression data, identified biomarkers and developed
gene expression signatures allowing for clinical distinction of different cancer types. For
building gene expression signatures I added a novel statistical method to the pool of
existing tools.
Gene expression signatures combine the expression levels of multiple genes to allow
for highly resolved and robust molecular tumour classification. In this work I defined
multiple gene expression signatures: One that allows the clinical distinction of brain tu-
mour types and others that allow the measurement of pathway activities in lymphomas.
For building gene expression signatures I developed a novel statistical method, which
combines the expression of multiple co-expressed genes to a single real valued index per
tumour sample.
My thesis addresses the molecular heterogeneity of two tumour types.
The first type are brain tumours. They can develop from different cells of origin.
While these cells of origin are all tumour stem cells, they nevertheless differ as do
the tumours they initiate. I describe how different cellular origins of glioblastomas
are reflected in their expression profiles and I develop a cell of origin gene expression
signature. Moreover, genomic aberrations like the mutation of oncogenes determine the
tumour phenotype and thus shape its expression profile. I describe how the temporal
order of these genetic events contributes to the heterogeneity of brain tumours, and
analyze the characteristic expression profiles of the different subtypes.
The second tumour type are lymphomas. Lymphomas represent a heterogeneous group
of cancers affecting cells of the immune system. 95% of lymphomas are B cell lym-
phomas and evolve during B cell differentiation. Differentiation includes crosstalk of
different signaling pathways. Most malignant B cell lymphoma use key factors of these
pathways to generate survival and proliferation signals. The activity of the dysreg-
ulated pathways differs between lymphoma types and thus shapes their expression
profiles differently. Two aggressive forms of lymphomas are Burkitt’s Lymphoma (BL)
and Diffuse Large B Cell Lymphoma (DLBCL). I characterize different patterns of gene
expression changes by B cell specific stimuli and associate these with different pathway
activities in DLBCL and BL. Furthermore I was able to show that LEF1 is aberrantly
expressed in BL cells. I identified LEF1 target genes and used these genes to build an
LEF1 activity index. This index can be used to measure LEF1 activity in lymphoma
samples. We showed that LEF1 activity is higher in Burkitt Lymphomas as compared
to Diffuse Large B-cell lymphomas.
2
Introduction
Cancer has become a leading cause of death. According to the World Health Organiza-
tion (WHO) cancer resulted in 7.6 million deaths worldwide in 2008 [50]. The biologist
Theodor Heinrich Boveri (1862-1915) was the first one to suggest that cancer might
arise from one single cell that was not able to separate chromosomes accurately [18].
Based on his studies he stated: “A malignant tumour cell is [...] a cell with a specific
abnormal chromosome constitution” [19]. Today it is widely accepted that cancer is a
genetic disease, caused by the deregulation of proto-oncogenes and tumour suppressor
genes in a cell.
Genes expressed in a normal cell as well as in a tumour cell define its type and behavior.
Processes like cell survival, apoptosis and functional responses are regulated. A major
control point for this regulation is transcriptional initiation. It is a highly regulated
process which depends on timing and on levels of expression of many genes. In cancer
such regulations are often changed or destroyed and so proto-oncogenes and tumour
suppressor genes are deregulated. Thus, a deeper understanding of gene expression
and gene regulation is essential for understanding normal development and diseases
like cancer.
One tool to monitor gene expression is the microarray technology [133]. Microarrays
make it possible to measure gene expression of thousands of genes simultaneously. They
are used to study whole genome transcription levels. Detection of transcripts is based
on hybridization of two cDNA strands. Microarrays consist of thousands of spots that
include different DNA sequences each interrogating a particular gene. Analyses in-
cluded in this thesis all make use of oligonucleotide arrays. Probes of oligonucleotide
arrays are synthesized directly on the chip. Oligonucleotides are about 25 nucleotides
long. There are about 35 probes per gene on the microarray. Each array is hybridized
with cDNA or RNA from one sample which is labeled beforehand with a fluorescence
dye. Signal intensities are read with a laser scanner. The signal intensity of one spot is
higher the more target molecules hybridize to the complementary strands at that spot
[163, 113, 133]. Thus, it is possible to make inference among samples, genes and their
expression levels.
3
4
Outline
The thesis is divided into four chapters. The first Chapter gives an overview of
computational methods used throughout the thesis. Amongst others I introduce a
method to summarize gene expression values to a single representative index.
Chapter 2 and Chapter 3 include tumour profiling projects addressing brain tumours
and lymphomas. Both chapters start with a biological introduction of the respective
tumour type. Chapter 2 divides into three Sections. In Section 2.2 I describe
how the temporal order of genetic events contributes to the heterogeneity of brain
tumours and I analyze the characteristic expression profiles of the different subtypes.
In the Sections 2.3 and 2.4 I describe how different cellular origins of glioblastomas
are reflected in their expression profiles and I develop a cell of origin gene expression
signature. Furthermore, I associate the different cellular origin of glioblastoma with
different functions of TGFβ.
Chapter 3 contains two further sections in addition to the biological introduction.
In Section 3.2 I characterize major patterns of gene expression changes by B cell
specific stimuli and associate these with different pathway activities in diffuse large B
cell lymphoma and Burkitt lymphoma. In Section 3.3 I identify LEF1 target genes,
allowing the measurement of LEF1 activity in lymphoma.
5
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Chapter 1
Methods
1.1 Summarizing gene expression profiles: Indexing
Gene and protein expression are tightly regulated processes. They are controlled by
internal and external conditions so that not all proteins are produced under all cir-
cumstances. Proteins which function together in a cell often have common regulatory
control elements and are thus coordinately expressed. Therefore those genes are co-
regulated and co-expressed.
In microarray data co-expression of genes is reflected by strong correlation between
expression levels. The standard correlation coefficient (i.e., the dot product of two nor-
malized gene expression vectors) conforms well to the biological notion of the meaning
of two genes being co-expressed. That is because the standard correlation coefficient
captures similarity in shape of the gene expression, but places no emphasis on the gene
expression magnitude.
I developed a method getIndex to summarize gene expression values of co-expressed
genes to a single real valued index per sample.
The getIndex function uses a gene expression matrix as input, with expression values
of genes in rows and samples in columns.
Additionally the function can take a sign vector, which assigns how a gene is meant to
react to a specific signal (+1 = up regulation, −1 = down regulation). This information
is not mandatory, but can be used if it is known a priori. If a sign vector is given to
the method the resulting index will represent the activity of the associated signal.
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The method can be divided into four main steps:
1. A gene-wise scaling of the data: All rows (genes) are normalized to mean zero
and standard deviation of 1. This is done in order to make gene expression values
comparable to each other.
2. A reference gene is determined, showing the highest sum of correlation coefficients
to all other genes.
If there is no sign vector given to the method, all gene expression values of genes
anticorrelated to the reference gene are multiplied by −1. Afterwards, the gene
expression values of all genes show positive correlation to the gene expression
values of the reference gene.
If there is a sign vector given to the function, the gene expression values of genes,
that are known to be down regulated by the associated signal are multiplied by
−1. Thereby the resulting gene expression values reflect the activity of the signal
associated with the sign vector.
3. The median polish procedure is used to decompose expression levels into into
several additive parts:
yij = µ+ gi + sj + rij
i ∈ {1, ..., n}, n = Number of genes
j ∈ {1, ...,m}, m = Number of samples
The gene expression values yij are split into an overall gene expression value µ,
a gene effect gi, a sample effect sj and rij . Where rij are the residuals of yij in
the additive model.
Median polishing is an iterative process. The procedure works by subtracting the
medians of each row (gene) from each element in the row, then the medians of
each column (sample) from each element in the column.
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The row medians are recorded in the gene effect vector and column medians in
the sample effect vector. This subtraction process is repeated until convergence.
The medians of the gene effect and sample effect vectors are then added up to
give the overall gene expression value µ and subtracted from each entry in the
gene effect vector and each entry in the sample effect vector resulting in a gene
effect vector g and a sample effect vector s.
The procedure returns the overall gene expression value µ, the sample effect vec-
tor s, the gene effect vector g and the estimated residuals. Because the median
polish procedure uses medians rather than means it is robust to outliers.
Note that the median polish procedure to decompose gene expression data is also
used to compute probe-set summaries in the popular normalization package RMA
for Affymetrix gene chips [84].
4. The getIndex method returns two variables. The first variable is the sample index
s, which is the sample effect estimated by the median polish procedure.
The second variable is the residual matrix R containing the residuals rij produced
by summarizing the data with the median polish procedure.
One should keep in mind that if the data does not fit the model, information is lost
during summarization. Hence data that does not fit the model should not be summa-
rized.
An example for a co-expressed gene cluster can be seen in Figure 1.1 (a), in contrast
to the gene cluster in Figure 1.2 (a).
The genes in Figure 1.1 (a) are highly correlated (Figure 1.1 (b)). The genes in Figure
1.2 (a) are chosen randomly and are mainly uncorrelated (Figure 1.2 (b)). The red line
in both Figures show the resulting index, when summarizing the corresponding genes.
x
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(a)
(b)
Figure 1.1: (a) Gene expression of 7 co-expressed genes in 20 samples, and index values after
summarizing the 7 genes in red. (b) Correlation coefficients of the seven selected genes (S
Genes)
(a)
(b)
Figure 1.2: (a) Gene expression of 7 randomly selected genes in 20 samples, and index values
after summarizing the 7 genes in red. (b) Correlation coefficients of the seven random genes
(R Genes)
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When summarizing gene expression values one should consider that information is lost.
If the lost information is too great, then summarizing does not make sense.
How munch information is lost can be seen by looking at the residuals produced by the
median polish. The residuals produced by summarizing gene expression values of the
two given gene clusters in Figure 1.1 (a) and Figure 1.2 (a) are shown in Figure 1.3.
As one can see, the randomly chosen genes produce very high residuals. In contrast to
that the highly correlated gene cluster produces residuals located around zero. Thus
by summarizing gene expression values of uncorrelated genes the loss of information is
too great and one should better look at the genes separately.
Figure 1.3: Matrix of residuals produces by the median polish summarization. The rows are
the genes, where R Genes are the randomly chosen genes and S Genes are the selected highly
correlated genes. S stands for Sample.
In conclusion getIndex provides a possibility of combining gene expression values to a
single real valued index per sample. This index can be used as a representative for the
summarized gene cluster. But if genes are not co-expressed, then summarization leads
to a loss of too much information and can be misleading.
x
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1.2 Explorative methods
1.2.1 Hierarchical Clustering
The goal of clustering is to partition the observed data set, D = e1, e2, ..., eN , into
a set of non-overlapping clusters. A K-cluster partition P of D can be specified as
P = P1, P2, ..., PK , such that
⋃K
k=1 Pk = D , and Pi ∩ Pj = ∅,∀i,j : i 6= j.
If we want to cluster N samples (ei ∈ D) or experiments for example and the features
are the genes whose expression is measured in each of the N experiments [135].
Hierarchical Clustering is a method widely used to split objects into groups also called
clusters, so that objects within a cluster are more similar to one another than to objects
from other clusters. Hierarchical Clustering is for example used to form descriptive
statistics to ascertain whether or not the data consists of distinct subgroups, each
group representing objects with substantially different properties.
An appropriate metric is necessary for the method, to measure the similarity/distance
between pairs of objects, and a linkage criterion, which specifies the similarity of sets
as a function of the pairwise distances of objects. In the following chapters I use the
euclidean distance as distance measure. The clustering algorithm takes as input the
already calculated N ×N distance matrix M , where N is the number of objects, and
each element in the matrix Mij records the proximity between the ith and jth object
dist(i, j) [56].
Hierarchical clustering starts with n objects and n clusters, so each object is assigned
to its own cluster. Then iteratively the two most similar clusters are joined into a new
cluster. That is done until only one cluster remains. Thus a hierarchical representation
is built, in which the clusters at each level of the hierarchy are created by merging clus-
ters of the previous level. At each step distances between the clusters are recomputed,
depending on the linkage criterion specified. As linkage criterion I use the complete
linkage method [56].
Complete linkage computes the distance between two clusters by taking the maximum
distance between a pair of clusters. Thus distance M(X,Y ) between cluster X and
cluster Y , can be described by the following expression: M(X,Y ) = max(dist(x, y)),
where dist(x, y) is the distance between elements x ∈ X and y ∈ Y . Complete linkage
tends to build compact clusters of approximately equal diameters [39].
The result of a hierarchical clustering can be visualized as a dendrogram or tree whose
branch lengths reflect the degree of similarity between the clusters, as assessed by a
12
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pairwise similarity function. By not choosing a priori a specific number of clusters,
hierarchical clustering provides an opportunity for a multi-resolution view of the data.
This is useful in exploratory data analysis [56].
1.2.2 Consensus Clustering
A problem in cluster analysis is to validate the clustering result. Consensus clustering
is a method to assess the “stability“ and robustness of clusters to sampling variability
[135]. The basic assumption of consensus clustering is that for two sets of data, each
representing a sample of objects from the same population, the clustering result should
not be radically changed. Thus, the more stable the clusters are to sampling variability,
the more confident we can be that the found clusters represent real structure. Consensus
clustering gives a consensus across multiple runs of a clustering algorithm and assesses
the stability of the discovered clusters [135].
Before applying the method one has to select a resampling scheme and a clustering
algorithm. The result of consensus clustering is a consensus matrix which quantifies
the agreement among the clustering runs over the given dataset D. A consensus matrix
is defined as a N × N matrix, that stores for each pair of samples (experiments) the
proportion of clustering runs in which these two samples are clustered together.
The first step of the method is to resample the original dataset D H-times. This is
done by drawing H-times a specific percentage of samples from the available samples.
Let the obtained new datasets be denoted as D(1), D(2), . . . , D(H). Then for each of
these datasets a clustering is done each resulting in a N×N connectivity matrix, M (h).
The entries of the M (h) matrices are defined as follows:
M (h)(i, j) =
{
1, if samples i and j belong to the same cluster
0, otherwise
Additionally the calculation of a N ×N indicator matrix, I(h) is needed. This matrix
indicates which samples were included in the different runs. Thus the (i, j)-th entry of
I(h) is 1 if the samples i and j are present in the dataset D(h), and 0 otherwise.
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In the last step consensus clustering calculates the consensus matrixM, which is defined
as the normalized sum of the connectivity matrices M (h).
M(i, j) =
∑
h
M (h)(i, j)∑
h
I(h)(i, j)
The consensus matrix M is symmetric and its elements are real numbers between 0
and 1. The entry (i, j) in the consensus matrix M represents the number of times the
samples i and j are assigned to the same cluster divided by the number of times both
samples were included in a set D(h). 0 values are recorded when a sample pair never
fell into the same cluster and 1 is recorded for sample pairs that always fell into the
same cluster.
If the samples of the matrix are rearranged, in such a way that samples belonging to the
same cluster are next to each other, a perfect consensus clustering would transform into
a block-diagonal matrix with all the values of the matrix being either 0 or 1 [135].
Based on the consensus matrix, summary statistics can be defined accounting for the
stability of a given cluster and additionally for the single members of a cluster. For
each cluster k ∈ K, a cluster consensus m(k) is defined. Furthermore for each sample
ei ∈ D and each cluster k a consensus mk(i) is defined. These statistics can be used to
validate cluster stability and to identify the more representative samples within each
cluster.
The cluster consensus m(k) can be defined as the average consensus index between all
pairs of samples belonging to the same cluster and can be computed as follows:
m(k) =
1
Nk(Nk − 1)/2
∑
i,j∈Ik
i≤j
M(i, j),
where I
(h)
k = j : ej ∈ k is the indicator matrix and Nk is the number of samples in
cluster k. For a perfect consensus clustering the cluster consensus’s m(k) would be 1
for all k‘s. The sample consensus mi(k) measures the average consensus index between
sample ei and all other samples in cluster k.
14
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The sample consensus can be defined for each sample ei and each cluster k as follows:
mi(k) =
1
Nk − 1{ei ∈ Ik}
∑
j∈Ik
j 6=i
M(i, j),
where Nk is the number of samples in cluster k and 1 {condition} is the indicator
function that is equal to 1 when the condition is true, and 0 otherwise. The sample
consensus mi(k) for a perfect consensus clustering and a given k, would be 1 for all
samples ei ∈ k, and 0 for the other samples.
The cluster consensus m(k) and the sample consensus mi(k) can be used to quantify
the stability of each cluster [135].
The consensus clustering method is implemented in the function consensusClustering
included in the package compdiagTools. It returns a consensus matrix, sample consensus
and cluster consensus values. In the next chapters I use the following subsample scheme:
I subsample the data 100 times, each time including 80% of the available samples.
The visualization of the consensus matrix helps to assess the cluster composition and
stability of each cluster. A color gradient is associated with the values ranging from 0 to
1, so that white corresponds to 1 and dark red corresponds to 0. Thus a block-diagonal
matrix corresponding to a perfect consensus clustering would be visualized as a heat
map including white blocks along the diagonal on a red background. Additionally the
sample consensus values are shown for each sample as row names on the left hand side
of the heatmap and the cluster consensus values are plotted below the heatmap for
each cluster [135].
1.2.3 Guided Clustering
Guided clustering is a method to combine experimental and clinical high-throughput
data [131]. It identifies clusters of genes that stand out in the experimental data and are
additionally strongly correlated in the clinical data. The clinical data consists of gene
expression profiles of patients with, for example, a specific disease. The experimental
data consists of gene expression profiles from a perturbation experiment containing a
perturbed and a control group [131].
The method is implemented in a R-package called GuidedClustering [131]. It needs the
following variables to be specified: Data.t, data.g, sigma, ncluster and label.g.
Data.t (Tij), also called clinical data, consists of expression profiles from patients.
15
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Data.g (Gij), also called the guided data, includes expression profiles from a perturba-
tion experiment. Sigma specifies the global smoothing strength. Ncluster defines how
many clusters the method should extract. Label.g defines the groups of the guided data
(data.g) , where 0 represents the control samples and 1 represents the perturbed sam-
ples. How the method uses these variables and how they are defined will be explained
in the following [131].
Let Tij be a set of clinical expression profiles and Gij a guiding dataset. The datasets
include genes in rows i and samples or expression profiles in columns j. The guiding
dataset includes two different types of expression profiles: Normal unperturbed celllines
(controls) and celllines where a specific pathway is perturbed. Thus the samples can
be labeled as perturbed (= 1) and unperturbed (= 0) resulting in a binary label vector
L [131].
Guided clustering calculates a matrix of pairwise gene similarities M . The gene simi-
larities are high if two genes are strongly correlated in the clinical data T and if their
gene expression in the guided data G is strongly correlated with the label vector L.
The method starts by calculating two matrices which capture the gene similarity on
both data sets separately. Then these two matrices are fused by matrix multiplication
resulting in the matrix M .
The matrix AT captures the similarity on the clinical data T . The matrix AT is defined
on the clinical data T for two genes g and has follows:
AT (g, h) = exp
(−(1− ω)(1−max(cor(g, h), 0))2
2σ2
)
,
where cor(g, h) is the Spearman’s correlation coefficient of the expression vectors of
genes g and h. The matrix AG captures the similarity of the genes on the guiding data
G. The matrix AG is calculated as follows for one gene g:
AG(g) = exp
(−ω(1− cor(g, L))2
2σ2
)
,
where cor(g, L) is the Spearman’s correlation coefficient of the expression vector of
gene g and the binary label vector L. The bandwidth of the Gaussian smoothing
function is specified by σ. Additionally ω ∈ 0 . . . 1 is a tuning parameter that balances
the information between the dataset G and T . The method takes a vector including
different values of σ as input and internally calibrates ω. The user can than choose,
depending on the resulting clusters, which σ to take [131].
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As already mentioned, the algorithm fuses the two different similarity matrices by
matrix multiplication (W = A
1/2
G ∗AT ∗A1/2G ). Using the resulting matrixW , the number
of beforehand specified (Ncluster) clusters are extracted. The extracted clusters include
genes that are strongly correlated within the clinical data T and are differentially
expressed in the perturbed dataset G.
In addition to the different clusters the method returns a consensus expression index
[131]. The consensus expression index is calculated based on the model that was also
used for index calculation in the first Section of this Chapter.
Guided clustering yields the opportunity to combine informations from experimental
and clinical gene expression data.
1.3 The Bioconductor package Limma
Limma [176] is a Bioconductor package to find differentially expressed genes between
e.g. under different conditions, in different tissues or developmental stages or at dif-
ferent time points. The package is designed to analyze complex experiments involving
comparisons between many transcripts simultaneously. The idea is to fit a linear model
to the expression values of each gene. Because empirical Bayes is used to borrow infor-
mation across genes, the analysis is also stable for an experiment with a small number
of samples. Within the linear model, several groups of samples can be defined and
compared. It is possible to include multiple confounding effects, such as dye or batch
effects. To define the linear model limma requires two matrices [175].
The first matrix is a design matrix, which defines different groups e.g. treated, untreated,
batch one and batch two are defined. Each row of a design matrix corresponds to a
sample in an experiment and each column corresponds to a coefficient to be estimated.
Thus the number of coefficients is defined by the number of columns in a design ma-
trix. The second matrix needed is a contrast matrix, which answers the question: Which
comparisons are to be made? Each contrast corresponds to a comparison between the
RNA targets e.g. treated− untreated [176].
Mathematically a linear model can be written as:
E[yj ] = Xαj
where yj is the expression data for the gene j, X is the design matrix and αj is the
vector of coefficients.
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The linear model is fitted to the data using the method lmFit(). The fitted model
returned by this method includes a coefficient component with estimated values for the
αj [176].
The contrasts are:
βj = C
T ∗ αj
where C is the contrasts matrix [176].
The next step is to apply contrasts.fit(), which again returns a model including now
the coefficients of interest, the estimated values for βj . Additionally it is possible to
obtain an ordered list of differentially expressed genes with logarithmic fold changes
and p-values. The list contains all genes included in the analysis. The next step is to
decide on a p-value threshold, genes with p-vales above this threshold are considered
to be significantly differentially expressed. The decision on the p-value criterion has
to be made by the individual researcher taking into account the experiment and what
further analysis and experimental steps will be done [176, 175].
1.4 Gene enrichment
1.4.1 Overrepresentation analysis
Microarray experiments are used to measure the expression of several thousands of
genes. First analysis steps often end in a list of differentially expressed genes. To de-
termine common functional groups of genes an enrichment analysis for specific Gene
Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
ways can be carried out. GO terms are defined by the GO database [5], where genes
are assigned to biological processes, molecular functions and cellular locations. KEGG
[93] is a collection of pathway maps of molecular interactions and reaction networks in
cells, and variants of them.
For each of these GO and KEGG terms one can compute a probability that a spe-
cific number of genes associated with one annotation term are present in a predefined
genelist, e.g. of differentially expressed genes by chance. The hypergeometrical distri-
bution is used to calculate this probability.
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Lets say we have N genes and M genes are for example annotated to a specific GO
term. Additionally n genes are found to be differentially expressed. Furthermore there
are k genes that are differentially expressed and are also annotated to that specific GO
term.
Then we can calculate the probability to find k differentially expressed genes annotated
in that GO term with the following formula:
P (X = k) =
(
M
k
)(
N −M
n− k
)
(
N
n
)
The probability needed is not for having a specific number k of genes but for having at
most k genes. Thus the cumulative probability needs to be calculated:
P (X ≤ k) =
k∑
y=0
(
M
y
)(
N −M
n− y
)
(
N
n
)
The analysis returns the GO terms or KEGG pathways that are overrepresented in a
given list of genes, for example differentially expressed genes. The resulting GO terms
and KEGG pathways can be used to describe the set of differentially expressed genes.
I used the method gokeggLister implemented in the package compdiagTools to do such
an analysis. This method returns HTML code that can be included in a HTML page.
The HTML code encodes a table with all GO terms and KEGG pathways with a p-value
below 0.1.
1.4.2 Gene Set Enrichment Analysis
Detecting modest changes in gene expression datasets is hard, due to a large number
of variables (genes), a high variability between samples, and often a limited number of
samples. The goal of Gene Set Enrichment Analysis (GSEA) is to determine modest
but coordinated changes in a priori defined sets of related genes. Such a set might for
instance include all genes connected to a specific pathway. [180]
GSEA considers experiments with genome wide expression profiles from samples be-
longing to two classes. A ranked genelist L = g1, . . . , gN is produced by ranking the
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genes based on a score between their expression and the group distinction by using any
suitable metric (r1 ≤ · · · ≤ rN ). For example genes can be ranked according to the fold
change between two groups. Additionally an a priori defined geneset S is given. S can
for example include genes encoding products in a specific pathway or sharing a specific
GO category.
GSEA determines whether the genes of a geneset S are randomly distributed through-
out L or can be primarily found at the top or the bottom of list L. It is expected that
sets, which are related to the phenotypic distinction, will show an enrichment in either
end of the list L.
The GSEA method consists of three steps. The first step is to calculate an enrichment
score (ES). That is done by recording the enrichment over the ranking, by calculating
the following sums:
PHIT (S, i) =
∑
gj∈S,j≤i
|rj |p
NR
PMISS(S, i) =
∑
gj /∈S,j≤i
1
N −NH
Where NR stands for: NR =
∑
gj∈S
|rj |p. The parameter p is used to control the influence
of the scores. In addition, the number of genes g1, . . . , gn that are also in geneset S are
counted, NH =
∑
gj∈S
1.
The ES is the maximum deviation from zero of the difference between PHIT and PMISS .
If p is set to 0, the ES(S) is reduced to the standard Kolmogorov-Smirnov statistic,
when testing the ranks at genes in S against a uniform distribution.
The second step is to assess the significance of the ES. Therefore the phenotype
labels are permuted 1000 times. Permuting the phenotype labels instead of the genes
maintains the correlation structure of the gene expression data. For each permutation
the ES is computed, which results in a distribution of random ES scores. Then the
ES score for the actual data is compared with the distribution (null distribution) of
the random ES scores.
The third step is to normalize the ES for the size of each geneset, yielding the normal-
ized enrichment score (NES). In addition a false discovery rate (FDR) is calculated,
corresponding to each NES, to control the proportion of false positives. Therefore the
tails of the observed and null distributions for NES are compared.
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GSEA is available from the following website: http://www.broadinstitute.org/gsea/.
Several existing genesets including positional genesets, curated genesets, motif gene-
sets, computational genesets and gene ontology genesets are also provided by that site.
[180]
1.4.3 The Bioconductor package Ordered list
OrderedList is a Bioconductor package for comparing ranked genelists, for example two
ranked genelists resulting from two knockdown experiments. The function compareList
implemented in the package OrderedList searches for similarities in two ranked genelists
[122].
As input two ranked genelists (GA and GB) of length m, starting with the strongest
up-regulated genes and ending with the strongest down-regulated genes per experiment,
are needed. The method computes a similarity score by comparing the two rankings of
the genelists.
First the overlap between the gene lists is computed. For each rank n, n = 1, . . . ,m, it
is counted how often genes appear in both ordered lists up to position n. The values
On(GA, GB) denote the size of the overlap at position n. The total overlap of posi-
tion n is defined as the overlap of up-regulated genes On(GA, GB) plus the overlap
of down-regulated genes On(f(GA), f(GB)), where f() refers to the flipped list with
down-regulated genes on top [199]. At position n it is given as:
An = On(G1, G2) +On(f(G1), f(G2))
The weights ω are chosen to decay exponentially with rank n:
ωα = exp−αn,
where α is a tuning parameter. A smaller α puts more weight on genes further down
the list. The similarity score S′α is defined as the sum over all weighted overlaps [199]:
S′α(GA, GB) =
m∑
1
exp(αn)An
The hole procedure is done twice, once with the original two ranked genelists and once
with the second genelist reversed. Thus the reversed genelist starts with the strongest
down regulated genes so that the up regulated genes in the first list are compared to
the down regulated genes in the second list.
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To estimate if the detected similarities are significant, compareList shuffles the two
ranked genelists 1000 times (by default) to generate 1000 random lists. Then the
method calculates similarity scores for the shuffled genelists generating a null distri-
butions for similarity scores. From this an empirical P-values and the 95% confidence
interval can be deduced [122].
CompareList yields a significant estimation for the similarity of genelists and graphically
illustrates the list comparison analysis [122].
1.5 Classification: Prediction Analysis of Microarrays
The problem of classification by microarrays is that there is a large number of genes from
which to predict a class, and most often a small number of samples. Prediction Analysis
of Microarrays (PAM) is a statistical technique for classification of gene expression
data using nearest shrunken centroids. Briefly, a standardized centroid for each class
is computed. This is the average gene expression for each gene in each class divided by
the within-class standard deviation for that gene. Then the method “shrinks” each of
the class centroids toward the overall centroid for all classes by an amount called the
threshold. To classify the method takes the gene expression profile of a new sample,
and compares it to each of these shrunken class centroids. The predicted class for that
new sample is the class whose centroid is closest, in squared distance to it.
As a byproduct the method identifies subsets of genes that best characterize each class
[183]. PAM is available in the Bioconductor package pamr which includes many useful
functions some are explained here [186].
Let us assume we have k classes (1, 2, . . . , k) and we want to build a classifier to predict
all k classes. Given is the expression values xij for each gene i = 1, 2, . . . , p and for
each sample j = 1, 2, . . . , n. Ck denotes the indices of the nk samples in class k.
The i-th component of the centroid for class k is the mean expression value for gene i
in class k and can be calculated as follows:
x¯ik =
∑
j∈Ck xij/nk.
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The i-th component of the overall centroid is:
x¯ik =
n∑
j=1
xij/n.
The method shrinks the class centroids toward the overall centroids.
Let
dik =
x¯ik − x¯i
mksi
where mk =
√
1/nk − 1/n and si is the pooled within-class standard deviation for gene
i.
s2i =
1
n−K
∑
k
∑
i∈Ck
(xij − x¯ik)2
Thus dik is a t-statistic for gene i, comparing class k to the other classes.
The method shrinks each dik towards zero giving new shrunken centroids and d
′
ik, which
is calculated as follows:
d′ik = sign(dik)(|dik| − 4)+
The “+” means positive part (t+ = t if t ≥ 0, and zero otherwise.). When the shrinkage
parameter4 increases, an increasing number of genes have all their d′ik = 0 [183]. Genes
are discarded if d′ik becomes zero. The new shrunken class centroid x¯
′
ik can then be
calculated as follows:
x¯′ik = x¯i +mk(si + s0)d
′
ik
The result depends on the shrinkage parameter 4.
Pamr.cv is a function to cross-validate the nearest shrunken centroid classifier produced
by pamr.train and thus it helps to determine the right amount of shrinkage [186]. The
method does a n-fold cross-validation to help choosing a shrinkage parameter 4.
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That means the data is randomly divided into n approximately equal-size parts (in-
cluding now different samples). The n parts are roughly balanced, that means the k
classes are distributed proportionally among each of the n parts. Then the model is
fitted n times, each time using 90% of the samples for training. The class labels of the
remaining 10% of the samples are then predicted. The errors on all n parts are added
together to compute an overall error.
The shrinkage parameter 4 should be chosen such that the cross-validated error is
minimized [183].
To predict new samples the package includes the function pamr.predict. The function
returns prediction information from a nearest shrunken centroid fit. As input it takes
the trained classifier, a matrix of features of which predictions are to be made and a
chosen shrinkage value. Then PAM classifies a new sample xj to belong to the nearest
shrunken centroid. To do so the distance between a class centroid and a sample is
measured by the discriminant score:
δk(xj) =
p∑
i=1
(xij − x¯′ik)2
(si + s0)2
− 2logpik
where pik is the prior probability of class k that is defined as the overall frequency of
class k in the population, hence
∑K
k=1 pik = 1. Usually pik is set to nk/n.
The prediction model can thus be defined as
fclass(xj ,4) = r, where δr(xj) = min
k
δk(xj)
The result of the classification depends on the chosen shrinkage parameter 4 [183].
1.6 Survival Analysis
1.6.1 Survival and hazard
Survival analysis attempts to answer different questions, for example: what is the
fraction of a population which will survive past a certain time point? How do particu-
lar influences or characteristics (confounding factors) increase or decrease the survival
time? Survival data is often censored. That means that for some patients the event of
interest did not occur during the study period.
24
1.6 Survival Analysis
Two related functions are generally used to describe survival data: The survival prob-
ability S(t) and the hazard h(t).
The survival probability S(t) is defined as the probability that a patient survives from
the starting point of the study to a specified future time t.
The survival probability can be estimated from observed survival times by using the
Kaplan Meier (KM or product-limit) method [94].
The hazard h(t) is defined as the instantaneous event rate for a patient who has already
survived to time t. The hazard reflects the incident event rate, while survival reflects
the cumulative non-occurrence of the event [27].
1.6.2 Kaplan-Meier survival estimate
The survival probability can be estimated from observed survival times by using the
KM method [94].
Suppose that in k patients events occur at distinct times t1 < t2 < t3 < · · · < tk
(all in the period of follow-up). The events are assumed to occur independently of
one another. Thus the probabilities of surviving from one interval to the next can be
multiplied to calculate the cumulative survival probability. The probability of being
alive at time tj , S(tj), can be calculated as follows:
S(tj) = S(tj−1)(1− dj
nj
)
where S(tj−1) stands for the probability of being alive at time tj−i, nj is the number
of patients to be alive just before tj and dj is the number of events at tj . Additionally
t0 = 0 and S(0) = 1. The value of S(t) is constant between the events. Hence the
estimated probability is a step function that changes values only at the times of events.
The estimator uses the information from each patient for as long as they are known to
be event-free [27].
The KM survival curve is a plot of the KM survival probability against time. The plot
provides a useful summary of the data and can be used to compare survival times of
different patient groups. The R-package survival provides the function survfit which
can be used to create survival curves given either a formula (e.g. KM) or a previously
fitted model.
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1.6.3 The log-rank test
Let us assume two groups of patients are given, differentiating by a certain character-
istic. To see if this characteristic makes a difference in survival one can plot for each of
these groups a KM survival curve. The question to ask now is, if these two KM curves
are “statistically equivalent”. If that is the case then there is no evidence to indicate
that the true survival curves are different. To test the “statistically equivalence” of two
KM curves a log-rank test can be used [104].
The log-rank test is a large-sample χ2 test, with the null hypothesis that two given
groups have identical survival and hazard functions. The log-rank statistic is com-
puted as follows: Let j = 1, ..., J be the distinct times of observed events in either
group. For each time j, the N1j and N2j are the number of patients still alive at the
start of period j in the respective group. Let Nj = N1j +N2j and let O1j and O2j be
the observed number of events in the groups at time j. The observations at time j are
defined as Oj = O1j +O2j . The log-rank statistic compares the observations O1j to its
expectation E1j under the null hypothesis and is defined as:
Z =
∑J
j=1(O1j − E1j)√∑J
j=1 Vj
,
where E1j = Oj
N1j
Nj
and the variance Vj =
Oj(N1j/Nj)(1−N1j/Nj)(Nj−Oj)
Nj−1 .
Thus the null hypothesis being tested is that there is no overall difference between the
two survival curves. Under the null hypothesis the log-rank statistic is approximately
χ2 distributed with one degree of freedom [104].
1.6.4 Cox proportional hazards model
The Cox proportional hazards (PH) model [32] is a multivariate approach for analyzing
survival data in medical research. It is a regression model, which describes the relation
between the hazard function and a set of covariates.
The Cox model is defined as:
h(t) = h0(t)× exp(b1x1 + b2x2 + · · ·+ bpxp),
where the hazard function h(t) is determined by a set of p covariates (x1, x2, . . . , xp)
and by the baseline hazard h0. The underlying hazard function corresponds to the
probability of reaching an event (dying) when all the xi are equal to zero [20].
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The aim of the analysis is to estimate the impact of the covariates xi on survival. This
is done by a maximum likelihood approach. The impact of the covariates is measured
by the size of the estimated coefficient bi. The baseline hazard function h0 is estimated
non parametrically, hence the survival times are not assumed to follow a particular
statistical distribution. The covariates (x1, x2, . . . , xp) act as factors on the hazard h(t)
at any time point t. Thus the hazard of the event in any group is a constant multiple
of the hazard in any other. This proportionality implies that the quantities exp(bi) are
called hazard ratios [20].
If bi is greater than zero (the hazard ratio is greater than one), the value of the ith
covariate increases, the hazard of the event increases and thus the length of survival
decreases. In other words a covariate i with a positive coefficient bi says that the hazard
is higher, and thus the prognosis worse with higher values of that covariate [104].
The function coxph provided by the R-package survival fits a Cox proportional hazards
regression model. The function takes as input a formula, that includes a response
variable on the left of a “∼” operator, and on the right the covariates. The response
variable on the left side is a survival object, as returned by the surv function and
includes the survival informations. In addition a data.frame needs to be provided
including the values for the covariates named in the formula on the right side [20].
The function returns a fitted model yielding coefficient estimates, standard errors and
hazard ratios. Furthermore an appropriate test of significance for each coefficient is
carried out by dividing the regression estimate b by its standard error SE(b) (Wald
statistic) [104].
In summary a Cox model is a statistical approach for exploring the relationship between
the survival of a patient and several explanatory variables. A Cox model estimates the
effect of each explanatory variable on survival after adjustment for other explanatory
variables. In addition, it allows to estimate the hazard of death for a patient, given
their prognostic variables [104].
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Brain tumours
Synopsis
First a brief introduction to brain tumours is given. The second Section describes how
the temporal order of genetic events contributes to the heterogeneity of brain tumours
and I analyze the characteristic expression profiles of subtypes. In the last two Sections
I describe how different cellular origins of glioblastomas are reflected in their expression
profiles. I develop a cell of origin gene expression signature differentiating between two
types of glioblastoma cancer stem celllines. In addtion, I connect the two types of
glioblastoma cancer celllines to different TGFβ responsiveness.
2.1 Biological introduction
Brain tumours are cells within the brain or the central spinal canal which are growing
abnormally. There are more than 120 types of brain tumours. They are sub-grouped by
the World Health Organization (WHO) classification system [124]. The first concept of
grading brain tumours with a systematic classification scheme was introduced in 1926
by Baily and Cushing [33]. The WHO classifications follows a histological principle:
Brain tumours are classified according to the type of normal tissue they most closely
resemble; their presumed cell of origin. For most brain tumours the actual cell of origin
is still unknown. Hence the concept of classifying the brain tumours according to their
presumed cell of origin is critical. Nevertheless, there are still no other diagnostic
approaches which do better. The WHO classification of brain tumours by morphology
is the ”gold standard” [184].
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Some tumour types are additionally assigned a grade, which ranges from Grade I (least
malignant) to Grade IV (most malignant). The grading estimates tumour malignancy
and patient’s prognosis [124, 6].
Glioblastoma Multiform (GBM) are graded by the WHO as grade IV. GBM are
the most common and deadly brain tumours in adults [123]. Patients have a short live
expectancy despite aggressive therapeutic approaches [42]. Glioblastomas are tumours
that form from malignant glial astrocytes: A type of glial cell in the brain and central
nervous system. They are the most malignant astrocytic gliomas. Glioblastoma multi-
form are associated with a high degree of vascularisation and angiogenesis [156]. The
vast majority of glioblastomas develop in the cerebral hemispheres. They consist of
cells with various morphologies. In addition glioblastoma multiform tumours consist of
cells that have lost their structural and functional differentiation as normal cells. These
cells are called anaplastic. The histological diagnosis of glioblastoma is usually made
on the basis of two distinctive secondary features. The first one is microvascular prolif-
eration, by which vascular cells and other vascular elements, such as vascular smooth
muscle cells and fibroblasts, divide. The second feature in glioblastoma is necrosis: The
presence of dying cells in living tissue. The presence of necrosis and/or micro-vascular
proliferation is essential for diagnosis because these features distinguish glioblastomas
from anaplastic astrocytomas [184].
GBM contain subpopulations of cells having stem cell-like properties, such as self-
renewal and the ability to differentiate into specialized cell types. These cells are called
cancer stem cells or tumour initiating cells [174, 83, 61]. Histological different GBM
exist and they resemble different types of cancer stem cells [10].
Central nervous system primitive neuroectodermal tumour (WHO grade
IV) (CNS PNET) is a malignant embryonal tumour. It got its name from its cells that
did not develop properly. Thus the neuroepithelial cells appear primitive: They are
small, they are round, they are densely packed and they are undifferentiated. Addition-
ally these cells show a high proliferation rate. Immature neuroepithelial cells still have
the capacity to differentiate into various neural celllineages. The PNET usually occurs
in children and young adults. Boys are more often affected than girls. PNETs are
often diagnosed wrongly [184]. One reason for this is that the immunophenotype and
the histology of PNETs are quite similar to medulloblastomas. Additionally PNETs
are far less common than cerebellar medulloblastoma. In contrast to medulloblas-
tomas, PNETs do not show an alteration of chromosome 17 or mutations of parts of
the hedgehog pathway, which are frequent features in classic medulloblastomas [184].
Additionally, in PNET the formation of rosette-like cell structures can be observed.
They tend to be large and to spread throughout the CNS [6].
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Atypical Teratoid/Rhabdoid Tumour (WHO grade IV) (AT/RT) is a rare,
highly malignant embryonal CNS tumour. AT/RTs can occur in any area of the CNS
but often involve the cerebellum. These tumours are associated with a loss of both
copies of INI1, a tumour suppressor gene on chromosome region 11q11.2. They pre-
dominantly affect newborns. Prognosis of patients is dismal [6]. In patients less than
18 years old, AT/RT accounts for approximately 2% of all brain tumours. Adults are
rarely affected. AT/RT contain rhabdoid cells: Cells that are rod-shaped. They also
contain regions with or without primitive neuroectodermal tumour-like areas and/or
cells differentiating along epithelial, mesenchymal, glial or neuronal lineages. They
sometimes contain hemorrhagic (profuse bleeding) or necrotic areas. Even areas com-
posed of small undifferentiated cells are not uncommon in AT/RT [184].
31
Chapter 2 Brain tumours
2.2 Specific genetic perturbations direct the development of
different brain tumour types from postnatal neural
stem/progenitor cells
This project was done in close collaboration with the group of Ulrike Nuber from the
department of laboratory medicine of the Lund Strategic Research Center for Stem
Cell Biology. The group of Ulrike Nuber did all the experiments. The microarray data
were produced and normalized by Falk Hertwig. I performed the statistical analysis
and evaluation of the data. The results are published in Cancer Research: “Definition
of Genetic Events Directing the Development of Distinct Types of Brain Tumours from
Postnatal Neural Stem/Progenitor Cells” by F. Hertwig, K. Meyer, S. Braun, S. Ek, R.
Spang, C. Pfenninger, I. Artner, G. Prost, X. Chen, J. Biegel, A. Judkins, E. Englund
and U. Nuber [76].
2.2.1 Motivation
Many of the morphological defined tumour types are still heterogeneous. They include
more than one subgroup. Gene expression profiling can help to understand the under-
lying mechanisms leading to different histological phenotypes. In most cases, it is still
unknown how cell-intrinsic and cell-extrinsic factors contribute to the development of
distinct brain tumour types. Furthermore, it is not clear if the mere accumulation of
genetic events or the order of them determines tumour phenotypes and to which extent
determined tumour types are stable or can be changed into another distinct type.
2.2.2 Over-expression of multiple genes leads to oncogenic transformation
of p53−/− postnatal NSC/NPCs
Neural stem cells were genetically perturbed with ten different oncogene combinations
and with the empty vector. The neuronal stem cells were p53−/−, which means that
the gene TP53, encoding for the tumour suppressor p53 is deleted on both alleles. p53
is an important regulator of the cell cycle.
Thus cells that do not express any p53, like the neuronal stem cells which we used, are
more susceptible to tumours. The oncogenes used for perturbing the p53−/− neuronal
stem cells were: HRAS, MYC, Bmi1 and Ezh2.
All possible double perturbations and single perturbations were conducted. We trans-
planted the different perturbed p53−/− neuronal stem cells into three primary mice.
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Oncogene Bmi1 alone, Ezh2 alone, the combination of Bmi1 + Ezh2 and the empty
vector control did not give rise to a tumour upon transplantation into mice. All other
perturbations led to tumour growth (in at least two out of the three mice).
2.2.3 Microarray hybridization and preprocessing
Isolated total RNA was analyzed on the Aligent 2100 Bionanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA). A generation of probes, hybridization to Affymetrix Gene
1.0 ST Array, washing and scanning were performed as suggested by the Affymetrix
standard protocol. 300 ng RNA was used for the first strand cDNA synthesis. Mi-
croarray data was normalized by the robust multi-array average (RMA) [85] using the
expression console software. For the analysis of the microarray data I used R [182] and
Bioconductor [64].
2.2.4 Over-expression of HRAS or MYC alone or in combination leads to
the development of three brain tumour types
According to histological analysis three tumour types developed: High grade gliomas,
PNETs and different epithelioid tumours with abundant giant rhabdoid cells, named
AT/RT-like in the following. AT/RT-like tumours developed from cells over-expressing
HRAS+MYC. Gliomas developed from cells over-expressing HRAS+Bmi1 HRAS+
Ezh2, or only HRAS. The PNETs developed from cells perturbed by three different
combinations: MYC +Bmi1, MYC + Ezh2, and MYC on its own.
The different histological features of the three tumour types are shown in Figure 2.1.
Gliomas showed features like abundant spindle-formed cells, necrosis and single giant
cells. These giant cells contained nuclei in differing numbers and of different sizes and
shapes. The PNETs consisted of round small cells having a large nuclear to cytoplasmic
ratio. Sometimes these cells formed rosette-like structures. The AT/RT-like tumour
consisted of cells of varying size with a round shape and prominent nucleoli. Several
cells had a nucleus peripherally located and a large cytoplasm.[76]
The stability of the developed tumours and their self-renewal capacity was shown by
performing further serial transplantations using FACS-isolated tumour cells [76].
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2.2.5 Clustering highlights the three histologically different tumour types
I performed an unsupervised clustering, including the microarray gene expression data
of the 26 tumour sphere samples (13 CNS PNET, 7 glioma and 6 AT/RT-like tumours).
I calculated pairwise euclidean distances between all samples based on the 5000 vari-
able genes across all the samples. Complete linkage was used to build the hierarchical
clustering. The resulting clustering tree shows three groups in accordance to the his-
tological classification (Figure 2.2).
Thus, the main differences in the data is induced by the histological tumour types. The
glioma phenotype is induced by MYC and the PNET phenotype by HRAS.
2.2.6 Identification of different gene expression patterns for the three
tumour types
I looked for genes specifically regulated in the three different tumour types. Thus I
searched for genes whose expression is differentially regulated in one of the tumour
types compared to the others (Figure 2.3).
I correlated the 5000 most variable genes across all samples j = 1, . . . , 26 to binary
vectors (b1, b2, b3) of length 26, where each entry represents a tumour sample. Thus for
each gene i = 1, . . . , 5000 three Pearson correlations (denoted as cor) were calculated,
as follows:
cpi = |cor(Xi, b1)|, where b1j =
1 if j is a PNET sample0 otherwise
cai = |cor(Xi, b2)|, where b2j =
1 if j is a AT/RT-like sample0 otherwise
cgi = |cor(Xi, b3)|, where b3j =
1 if j is a Glioma sample0 otherwise
The Pearson correlation coefficients of the i genes and the different labels were sum-
marized in a correlation vector:
v = (cp1, cp2, . . . , cp5000, ca1, ca2, . . . , ca5000, cg1, cg2, . . . , cg5000)
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From these vector v the 1000 genes showing the highest correlation coefficients were
chosen for further analysis. The expression values of these genes are shown in a heatmap
in Figure 2.3.
Additionally I tested if these genes were differentially expressed between tumour types.
I fitted the following linear model using the R package limma [176]:
E[yj ] = Xαj ,
where yj is the expression data for gene j, X is the design matrix and αj is a vector of
coefficients for each gene j to be estimated.
The design matrix X determines how the coefficients are to be estimated. I used the
following design matrix X to model the data:
X =

Glioma PNET AT/RT
S1Glioma 1 0 0
...
...
...
...
S6Glioma 1 0 0
S1PNET 0 1 0
...
...
...
...
S13PNET 0 1 0
S1AT/RT 0 0 1
...
...
...
...
S7AT/RT 0 0 1

The model included three different tumour types, thus 3 different coefficients for each
gene j were estimated. To validate that the previously found genes are differentially
expressed between tumour types, the contrast βj were computed as follows:
βj = C
T ∗ αj ,
where αj is a vector containing the 3 estimated coefficients for each gene j and C is
the following contrast matrix:
C =

C1 C2 C3
Glioma 1 −0.5 −0.5
PNET −0.5 1 −0.5
AT/RT −0.5 −0.5 1

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Thereby defining how the coefficients αj should be combined to calculate the βj . It
is then tested for every gene j if the contrasts βj are unequal zero, yielding a p-value
(adjusted after Benjamini Hochberg [12]) for each gene and each contrast estimated.
All previously selected, highly correlated 1000 genes showed an adjusted p-value smaller
than 10−6.
Figure 2.1: Representative macroscopic and microscopic images of Hematoxylin/eosin-stained
paraffin sections of the three different brain tumour types (Scale bars: 50 µm). HRAS over
expression: Glioma features, necrosis (arrow), single giant cells containing multiple nuclei
(arrow heads). MYC over expression: PNET features, small cells forming rosette like struc-
ture (magnified section). MYC + HRAS over expression: AT/TR-like features, cells having
eosinophilic cytoplasmic inclusions (arrow head). (Figure taken from a publication by Nuber
et al [76].)
Figure 2.2: Unsupervised clustering of the gene expression data from 26 tumours which de-
veloped after primary, secondary and tertiary transplantation. The clustering was based on
euclidean distances. The distances were calculated between all samples based on the 5000
most variable genes across all the samples. The labels are the internal array sample numbers,
which can be found in the appendix table A1. (Figure included in publication by Nuber et al
[76].
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Figure 2.3: Heatmap of genes reflecting the three different tumour types. Genes were plotted
along the y-axis and tumour samples along the x-axis. Expression levels: low (blue), high
(yellow) (Figure included in publication by Nuber et al [76].)
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2.2.7 Histological AT/RT-like tumour are related to ER-stress
AT/RT tumours are associated with a loss of both copies of the tumour suppressor gene
SMARCB1 (SNF5/INI1/BAF47). But the AT/RT-like samples resembling these
phenotype did not show a reduced Smarcb1 RNA level in comparison to the other two
tumour types.
Thus we took a closer look at geneset A shown in Figure 2.3 to get a better idea of
the AT/RT-like phenotype. This geneset includes genes up-regulated in the pheno-
type AT/RT-like in comparison to the other two phenotypes. Using a whole genome
rVISTA analysis of transcription factor binding sites [54], conserved binding site mo-
tives were found 2500 bp upstream of genes from group A. Only one conserved binding
site motif was significantly over-represented with an adjusted p-value smaller 0.005,
namely NFE2. The sequence motif NFE2 is named after a binding site motif of the
hematopoietic transcription factor NF -E2. But this motif is also known to bind five
other transcription factors: NRF1-3 and BACH1-2. These transcription factors form
together the Cap ’n’ collar (CNC) family of transcription regulators [137]. Several of
the genes in group A were found to be targets of the transcription factor CNC and of
NF-κB. These two transcription factors are both known to play a role in the unfolded
protein response (UPR) [75]. The UPR pathway is activated by endoplasmic reticulum
(ER) stress. That occurs when the amount of unfolded proteins exceeds the folding
capacity of the endoplasmic reticulum. From geneset A, including 134 genes, 43 genes
were associated with ER stress (32, 1% genes of geneset A). Triggers for the UPR
pathway in tumours are for example hypoxia, glucose and amino acid starvation.
To investigate if the human AT/RT tumours can be related to ER stress, a list of pre-
viously identified genes, being up-regulated in human AT/RT and up-regulated upon
deletion of Smarcb1 in mouse embryonic fibroblasts [86], was used. It was possible to
show a relation between 35 of these genes (30.7%) to ER stress.
We were able to show that upon SMARCB1 reduction the phosphorylation of eIF2α
increases. EIF2α is a central component of one of three UPR branches. Dephos-
phorylation of eIF2α is done by a catalytic sub-unit of protein phosphatase-1 (PP1c).
SMARCB1 binds to that catalytic sub-unit of PP1 (PP1c) and additionally to the
PP1 regulatory sub-unit 15. SMARCB1 increases PP1c in active solution [196]. An
explanation for the increase of eIF2α phosphorylation in SMARCB1 knockdown cells is
a decreased activity of PP1c. But phosphorylation of eIF2α is known to enhance apop-
tosis and proteasome inhibition. Thus, it was tested if in AT/RT the over-activation of
eIF2α could be of therapeutic use. And indeed, the treatment of MCF7-SMARCB1
knockdown cells with proteasome inhibitor Bortezomib leads to an increased number
of apoptotic cells (determined by FACS analysis).
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Such an approach could be a possible treatment for AT/RT and related malignancies
with SMARCB1 loss-of-function. A schematic representation of the connection be-
tween SMARCB1 and eIF2α phosphorylation can be found in Figure 2.4.
Figure 2.4: Schematic representation of the connection between SMARCB1 and eIF2α phos-
phorylation. (Figure included in publication by Nuber et al [76].)
2.2.8 Defining a molecular signature differentiating between three tumour
types
I did a supervised classification to investigate how many genes were necessary to clas-
sify and predict the three tumour types.
Thus I trained a shrunken centroid classifier on the 5000 most variable genes across
all the samples using the method implemented in the R package pamr [183]. As input
the method got the gene expression profiles including the 5000 preselected genes and
the association of samples to the 3 defined classes: PNET, AT/RT-like and Gliomas.
A 10-fold cross-validation was done, splitting the data into 10 equal-sized parts, which
were roughly balanced. Then the model was fitted 100 times, each time only 90% of
the samples were used, the remaining 10% were used to test the resulting classifier.
The errors of all 100 runs were added together to compute the misclassification error.
This whole procedure is automatically done with different choices of shrinkage values4.
In Figure 2.5 the misclassification errors are plotted against the different choices of 4,
shrinkage values. The higher the shrinkage the fewer genes are included in the classifier.
On top of the figures it is shown how many genes were still included in the classifier
after shrinkage with the corresponding 4.
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I chose a 4 shrinkage value of 13.7, where no misclassification was done in the cross-
validation. That shrinkage (4 = 13.7) resulted in a classifier of seven genes. The gene
expression values of these seven genes within the different tumour samples are shown
in Figure 2.5 (b).
(a) (b)
Figure 2.5: (a) PAM classifier, (b) Gene expression values of the seven classifier genes plotted
against the 26 tumour sphere samples. (Red: Glioma samples, Green = CNS PNET samples,
Blue: AT/RT-like samples) (Figures included in publication by Nuber et al [76].)
2.2.9 The CNS PNET phenotype induced by MYC is unstable and can be
converted into the AT/RT-like tumour type
It was possible to specify the developing tumour type by the expression of different
specific oncogenes in postnatal neural stem cells. Now we examined if an established
tumour phenotype can be converted into another one by a consecutive perturbation.
Thus, we generated Glioma and CNS PNET tumours by transplanting 500, 000 neural
stem cells (p53−/−) over-expressing HRAS or MYC. Cells from two different glioma
and two different PNET were isolated. After that, the glioma cells were transduced with
viral vectors over-expressing MYC and the PNET cells with vectors over-expressing
HRAS. Glioma and PNET cells now over-expressing HRAS and MYC were picked
and transplanted into mice. The resulting daughter tumours expressed both MYC and
HRAS. The daughter tumours, which developed from glioma cells, retained most of
their original features.
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CNS PNET daughter tumours converted into AT/RT-like tumours. These converted
tumours consisted of cells with a rhabdoid morphology and were positive for AT/RT-
like tumour markers. Microarray gene expression profiles were done from FACS-purified
tumour sphere cells from one glioma mother tumour and one CNS PNET mother
tumour, and from four daughter tumours.
I used the seven gene classifier, which had been trained beforehand, to predict the new
daughter tumours. I used the pamr.predict function implemented in the bioconduc-
tor package PAM . The function returned the prediction information, from a nearest
shrunken centroid fit. For input it took the 7 gene classifier, the matrix of gene expres-
sion values of the daughter tumours and the already chosen shrinkage value of 13.5.
Then PAM calculates the distances to the different class centroids by using the gene
expression values of the seven genes and classifies new samples to the nearest shrunken
centroid. It returned the posterior class probabilities, given in the table 2.1.
Glioma PNET AT/RT
Daughter Tumour 48 0.031 0.967 0.001
Daughter Tumour 49 0.967 0.006 0.027
Daughter Tumour 50 0.000 0.000 1.000
Daughter Tumour 51 0.000 0.000 1.000
Daughter Tumour 52 0.954 0.021 0.025
Daughter Tumour 53 0.935 0.045 0.019
Table 2.1: Table of posterior class probabilities
The daughter tumours of the HRAS induced gliomas, which developed upon MYC
over expression were classified as gliomas. In contrast to that, the daughter tumours
of the MYC induced CNS PNET, which developed upon HRAS over expression were
assigned to the AT/RT-like group. The expression values of the 7 classifier genes in
the daughter tumours can be seen in the heatmap shown in Figure 2.6)
Thus, it was possible to show the shift from the phenotype of CNS PNET to the phe-
notype of AT/RT-like tumours by over expression of HRAS. However the phenotype
of the glioma cells could not be changed, even if both daughter tumours now also ex-
pressed MYC and HRAS.
That means that certain in vivo tumour phenotypes are plastic and can be converted
by an additional genetic event. Furthermore, the results show that the order of the
genetic events plays an important role and directs the development of different in vivo
tumour types (Figure 2.7).
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Figure 2.6: Gene expression profile of classifier genes. Rows corresponding to the seven classifier
genes. Columns corresponding to sphere-cultured tumours cells samples. (Figure included in
publication by Nuber et al [76].)
Figure 2.7: Schematic overview of consecutive perturbations (Figure included in publication by
Nuber et al [76].)
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2.2.10 Discussion
Several insights in the origin of brain tumours, and the role of genetic alterations in
specifying tumour phenotypes were found. We showed the involvement of the UPR in
tumours with loss of SMARCB1. We demonstrated that three different brain tumour
types can develop from the same pool of p53−/− postnatal NSC/NPCs. Additionally
we could demonstrate that the development of the three different brain tumour types
is determined by the type and order of genetic perturbations. All three associated
human tumour types occur in younger patients. An explanation for this could be that
the cell-of-origin NSC/NPCs were extracted from young (four-week old) mice. These
cells show a higher proliferative rate than NPC/NPCs from older animals.
HRAS mutations are not commonly known in human gliomas, but an increase in copy
numbers of RAS/RAF genes and an increase of RAS activity was found [142, 90].
MYC is known to be up-regulated in human AT/RTs [127] and in human CNS PNETs
MYC and additionally MYCN is often amplified [8].
The majority of AT/RT cases are connected to an inactivation of the tumour suppressor
gene SMARCB1 [148]. There was no evidence for loss-of-function of SMARCB1 in
the murine AT/RT-like tumours, but other similarities were found between the gene
expression pattern of these tumours to the human AT/RTs and to mouse fibroblasts
having no Smarcb1. The results suggest that different genetic events can lead to the
development of similar tumour phenotypes.
In addition to already known phenotypic and genetic changes, which can appear during
the development of the same tumour type, the co-existence or sequential occurrence of
two different malignant tumours within the same tissue has been reported [49]. Here
it was possible to show that an established in vivo tumour type (CNS PNET) can
be transformed into another tumour type (AT/RT-like tumour) by the over-expression
of a single gene. It was previously described that the insertion of the v-Ha-ras gene
into a small cell lungcancer cellline which already over expressed MYC, induces in
vitro a transition to a large cell undifferentiated lungcarcinoma, whereas no transition
appeared when v-Ha-ras was inserted in small cell lungcancer celllines without MYC
over expression [128]. Here we could show that a single gene led to the transition of one
in vivo tumour type to another. Previous studies found that the order of expressing
transcription factors determines the specification of normal hematopoietic cells [87]. In
the case of lung neoplasia it was shown that the relative order of K-ras and APC gene
mutations direct the grade, but not the tumour type [91].
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Within this study, it was possible to give a proof-of-principle that the order of genetic
events can direct the development of an in vivo tumour type. The only difference is
that the system used is based on the over expression of MYC and HRAS under the
CMV promoter and that an ex vivo step is included.
MYC is known to promote cellular reprogramming in induced pluripotent stem cells
which have broad developmental potential [141]. An explanation that MYC could not
turn glioma cells over-expressing HRAS into the AT/RT-like phenotype could be, that
the binding sites of genes required for the development of the AT/RT-like tumour type
are inaccessible in the glioma cells.
Furthermore, we were able to identify unique gene expression profiles per tumour type
by that identifying genes that were only regulated in the murine AT/RT-like tumours.
It was possible to associate these genes to an up-regulation of the UPR. Given this
we were able to highlight that SMARCB1, a tumour suppressor primarily known for
its role in chromatin remodeling, has an additional function associated to the UPR.
The UPR helps to cope with conditions that lead to an increased number of misfolded
proteins. This can occur in rapidly growing tumours during hypoxia and nutrient depri-
vation. The activation of the UPR pathway can lead to different results - an increased
survival or cell death. This result depends on different branches of the UPR and the
dynamics of the response. The murine AT/RT-like tumours and their expression pro-
files are associated to an up-regulation of the UPR. Moreover, eosinophilic cytoplasmic
inclusions, another feature of AT/RT, can be found in cells that are under ER stress
[197] and in some of the tumours resembling the AT/RT-like phenotype.
Due to the rapid growth of these tumour-spheres and due to the lack of glucose, the
UPR is activated. Another reason for the activation of UPR is the over-expression
of MYC and HRAS. MYC enhances protein translation, and thereby increases the
ER protein load. Additionally, the mutated HRAS, that was used in the study, (V12
HRAS) particularly activates the UPR pathway [40].
The analysis of previously published gene expression profiles from human AT/RTs lack-
ing SMARCB1 and Smarcb1-deficient mouse embryonic fibroblasts [159] also shows
that genes related to the UPR are activated. It was shown that the SMARCB1 pro-
tein activates PP1c-GADD34 in solution [196]. Here it was also possible to show that
reduced levels of the protein SMARCB1 are associated with an elevated cellular sensi-
tivity to eIF2α phosphorylation, which is a central UPR mechanism. Sustained eIF2α
phosphorylation confers cytoprotection against hypoxia, oxidative stress, and long term
glucose deficiency, all of which represent typical in vivo conditions of rapidly-growing
tumours [14, 72, 106, 138, 195].
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Importantly, the application of the proteasome inhibitor bortezomib results in higher
apoptosis rate of cells with reduced SMARCB1 levels. Bortezomib leads to an increase
of ER stress and synergizes with the chemical inhibitor of the GADD34-PP1c complex
[169]. Thus, future studies should further investigate whether such an approach could
be used as a novel targeted strategy for treating AT/RTs and other related malignan-
cies.
In conclusion, the results indicate that an established in vivo tumour type (here CNS
PNET) shifts to another tumour type (here AT/RT-like) by the over expression of a
single gene (here HRAS). Additionally, we were able to show that the order of genetic
changes can direct the specification of a tumour type. HRAS over expression after
MYC over expression leads to AT/RT-like tumours, whereas the reverse order (first
the over expression of HRAS and second MYC over expression) results in the persis-
tence of the glioma phenotype. We defined a gene signature differentiating between the
tumour types and using the signature, confirmed the shift between tumour types.
Thus, not only the cell-of-origin, genetic and epigenetic events can influence the specifi-
cation of tumour types but also the order of genetic events. Furthermore, we identified
tumour type specific expressed genes. These genes indicate that AT/RT and AT/RT-
like tumours are associated with the activation of the UPR. We could demonstrate that
the involvement of SMARCB1 in regulating the UPR could be therapeutically used.
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2.3 Gene expression data of different glioblastoma-derived
CSC indicate different cells of origin
This project was done in close collaboration with the group of Christoph Beier from
the department of Neurology, University of Regensburg. I performed the statistical
analysis together with Claudio Lottaz. Parts of this work are published in the article:
“Transcriptional Profiles of CD133+ and CD133 Glioblastoma-Derived Cancer Stem
Celllines Suggest Different Cells of Origin“ by C. Lottaz, D. Beier, K. Meyer, P. Kumar,
A. Hermann, J. Schwarz, M. Junker, P. Oefner, U. Bogdahn, J. Wischhusen, R. Spang,
A. Storch and C. Beier in Cancer Research [121].
2.3.1 Motivation
Many of the morphological defined tumour types are still heterogeneous. They include
more than one subgroup. Additionally, in most cases it is still unknown which cell
types give rise to different tumour types.
Growing evidence suggests that glioblastoma multiform develop from different cancer
stem cells (CSC) or tumour initiating cells (TIC). In the following we are going to
compare gene expression profiles of different possible founder cells with 17 GBM CSC
lines. We address the question, whether it is possible to connect the GMB CSC lines
to their corresponding founder cell.
It is already known that a subgroup of astrocytic GBM lead to CD133− CSC lines which
differ in their gene expression profiles and their phenotypic properties from CD133+
CSC lines. Thus, the histologically different entities of GBM might have developed from
different GBM CSCs. One hypothesis is that different cells of origin exist [10] and give
rise to different tumour subtypes. Postulated founder cell populations include mature
astrocytes [189], unipotent ”restricted” progenitor cells and astrocytic progenitor cells
combined with mesenchymal stem cells (MSC) [179, 16]. Furthermore, adult neural
stem cells (aNSC) from the sub-ventricular zone (SVZ) of the adult brain and fetal
neural stem cells (fNSC) may be potential populations of founder cells. aNSC do
not express the GBM marker CD133. But aNSC share many properties with their
malignant counterparts [61, 174].
Recently, Phillips and colleagues determined a 35-gene signature that divided GBM
into three subgroups. They connected the three types to different stages of neurogene-
sis, correlated with patient prognosis and described a pattern of disease progression.
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Due to the physiological functions of the signature genes and their gene expression
pattern, the three groups were named: ”proneural”, ”mesenchymal” and ”prolifera-
tive” [154]. Whether these three subtypes develop due to different CSC origins is still
unclear.
We address this question by analyzing gene expression profiles of different founder cell
populations and 17 GBM CSC lines. The CSC lines had been shown to preserve the
phenotype of the original tumour and hardly acquire new mutations when propagated
in vitro [115].
2.3.2 Microarray preprocessing and quality control
The microarray data consisted of different chip types. It was merged by matching
probe sets using the matchprobes extension from the Bioconductor [64] extension for
R [182]. The publicly available data was jointly normalized with our data. Gene
expression values were background corrected and normalized on probe level using the
variance stabilization method by Huber et al [80]. The normalized probe intensities
were summarized into gene expression levels by using an additive model described in
Irizarry and colleagues [84] fitted by the median polish procedure [187].
2.3.3 Identification of two different groups of GBM CSC lines
We compared 17 GBM CSC lines with different founder cell populations. As founder
cell population we used gene expression profiles from three human astrocytes, three
human neurons, two fNSC lines, three aNSC lines and from three MSC lines. First I
did a hierarchical clustering. I calculated pairwise euclidean distances between samples
based on the 500 most variable genes across all samples. Then complete linkage was
used to cluster the samples. The clustering revealed three groups and is shown in Figure
2.8. The GBM CSC lines only fall in two of the three groups. One of these groups
also contains the fNSC lines and the other contains the aNSC lines. The third cluster
is formed by the rest of possible founder cell populations: Neurons, astrocytes and
MSC. In the clustering image (Figure 2.8) the correlation between CD133 expression
and transcriptional similarity to either aNSC or fNSC lines can be observed. All of the
CD133+ neurosphere like growing GBM CSC lines clustered together with the fNSC. In
contrast to that the two CD133−/+ semi-adherent growing and all adherently growing
GBM CSC lines, except two CD133− clustered with aNSC [121].
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Figure 2.8: Unsupervised complete linkage clustering based on euclidean distances between
samples (lp: late passage; ep: early passage; GS: Glioblastoma Sample; R: cellline from Re-
gensburg; neurosphere: +/− neurosphere formation, CD133: +/− CD133 expression)
I used the consensus clustering method [135] to validate the robustness of the three
clusters. The method took the gene expression matrix for input, including gene expres-
sion values of the 500 most variable genes in rows and the samples to be clustered in
columns. Then the data was resampled 100-times by repeatedly drawing 80% from the
given samples. After that a clustering was done for each of these datasets resulting in a
connectivity matrix. Consensus clustering returns a consensus matrix and additionally
sample consensus values for each sample and cluster consensus values. The consensus
matrix includes real numbers between 0 and 1. The entry (i, j) in a consensus matrix
represents the number of times the samples i and j are assigned to the same cluster
divided by the number of times both samples were included in a resampled dataset.
The result of the consensus clustering run is visualized in Figure 2.9, where a color
gradient is associated with the values ranging from 0 to 1, so that beige corresponds to
1 and dark red corresponds to 0.
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The consensus clustering showed that all three clusters are robust against sampling
variability, all having a cluster consensus greater than 0.7
Figure 2.9: Consensus clustering result: The counts are visualized in a color-coded consensus
matrix (dark red = 0 pairs that never clustered together, beige = 1 pairs that always clustered
together). Additionally the sample consensus values are shown for each sample as row names
on the left hand side of the heatmap and the cluster consensus values are plotted below the
heatmap for each cluster
2.3.4 Associating uniquely expressed genes with the two different groups
of GBM CSC lines
To get an impression of the differences between the three clusters (C1, C2, C3) I
searched for genes uniquely expressed by one of them. Thus I searched for genes whose
expression is differentially regulated in one of the clusters compared to the other two.
I correlated the gene expression values for each gene i given in all samples j = 1, . . . , 39
to binary label vectors (b1, b2, b3) of length 39, where each entry j represents a sample
included in one of the three clusters.
49
Chapter 2 Brain tumours
Thus for each gene i three Pearson correlations (denoted as cor) were calculated, as
follows:
xi = |cor(Xi, b1)|, where b1j =
1 if j is a sample of cluster 10 otherwise
yi = |cor(Xi, b2)|, where b2j =
1 if j is a sample of cluster 20 otherwise
zi = |cor(Xi, b3)|, where b3j =
1 if j is a sample of cluster 30 otherwise
This resulted in 3 vectors (x, y, z) containing for each gene i the Pearson correlation
coefficients to one of the binary label vectors (b1, b2, b3). From each of these vectors I
selected the 100 genes with the highest correlation coefficients, resulting in 300 genes
highly correlated with one of the group label vectors. Thus I found an individual tran-
scriptional profile per group (Figure 2.10).
We compared the transcriptional profiles of the 17 GBM CSC lines. These profiles
revealed focal adhesion proteins and genes associated with the extracellular matrix.
Furthermore many genes associated with TGFβ activity and TGFβ/bone morpho-
genetic protein (BMP ) signaling pathway were found up-regulated in type II GBM
CSC lines compared to type I [121]. Following this line, the different types of TGFβ
responsiveness were checked. It was found that all type II GBM CSC lines were respon-
sive, and show a reduced migration and proliferation rate after treatment with TGFβ.
The type I GBM CSC lines displayed no altered growth, clonogenicity and migration
after TGFβ treatment. In Section 2.4 I describe the role of TGFβ in more detail.
From recent comparisons of fNSC and aNSC one already knows which genes are ex-
pected as differentially expressed [130]. Among others we found the following genes:
DCX, CD44, PDGFRα, EGFR and CD133. All of these markers were low or nega-
tively regulated in aNSC and had a high expression in fNSC. The exception was CD44,
which was down-regulated in fNSC and highly expressed in aNSC.
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In the following, these markers were used to show the relationship between the two
types of GBM CSC lines resulting from the clustering and the fNSC/aNSC lines. Both
types of GBM CSC lines (aNSC, fNSC) express nestin as was also previously described
by Beier and colleagues [10]. The type I CSC lines all express CD133, PDGFRα
and EGFR similar to the fNSC. They also contain DCX-positive cells like fNSC. In
contrast to that the type II CSC lines express CD44 but not PDGFRα, CD133 and
they do not contain DCX-positive cells. But they also show an expression of EGFR.
The expression of these markers vary within the different types of GBM CSC lines. But
still the similar marker expression of the putative founder cells and their corresponding
GBM CSC type underscores the close relationship [121].
In the following I refer to the GBM CSC lines in cluster 2 as type I CSC lines and to
the GBM CSC lines in cluster 3 as type II CSC lines (Figure 2.10).
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Figure 2.10: Heatmap of 300 genes. For each cluster 100 over expressed genes were found by
correlation. Rows reflect genes and columns reflect samples. Expression levels: low (blue),
high (yellow)
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2.3.5 The difference between the two types of GBM CSC lines is
independent of growth pattern
The clustering not only reflected the CD133 expression but also the growth pattern of
the GBM CSC lines (Figure 2.8). In the following, we show that the growth pattern is
not the variable driving the gene expression differences between the GBM CSC types.
I included four further gene expression profiles from type I and type II CSC lines in
the analysis (Type I: R18 and R54 ; Type II: R8 and R53). These CSC lines were
cultured as a semi-confluent monolayer on laminin (Figure 2.12 (a)). Furthermore, I
included CSC lines published by Pollard and colleagues, which had always been grown
on laminin [157]. I calculated euclidean distances between all the samples based on
the 2000 most variable genes across all the samples. Here, ”all the samples” stands for
all GBM CSC gene expression profiles grouped in cluster 2 and cluster 3 (Figure 2.8)
together with the newly included gene expression profiles. I used complete linkage to
do an unsupervised hierarchical clustering. The clustering result is visualized in Figure
2.11. Irrespectively of the growth pattern the new CSC lines are grouped with type I
and type II GBM CSC lines.
To show that the growth pattern does not influence the transcriptional profiles, I used
a linear model approach implemented in the R package limma [176] to identify genes
that were differentially expressed between the celllines grown on laminin (L) and the
corresponding celllines not grown on laminin (nonL). The linear model used was:
E[yj ] = Xαj ,
where yj is the expression data for gene j, X is the design matrix and αj is a vector
of coefficients for each gene j to be estimated. The following design matrix X and
contrast matrix C were used:
X =

L nonL P1 P2 P3
R54L 1 0 1 0 0
R18L 1 0 0 1 0
R08L 1 0 0 0 1
R53L 1 0 0 0 0
R54 0 1 1 0 0
R18 0 1 0 1 0
R08 0 1 0 0 1
R53 0 1 0 0 0

C =

L− nonL
L 1
nonL −1
P1 0
P2 0
P3 0

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The design matrix determines which and how the 5 coefficients for each gene j are to be
estimated. The model took the two different growth patterns and the different celllines
(pairs: P1,P2,P3) into account. The fourth pairing of the celllines, R53 and R53L,
was implicitly modeled, such that P4 is determined by not being P1, P2 or P3.
The contrast βj were computed as follows:
βj = C
T ∗ αj ,
where αj is a vector containing the 5 estimated coefficients and C is the contrast
matrix. The result yields the opportunity to see if there are any genes differentially
expressed between the two growth pattern groups (L and nonL). No genes were found
to be significantly differentially expressed between the two groups, all having p-values
(adjusted after Benjamini Hochberg [12]) larger than 0.05.
Furthermore, the growth pattern of the putative founder cells were contrary to the
growth pattern of the associated GBM CSC lines (Figure 2.8 and 2.12 (b)). Thus, the
growth pattern did not drive the differences of the GBM CSC line profiles.
Figure 2.11: Unsupervised clustering using complete linkage. Clustering used euclidean dis-
tances calculated between all samples based on the 2000 most variable genes across all samples.
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(a) (b)
Figure 2.12: (a) Growth pattern of CSC lines after seven days with or without laminin
(b) Growth pattern of fNSC and aNSC
2.3.6 Defining a 24-gene-signature differentiating between the two types
of GBM CSCs
We connected the two types of GBM CSC lines to TGFβ responsiveness. This might
be relevant for patient selection benefiting from an anti-TGFβ treatment. But an
actual patient-selection, based on the GBM subtype requires a molecularly defined
gene signature. Thus, I used shrunken centroid classification, as implemented in the R
package pamr [183], to train a classifier which discriminates between GBM CSC line
type I and type II.
Thus I trained a shrunken centroid classifier on the 5000 most variable genes across all
the samples. For input the method got the gene expression profiles including the 5000
preselected genes and the association of samples with the 2 defined classes: GBM CSC
line type I and type II. A 10-fold cross-validation was done, splitting the data into 10
equal-sized parts, which were roughly balanced. Then the model was fitted 100 times,
each time only 90% of the samples were used, the remaining 10% were used to test
the resulting classifier. The errors of all 100 runs were added together to compute the
misclassification error. This was done for different choices of shrinkage 4.
In Figure 2.13 the misclassification errors is plotted against the different choices of 4,
shrinkage values. The higher the shrinkage the fewer genes are included in the classifier.
On top of the figures the number of genes still included in the classifier after shrinkage
with the corresponding 4 is shown.
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Figure 2.13: PAM results of training a classifier discriminating between GBM CSC line type I
and type II. The misclassification errors is plotted against the different choices of 4, shrinkage
values.
I used a 4 shrinkage value of 4.8 to identify 29 probe sets (representing 24 genes, see
Figure 2.14) discriminating the GBM CSC lines with minimal cross-validation error.
In the following I refer to this signature as the ”24-gene-signature”.
Figure 2.14: Heatmap of gene expression values of the 24-gene-signature within the training
data. Rows correspond to transcripts, columns correspond to samples (low expression = blue,
high expression = yellow).
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2.3.7 Prediction of CSC and fetal Neural Stem Cell lines using the
24-gene-signature
To test the 24-gene-signature, I classified gene expression profiles of six recently char-
acterized CSC and fNSC lines [117]. Pollard and colleagues cultured these CSC lines
on laminin. All six CSC lines showed the same adherent growth pattern [157].
I used the pamr.predict function implemented in the bioconductor package PAM . The
function returns prediction information, from a nearest shrunken centroid fit. It took
the 24-gene-signature, the matrix of gene expression values of the gene expression pro-
files to be predicted and the already chosen shrinkage value of 4.8 for input. Then PAM
calculates the distances to the different class centroids by using the gene expression val-
ues of the 24-gene-signature (Figure 2.15) and classifies the new expression profiles to
the nearest shrunken centroid. Additionally the method returns the posterior class
probabilities (table in Figure 2.2).
All published features agree with the resulting classification (Figure 2.15). All fNSC
lines are recognized correctly by the gene signature and fall into the cluster of type
I GMB CSC lines. The CD133+ CSC lines except for GS179 are classified as type
I. GS179 is classified as type II, but this cellline expresses GFAPδ filaments which
are specific for the SVZ. These filaments were not detected in the analyzed type I CSC
lines, so the classification into the group of type II is reasonable. The CD133− CSC line
GS166 is classified as expected as type II. Thus, all CSC lines were correctly classified
irrespective of culture-condition and growth pattern.
x
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CSC type II CSC type I
G166-NS B (GSM379855) 1.000 0.000
G174-NS (GSM379856) 0.954 0.046
GS-179-NS A (GSM379857) 1.000 0.000
GS-179-NS B (GSM379858) 0.966 0.034
G144-GliNS1 (GSM379870) 0.290 0.710
GLiNS2 (GSM379871) 0.000 1.000
G144-NS A (GSM379872) 0.005 0.995
G144-NS B (GSM379873) 0.002 0.998
G166-NS A (GSM379874) 1.000 0.000
Fetal NSC (GSM379865) 0.000 1.000
Fetal NSC (GSM379866) 0.001 0.999
Fetal NSC (GSM379867) 0.002 0.998
Fetal NSC (GSM379868) 0.011 0.989
Fetal NSC (GSM379869) 0.000 1.000
Table 2.2: Table of posterior probabilities for the predicted samples published by Pollard and
colleagues [157]
Figure 2.15: Tabel including the posterior probabilities for the predicted samples published
by Pollard and colleagues and heatmap of gene expression values of the 24-gene-signature
in six different CSC lines and four fNSC lines (Samples published by Pollard and colleagues
[157])(low expression = blue, high expression = yellow).
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2.3.8 Comparison of our classification system with the subgroups related
to the 35-gene-signature
I compared our classification with the subgroups related to the 35-gene-signature estab-
lished by Phillips and colleagues [154]. The three different GBM subtypes characterized
by Phillips et al are referred to as proneural, mesenchymal and proliferative. I calcu-
lated an GBM CSC index representing the expression of the 24-gene-signature on 100
high-grade glioma samples from Phillips et al, by using the getIndex method explained
in Section 1.1. The GBM CSC index reflects the expression of the 24-gene-signature
within these samples. A low index represents a type II-like expression profile and a
high index represents a type I-like expression profile.
The 24-gene-signature clearly distinguishes the mesenchymal from the proneural sub-
type (Figure 2.16). The proneural subtype is associated with an high CSC Index
suggesting a connection between type I GBM CSC lines. The mesenchymal subtype is
associated with a low CSC index indicating that these GBMs might be driven by type
II GBM CSCs. The subgroup referred to as proliferative is ambiguous and presents a
continuum between the other two types of GBM CSC lines. One reason for this could
be that in some GBMs there is not only one type of CSCs present which drives the
tumour but a mixture of GBM CSCs.
(a) (b)
Figure 2.16: (a) Heatmap of gene expression values of the 24-gene-signature in 100 high-grade
glioma samples. The samples are ordered according to the calculated GBM CSC index based
on the 24-gene-signature (low expression = blue, high expression = yellow). The color bar
above the heatmap represents the three, by Phillips and colleagues defined, subgroups [154](red
= mesenchymal, green = proliferative, blue= proneural). (b) Boxplots of GBM CSC index
values of samples grouped into the three subgroups characterized by Phillips and colleagues.
Calculation of the GBM CSC index was based on the 24-gene-signatur (red = mesenchymal
,green = proliferative, blue= proneural).
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2.3.9 Discussion
Phillips and colleagues characterized three molecular subgroups of GBM associated
with different stages of neurogenesis [154],[115]. Conversely, Beier and colleagues [10]
and Guenther and colleagues [68] described two types of CSC lines which were derived
from newly diagnosed GBM and cultured in medium.
This study now uses these three reports and suggests that a reason for the heterogeneity
of GBM is that different cells of origin lead to different types of GBM CSC. The collected
data suggests that, together with a recent study by Kenny and colleagues [96], neither
the culture conditions (+/−ECM proteins) nor the growth patterns have a dominant
effect on the transcriptional profile and with that on the group assignment of CSC lines.
In fact, the assignment to one of the groups describes a profound biological difference
as also indicated by the different age of patients. The 24-gene signature derived from
in vitro CSC lines can now be used to classify primary GBM samples directly ex vivo
without culturing.
The cell of origin of GBM is still vague. In line with a previous report [115], it was
shown that all GBM CSC lines do not cluster with astrocytes but with NSC lines.
Thus, most likely GBMs originate from cells that have preserved features of NSC or
acquired these features, for example by de-differentiation. However, such a statement
cannot be made for approximately 60% of the GBM that did not lead to CSC lines
on propagation in NSC medium [61, 10, 147]. The limitation of this study is that it
was not possible to observe the transformation of a putative founder cell into a GBM
CSC. Thus, based on the results, it was only possible to generate hypotheses which
need further validation. Only new conditional in vivo experiments will allow final
conclusions.
Nevertheless, our data suggests that CD133 negative type II GBM CSC may be derived
from CD133 negative aNSC located at the SVZ/ hippocampus [152]. But the type II
CSC lines are still a heterogeneous group. A reason could be that different molecular
mechanisms may be involved in the genesis. In the future, larger series will be needed
to identify possible subgroups within the type II CSCs.
In contrast, at this moment it is not possible to connect the CD133 positive type I
GBM CSC to a specific cell of origin, which has preserved or acquired a phenotype like
the fNSC. Putative candidate cells could be among others the CD133 positive radial
glia-like ependymal cells already published by Coskun and colleagues [31]. Another
possibility could be the reprogramming of aNSC into pluripotent embryonal stem cells,
which was already shown to be possible by activation of the transcription factor Oct4
[99].
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Thus, the similarities between type I CSC lines and fNSC lines could also have occurred
due to the reacquisition of fNSC features by a aNSC. Therapies for GBM should aim
at eliminating the CSCs and not only aim at inhibiting certain pathways [11, 155]. To
target the CSCs as effectively as possible it is important to know which kind of CSC
is responsible for the tumour. In parts, this may be possible by grouping of GBM
based on CD133 expression. Nevertheless, we suggest a 24-gene-signature which is
more accurate than the expression of CD133, and thus, should be evaluated further for
its potential.
In conclusion, the existence of two distinct types of GBM CSC lines was shown. Dur-
ing transition from the respective NSC to the related CSC, the loss of the appropriate
differentiation potential may be the most critical event. But although additional al-
terations, giving rise to an accelerated proliferation, are required for the malignant
phenotype (particularly in type II GBM CSC), the collected data provides a deeper
insight into the development of GBM, their heterogeneity, and the according variable
prognosis of patients. In future, this may lead to a more personalized and improved
therapy targeting GBM CSCs.
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2.4 The glioblastoma CSC subtype TGFβ-dependently
determines the degree of immune infiltration
This project was done in collaboration with the group of Christoph Beier from the
department of Neurology, University of Regensburg. Together with Claudio Lottaz I
carried out the statistical analysis and evaluation of the microarray data. Parts of this
work are published in the article: ”The Cancer Stem Cell Subtype Determines Immune
Infiltration of Glioblastoma” by C. Lottaz, D. Beier, K. Meyer, P. Kumar, A. Hermann,
J. Schwarz, M. Junker, P. Oefner, U. Bogdahn, J. Wischhusen, R. Spang, A. Storch
and C. Beier in Stem Cell and Development [9].
2.4.1 Motivation
GBM are heterogeneous and consist of distinct molecular subtypes [117, 82]. So far
only two types of GBM subtypes have been identified by transcriptional [154], genetic
[192] and proteomic studies [22]: the proneural subgroup of GBM and the mesenchy-
mal subgroup. But additional subtypes are likely to exist. In Section 2.3 I describe
two types of different CSC lines CD133+ and CD133− contributing to the hetero-
geneity of GBM [121]. I have already shown a connection between different GBM
CSCs and the proneural and mesenchymal phenotype. In addition, I derived a 24-gene-
signature differentiating between the ”proneural-like CSC” lines, being CD133+ and
the ”mesenchymal-like CSC” lines being CD133−. It was observed that patients suf-
fering from mesenchymal GBM have more infiltrating immune cells and show a longer
survival in comparison to patients with proneural GBM [160]. The underlying mecha-
nism of the variable immune infiltration remains unknown.
In this study we show that TGFβ regulates proliferation, migration, and tumourigenic-
ity of mesenchymal cancer stem cells (CSC). In contrast, proneural CSC resist TGFβ
due to TGFR2 deficiency. In vivo mesenchymal glioblastoma shows a substantially in-
creased infiltration of immune cells while proneural glioblastoma display minor immune
infiltration. On a functional level, proneural CSC lines cause a significantly stronger
TGFβ-dependent suppression of NKG2D expression on CD8+ and CD68+ cells in
vitro which provide a mechanistic explanation for the reduced immune infiltration of
proneural glioblastoma. Thus, the molecular subtype of CSC TGFβ-dependently con-
tributes to the degree of immune infiltration.
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2.4.2 Microarray hybridization and preprocessing
Acquisition of microarray data was described in [10]. For the analysis I used R [182] and
Bioconductor [64]. Expression values were corrected and normalized using the robust
multi-array average (RMA) [85] method implemented in the Affymetrix package.
2.4.3 Proneural GBM show a reduced immune infiltration
We stained microglia with markers for cytotoxic T-lymphocytes CD8+ and CD68+ in
a series of GBMs to show the varying degrees of immune infiltration. Double staining
with the proneural marker genes Olig2 and CD8/CD68 revealed an anti-correlation
of the proneural marker expression and the immune infiltration markers (Figure 2.17).
Thus, as expected the proneural GBM show reduced immune infiltration.
Figure 2.17: Olig2, DLL3, NeuN, YKL-40, CD44, VEGF, CD8, and CD68 expression in GBM
(n=19) was quantified by a blinded rater (CPB). The expression of markers for proneural
GBM (DLL3, Olig2, NeuN) correlated with the amount of infiltrating CD8, and CD68 cells.
Representative images of Olig2 and CD8+ and CD68+ staining are given. (Figure taken from
publication by Beier et al [9].)
2.4.4 TGFβ responsiveness is determined by the expression of TGFR2
I analyzed gene expression profiles of nine CSC lines, three mesenchymal-like and six
proneural-like CSC lines. The assignment to the two subtypes of GBM and their ap-
propriate CSC is given in Section 2.3 using the 24-gene-signature (Figure 2.18 (a)).
Here we show that the effects of TGFβ vary between the two groups.
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We tested whether SMAD2 was phosphorylated after treatment with TGFβ. All
mesenchymal celllines and one proneural cellline showed a time-dependent TGFβ-
induced SMAD2 phosphorylation (appendix Figure A1). Although there is no au-
tocrine SMAD2 phosphorylation in any of the CSC lines in vivo, it was possible to
detect TGFβ mRNA and unprocessed TGFβ in vitro and the expression of TGFβ
1 and 2 in vivo. All celllines which are not responsive to TGFβ show a significantly
decreased expression of the TGFβ receptor TGFR2. More precisely, five resistant CSC
lines show a lower expression of TGFR2 than four, which show a SMAD2 phosphory-
lation after TGFβ treatment (appendix Figure A2 ). This could explain the molecular
mechanism leading to different resistances of the CSC lines to TGFβ.
(a) (b)
Figure 2.18: (a) Heatmap of the 24-gene-signature in 9 CSC lines (low expression = blue, high
expression = yellow). The color bar above the heatmap represents the GBM CSC types (red=
mesenchymal-like, blue=proneural-like) (b) The gene expression index calculated based on the
TGFβ target genes plotted against the relative change of proliferation after TGFβ treatment.
The samples represented by blue dots were classified as proneural-like, the green samples as
mesenchymal-like.(Figures taken from publication by Beier et al [9].)
2.4.5 Mesenchymal-like CSC lines are responsive to TGFβ treatment
The effects of TGFβ 1, 2 and the combination of both were the same in all experi-
ments. In the mesenchymal-like CSC lines we observed that TGFβ has an influence on
migration, proliferation and tumourgenicity. But it did not affect colongenicity or the
proportion of CD133+ cells and it did not alter the differentiation profile. In contrast
to that TGFβ incubation in proneural-like CSC lines lacking SMAD2 phosphorylation
and the expression of TGFR2 did neither affect migration nor stem cell properties. An
exception was the proneural-like CSC line R11 that was resistant to TGFβ treatment
despite SMAD2 phosphorylation.
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In order to understand this discrepancy the TGFβ-LIF mediated signaling pathway
[151] was tested to see whether it might be operational in this GBM CSC line. Until
now the medium used for the experiments was routinely supplemented with LIF . This
fact obscured the LIF -depending growth-promoting effects triggered by TGFβ. The
experiment was reproduced using LIF -free medium. It was possible to observe an
increased proportion of clonogenic cells confirming the presence of the described TGFβ-
LIF -STAT3 mediated signaling pathway in the CSC line R11. In all other celllines the
TGFβ mediated effects were independent of LIF . Thus, R11 was dependent on the
TGFβ-LIF -STAT3 signaling pathway and hence resisted TGFβ treatment as long as
LIF was available (appendix Figure A2).
2.4.6 Defining TGFβ target genes and a TGFβ response index
To identify GBM that respond to TGFβ, I used gene expression data to define TGFβ
target genes. I compared transcriptional profiles of TGFβ responsive CSC lines (R8,
R53) with and without TGFβ treatment. I used a linear model approach implemented
in the R package limma [176] to identify genes that were differentially expressed be-
tween the celllines treated with TGFβ and without treatment. The linear model used
was:
E[yj ] = Xαj ,
where yj is the expression data for gene j, X is the design matrix and αj is a vector of
coefficients for each gene j to be estimated.
The following design matrix X and contrast matrix C were used:
X =

TGFβ nonTGFβ R8
R8 0 1 1
R53 0 1 0
R8TGFβ 1 0 1
R53TGFβ 1 0 0

C =

TGFβ − nonTGFβ
TGFβ 1
nonTGFβ −1
R8 0

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The design matrix determines how the 3 coefficients for each gene j were estimated.
The model took the two different treatments and the different cellline pairings into
account. The second cellline R53 was implicitly modeled, in a way that being cellline
R53 is determined by not being cellline R8.
The contrast βj were computed as follows:
βj = C
T ∗ αj ,
where αj is a vector containing the 3 estimated coefficients and C is the given contrast
matrix. The result was a list of differentially expressed genes between the TGFβ treated
and untreated gene expression profiles of the CSC lines. From that list I selected 100
genes showing the highest log fold change, between control and TGFβ treated samples.
All the genes showed an absolute log fold change higher than 1.47.
I calculated a TGFβ-response index on the gene expression profiles of 9 CSC lines based
on the 100 TGFβ target genes, by using the method getIndex described in Section 1.1.
This TGFβ index was used as representative for TGFβ signaling. We could show that
the relative change of proliferation after TGFβ treatment is highly correlated to the
TGFβ response index. Thus we were able to observe an increase in proliferation when
treating the celllines with TGFβ (Figure 2.18 (b)).
2.4.7 Associating TGFβ response with the type of GBM CSC line
For further analysis, I used expression profiles of 80 well-characterized GBM samples
published by Murat and colleagues [140].
I calculated pairwise euclidean distances between all the samples only using the gene
expression values of the 100 TGFβ target genes. Then I clustered the 80 GBM samples
using the complete linkage method. The clustering resulted in two clusters. To validate
the robustness of the found clusters I used the consensus clustering method [135]. The
method took the gene expression matrix, with the 100 TGFβ target genes in rows and
the samples to be clustered in columns for input. Then the data was resampled 100-
times by repeatedly drawing 80% from the given samples. After that a clustering was
done for each of these dataset resulting in a connectivity matrix. Consensus clustering
returned a consensus matrix and additionally sample consensus values for each sample
and cluster consensus values.
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The consensus matrix includes real numbers between 0 and 1. The entry (i, j) in a
consensus matrix represents the number of times the samples i and j are assigned to
the same cluster divided by the number of times both samples were included in a re-
sampled dataset. The result of the consensus clustering based on the expression values
of the 100 TGFβ taget genes is visualized in Figure 2.19 (a), where the color gradient
is associated with the values ranging from 0 to 1, so that beige corresponds to 1 and
dark red corresponds to 0.
The two resulting clusters were defined as a TGFβ responsive cluster characterized by
expression patterns typical for activated TGFβ signaling and a TGFβ unresponsive
cluster. The TGFβ responsive cluster comprised of only 22 of the 80 GBM samples
indicating that TGFβ signaling is only active in a subgroup of GBM.
To connect these two groups of different TGFβ responsive GBMs to the previously
defined subgroups (proneural-like and mesenchymal-like GBM), I used the 24-gene-
signature defined in Section 2.3. Again I clustered the 80 GBM samples, but now the
pairwise euclidean distances were calculated based on the 24-gene-signature. Two clus-
ters were found. To validate the robustness of the newly found clusters I followed the
same analysis steps as above, the only difference was that instead of using the TGFβ
target gene expression, the expression of the 24-gene-signature was used. I obtained
two clusters that turned out to be highly stable with respect to sub-sampling. The
result of the consensus cluster analysis, on the basis of 24-gene-signature, is shown in
Figure 2.19 (b).
Many samples classified as mesenchymal-like are TGFβ responsive or more precisely
do express TGFβ target genes and many samples classified as proneural-like are unre-
sponsive to TGFβ treatment.
To validate the connection between TGFβ responsiveness and the two different types
of GBM CSC lines I calculated two indices for the 80 GBM samples with the getIndex
method described in Section 1.1. The first index was the TGFβ response index, which
was calculated based on the gene expression of the TGFβ targets.
The second index was based on the gene expression of the 24-gene-signature. The
two calculated indices were highly anti-correlated (r = −0.885). Thus, most TGFβ
responsive GBM samples are similar to mesenchymal-like CSC lines and conversely
TGFβ unresponsive GBM samples mainly display a proneural-like CSC expression.
The heatmap in Figure 2.20 displays the gene expression of the 24-gene-signature in
the 80 GBM samples and shows the connection of the 80 samples to TGFβ responsive-
ness.
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All this leads to the conclusion that the 24-gene-signature not only indicates different
cells of origin but also distinguished GBM with and without active TGFβ signaling
and with that, TGFβ responsiveness respectively in vivo and in vitro. These results
might help to identify patients who may benefit from TGFβ targeting therapies.
(a) (b)
Figure 2.19: Consensus clustering results of 80 GBM samples, (a) based on 100 TGFβ target
genes, discriminating GBM samples after the activity of TGFβ signaling; (b) based on the
24-gene signature discriminating proneural-like and mesenchymal-like GBM samples. Side
bar indicates in which TGFβ responsiveness clusters the corresponding sample fell in (a) The
counts of how often samples clustered together are visualized in a color-coded consensus matrix
(Dark red = pairs that were never clustered together, beige = pairs that always clustered
together)
2.4.8 TGFβ mediates immunosuppression in proneural-like CSC
The presence of GBM with different responsiveness to TGFβ suggests that TGFβ has
different predominant functions depending on the GBM subgroup. Given the almost
complete TGFβ resistance and the expression of TGFβ in proneural like CSC an
immunosuppresive function of TGFβ in this subtype can be assumed. The TGFβ-
induced down-regulation of NKG2D receptor expression on CD8+ T-cells and NK-cells
in vitro was investigated [57]. The TGFβ signaling was blocked by TGFR1 kinase
inhibitor SD-208 [188] to differentiate between TGFβ dependent and independent
effects.
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Peripheral blood mononuclear cells (PBMC) cultured with supernatant CSC lines re-
mained without effect.
Thus, in the absence of immune cells CSC lines do not secrete active TGFβ. But
co-culturing of PBMC with CSC lines revealed an increased TGFβ dependent down-
regulation of NKG2D on NK-cells and of CD8 T-cells. The increase of TGFβ depen-
dent down-regulation of NKG2D is more dominant in the proneural-like CSC lines.
Thus, the TGFβ dependent immuno-suppression is enhanced by proneural-like CSC
lines which are therefore resistant to TGFβ treatment.
Figure 2.20: Heatmap of the 24-gene-signature expression within 80 GBM samples (pub-
lished by Murat and colleagues [140] ). Samples (columns) are ordered according to 24-
gene-signature-index. (low gene expression = blue, high gene expression = yellow). Samples
expressing TGFβ regulated transcripts are labeled in red.
Additionally, I compared the expression of a geneset associated with innate immune
response between the TGFβ responsive and unresponsive subgroups. The geneset was
published by Murat and colleagues [140] and consisted of 134 genes. In line with the
assumption that TGFβ resistant GBM show an increased immuno-suppression, I found
that the geneset has on average higher expression levels in GBM samples assigned to
the proneural-like CSC subgroup (Figure 2.21).
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x
Figure 2.21: Heatmap of 134 genes associated with innate immune response published by Murat
and colleagues [140]. Samples (columns) were sorted according to an index calculated on the
shown genes, genes (rows) were clustered (low gene expression = blue, high gene expression =
yellow). Samples expressing of TGFβ regulated transcripts are labeled in red.
2.4.9 Discussion
We were able to reveal a relationship between GBM and proneural-like respectively
mesenchymal-like CSCs indicating a profound biological difference in the function of
TGFβ in these tumours. Tumours expressing transcripts of proneural-like CSC also
express TGFβ in vivo. TGFβ is so far the most potent immuno-suppressive cytokine
known. Thus, it may suppress the function and invasion of immune cells in proneural
GBM [160, 172]. It was possible to substantiate this hypothesis using functional as-
says which revealed a significantly stronger TGFβ dependent suppression of NKG2D
receptor expression on NK- and T-cells by proneural-like CSC lines in comparison to
mesenchymal controls [9].
The different responsiveness of the CSC to TGFβ and the immunosuppression effects
provides a possible explanation for the refractory phenotype of proneural GBM in an
otherwise highly promising vaccination study on GBM patients [160]. Immune thera-
pies applied to tumours maintained by proneural-like CSC should therefore also aim at
the attenuation of TGFβ mediated immuno-suppression.
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Thus, the identification of the CSC subtype in GBM based on the 24-genes signature
will help to guide both TGFβ targeting and immune therapies by identifying GBM
with strong TGFβ-dependent immune paralysis. Conversely, the functions of TGFβ
in GBM maintained by mesenchymal-like CSC are manifold and TGFβ may either
inhibit or promote tumour growth. Thus extreme caution is called for when applying
of TGFβ targeting therapies to mesenchymal GBM.
In conclusion the CSC subtype determines, if TGFβ signaling is active or not active
and with that it determines the degree of immune infiltration and local immune paral-
ysis. Thus, the identification of the CSC subtype driving a GBM will help to guide
TGFβ targeting and immune therapy decisions.
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Synopsis
In the first Section of this Chapter is an introduction to lymphoma biology. In the
second Section human transformed germinal center B cells were used to identify pat-
terns of gene expression changes in response to B cell specific stromal stimuli. These
patterns indicate different pathway activaties in Diffuse Large B Cell Lymphomas and
Burkitt Lymphomas. In the third Section I identify LEF1 target genes, allowing for the
measurement of LEF1 activity in lymphoma. LEF1 activity in Burkitt Lymphomas is
higher compared to DLBCL.
3.1 Biological introduction
Lymphomas are a heterogeneous group of cancers affecting cells of the immune system,
called lymphocytes. Lymphomas are classified based on the cell they originate from: B
cell lymphomas originate from B lymphocytes/B cells and T cell lymphomas originate
from T lymphocytes/T cells.
95% of lymphomas are B cell lymphomas and develop during B cell differentiation
[109]. The steps of B cell development can be associated with different structures of
the B cell receptor (BCR). The BCR consists of two heavy-chain and two light-chain
immunoglobulin (Ig) polypeptides, which are covalently connected by disulfide bridges.
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Early B cell development takes place in the bone marrow, where the B cell precursor
rearranges the DNA of Ig heavy-chain and light-chain genes and is equipped with
a functional BCR. The BCR is responsible for detecting pathogens. Each B cell is
equipped with a different BCR. Only when expressing a functional BCR does the B
cell get signals to differentiate into a mature naive B cell and leave the bone marrow.
If the mature naive B cell encounters an antigen that binds to the BCR, the B cell gets
activated and enters into the germinal center reaction. Within the germinal centers
(GC) the B cell undergoes clonal expansion and class-switch recombination. During
these processes the BCR coding gene is further mutated and changed optimizing the
fit to its antigen. The normal B cell depends on BCR expression, as well as on further
signals from the micro-environment [109].
Most malignant growing B cell lymphomas use factors, necessary for normal B cell
differentiation, to get survival and proliferation signals.
Lymphomas can be separated into two major categories: Hodgkin’s lymphomas (HL)
and non-Hodgkin’s lymphomas (NHL). In 2008 the incidence rate for NHL was 5.1 new
cases per 100, 000 persons. The Age-World-Standardized incidence rate (ASR(W))
is calculated by the WHO. The WHO collects a set of genetic and histopathological
criteria for classifying tumours of hematopoietic and lymphoid tissues. Based on these
criteria lymphomas are classified and treated. NHL comprises of many different types of
B cell lymphoma, which can be distinguished in indolent (slow-growing) and aggressive
(fast-growing) types [88].
Two aggressive forms of NHLs are Burkitt’s Lymphoma (BL) and Diffuse Large B Cell
Lymphoma (DLBCL) [66].
3.1.1 Burkitt’s Lymphoma (BL)
The Burkitt Lymphoma (BL) was first described by Denis Burkitt in 1958 as the most
prevalent childhood lymphoma located in the jaws of African children [24]. The BL
accounts for 2% of all lymphomas [109], but in Europe and the United States sporadic
BL is the most prominent childhood NHL accounting for 30% of all NHL cases [201].
There are three different types of BL: The endemic BL, the sporadic BL and the im-
munodeficiency associated BL. The endemic BL is associated with an infection of the
Epstein-Barr-Virus (EBV) and is found in Equatorial Africa. Tumours with the same
characteristics, but not associated with an EBV infection, can be found in many parts
of the world and are called sporadic BL [21, 108]. Sporadic BLs account for 1-2% of all
adult lymphomas in Western Europe and the United States.
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The immunodeficiency BL is associated with an infection of the human immunodefi-
ciency virus (HIV).
Immunophenotype characteristics of BL are high expression levels of CD10 and BCL6.
There is no expression of BCL2 and CD5. The fraction of cells proliferating is at
least 90%, assessed by immunohistochemistry using the proliferation marker protein
Ki67 [43, 73]. Most BL harbor a deregulated c-Myc expression as a consequence of
an IG-MYC translocation. In that case the proto-oncogene MYC is translocated
into one of the immunoglobulin gene loci. The translocated allele of MYC is highly
expressed whereas the normal allele is usually silent. High c-Myc activity can lead to
a high proliferation rate and, in the absence of survival signals, to apoptosis [81]. Rare
BL cases lacking the MYC rearrangement may up-regulate the expression of MYC
by other mechanisms [116]. Recent gene expression studies have shown that typical
BL cases have a characteristic molecular signature [81, 35]. This signature consists
of 58 genes which can be used to calculate a continuous BL-index. Using this index,
one can distinguish between molecular BL (mBL), non-molecular BL (non-mBL) and
intermediate lymphoma [81].
BL is treated with regimens of chemotherapy including cyclophosphamide, vincristine,
doxorubicin and high-dose methotrexate. A monoclonal antibody drug called rituximab
may also be given, usually with chemotherapy. If the disease is not treated, BL is lethal
within several months. Long-term remission can be achieved in approximately 50% of
patients [149, 201].
3.1.2 Diffuse Large B Cell Lymphoma (DLBCL)
Compared to BL which is a quite defined group of lymphomas, Diffuse Large B Cell
Lymphoma (DLBCL) is a heterogeneous disease. DLBCL accounts for 30-40% of all
lymphomas and thus is the most frequent NHL. The morphological differences and the
diversity in clinical presentation and outcome leads to the assumption that DLBCL
comprises several disease entities [55, 109].
Different genetic aberrations are found in DLBCL. A translocation of the proto-oncogene
BCL6 is found in 35% of DLBCL cases. Bcl6 is a transcription repressor and is es-
sential for germinal center formation [41, 58]. In a subgroup of DLBCL cases the
proto-oncogene MYC is translocated into one of the immunoglobulin gene loci [7, 111].
DLBCL show a high aberrant activity of survival signals. One of these signals is the ac-
tivated NF-κB pathway which blocks apoptosis [51, 37]. Furthermore, DLBCL acquire
survival properties by an aberrant activity of the BCR signaling pathway [38].
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There are four major gene expression studies published investigating the heterogeneity
of DLBCL.
Alizadeh and colleagues [2] substratified DLBCLs depending on their similarity to dis-
tinct differentiation stages of normal B cells into ABC-like and GCB-like DLBCLs.
The activated B cell like or ABC-like DLBCLs are similar to activated post GC B
cells, whereas the GC B cell like or GCB-like DLBCLs are similar to B cells during the
germinal center reaction. ABC-like DLBCLs show a high aberrant activity of NF-κB
and have a worse prognosis compared to GCB-like DLBCLs, which are dominated by
abberant BCL6 [2, 168, 112].
Monti and colleagues [134] found three different subtypes of DLBCL: They name them
by expression characteristics as “oxidative phosphorylation”, “B cell receptor/prolifera-
tion” and “host inflammatory response”.
Ci and colleagues [26] used a Bcl6 ChIP-on-Chip assay to obtain 1361 Bcl6 target
genes. They associate the GCB-like DLBCLs [2] and the ”B cell receptor/proliferation”
lymphomas [134] with high Bcl6 activity. Bcl6 target genes were found to be repressed
within these sub groups.
Bentink and colleagues [13] classified aNHL based on oncogene associated patterns,
called gene modules. These gene modules were associated with the oncogenes: MYC,
RAS, SRC, β-catenin and E2F3. They transfected quiescent primary human mam-
mary epithelial cells (HMECs) singly with each of the five human oncogenes and used
a semi-supervised machine learning methodology to generate these modules. They
combined the modules to patterns of oncogene activity called Pathway Activation Pat-
terns (PAPs). DLBCLs can be classified into four different pathway activation patterns
(PAP1-PAP4). All DLBCLs defined as “intermediate” by the mBL index, which could
not be allocated to one of the four major PAPs (PAP1-PAP4), were assigned to a fifth
group, called “molecular individual lymphoma” (mind-L) [81, 13]. It is not yet clear
which pathway activities define the mind-L group [13].
DLBCL tumours are treated with a combination of cyclophosphamide, hydroxydaunoru-
bicin, vincristine and prednisolon (CHOP). Treatment was improved by adding Ritux-
imab, a monoclonal antibody against the B cell specific marker CD20 (R-CHOP).
However 30% of DLBCL patients do not completely respond to the therapy, are resis-
tant to it, or relapse soon after treatment [92, 29].
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3.2 Pathway activities in human transformed GC B cells and
lymphomas
This project was done in cooperation with the group of D. Kube from the department
of Haematology and Oncology, University Medical Center Go¨ttingen. Experiments
were done by A. Schrader. I performed the statistical analysis and evaluation of the
microarray data. Parts of the work are published in Cell Communication and Signaling:
”Global gene expression changes of in vitro stimulated human transformed germinal
center B cells as surrogate for oncogenic pathway activation in individual aggressive B
cell lymphomas“ by A. Schrader, K. Meyer, F. von Bonin, M. Vockerodt, N. Walther,
E. Hand, A. Ulrich, K. Matulewicz, D. Lenze, M. Hummel, A. Kieser, M. Engelke, L.
Trmper, D. Kube [171].
3.2.1 Motivation
The current criteria to distinguish BL from DLBCL, like morphology, immunopheno-
type, and genetic abnormalities, do not allow for a reliably reproducible classification
and the pathological mechanisms behind these criteria are poorly understood [181].
NHL cells proliferate actively and retain many of the immunophenotypic characteris-
tics of B lymphocytes. Nevertheless, they are monoclonal tumour B cells, displaying
characteristic nonrandom chromosomal abnormalities. Resulting from genetic aberra-
tions the expression of tumour suppressor genes or protooncogenes can be deregulated,
leading to a loss of cell growth and proliferation regulation. Cellular genes can be
placed under different control elements and may switch off cellular growth regulation.
In addition, specific combinations of signals for short or long term stimulation are
provided to GC B cells through externally derived signals obtained from cells in the
microenvironment [103, 110]. These include CD40L, BAFF and IL21. Furthermore, B
cell specific activation can be mediated via antigenerecognition or via Toll like receptor
activation by the bacterial component lipopolysaccharide. Theses stimuli are described
in more detail in the following paragraph.
As already mentioned, a recent large-scale gene expression profiling of NHL tumour
samples revealed a molecular definition for BL, by describing a Burkitt specific signa-
ture. This signature was used to model an index of “Burkitt-likeness” (mBL-index)
and can be used to distinguish BL from DLBCL [81, 35].
We ask the question to which extent different pathways are responsible for the differ-
ences in gene expression that distinguish individual DLBCL and DLCBL from BL.
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To get an insight into the cell signaling networks in individual human mature aNHL,
human transformed GC B cells were stimulated with B cell specific stromal stimuli to
identify patterns of gene expression changes.
3.2.2 Stromal signals affecting B cells
In peripheral secondary lymphoid organs B cells encounter foreign antigens. Antigen
stimulated B cells develop to form germinal centers. The micro-environment within
germinal centers not only provides antigen stimulation through the BCR, but addi-
tionally, B cells interact with T cells, macrophages, follicular dendritic and reticular
cells. Signals influencing the development of a B cell can be discriminated into intrinsic
signals, that do not depend on the surrounding micro-environment and paracrine sig-
nals, that are mediated by the micro-environment surrounding the B cell. Important
paracrine signals are mediated by CD40, IL21 and BAFF. Central intrinsic signals in-
clude the engagement of the B cell receptor (BCR) and the Toll like receptors (TLRs).
The TLRs are receptors of the innate immune response which are needed to recognize
non-self molecules [109, 44, 98, 105, 173].
BCR: B cell receptors cluster upon antigen recognition on the surface of a B cell [198].
Here BCRs are activated by αIgM F(ab)2 fragments. These induce the crosslinking and
thereby activation of BCR. The BCR activation triggers a variety of signaling pathways
including calcium signaling, PI3K/AKT, NF-κB and MAPK signals. These signal
transduction pathways, initiated through the BCR, determine the fate of B cells within
a context of BCR affinity to the antigen, expression levels of stimulatory or inhibitory
coreceptors and the differentiation stage of B cells. Activation of the BCR complex
initiates a signaling cascade that confers positive selection, proliferation, apoptosis
or differentiation depending on defined combinations of costimulatory signals. These
costimulatory signals can be intrinsic signals and paracrine signals. GC B cells undergo
apoptosis, if not rescued through germinal center survival signals. (BCR signaling
reviewed by Wang and Clark [193])
LPS: Bacterial lipopolysaccharide (LPS), which is a component of the cell wall of
Gram-negative bacteria, is specifically recognized via Toll like receptor 4 (TLR4). TLR4
belongs to the family of pattern recognition receptors (PRRs). This recognition is part
of the innate immune response [161, 78, 158, 25]. The activation of TLR4 triggers the
activation of NF-κB and MAPK signaling [45, 161, 107].
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It has already been shown that some lymphomas use the constant activation by a
persisting microbial antigen for growth. For example, the chronic infection with He-
licobacter pylori can lead to a chronic gastritis and subsequent to the development of
MALT lymphomas [48, 203]. Furthermore, ABC DLBCLs were found to have highly
recurrent oncogenic mutations affecting MYD88, an adaptor protein that mediates toll
like receptor signaling [143].
CD40: CD40/TNFRSF5 belongs to the family of TNF receptors [119]. It is activated
by using a specific ligand CD40L (called CD154). CD40L is expressed by CD4+ T
helper cells. B cells are stimulated by T helper cells via CD40L [4, 114].
This co-stimulation helps to mediate the positive selection of the right B cell clone
during immune response. CD40 mediates NF-κB and MAPK signals [52, 53, 15, 60]. It
has been shown that CD40 activation can have positive effects on cell survival and cell
proliferation. This includes examples were the CD40 signal rescues BL and DLBCL
cells from apoptosis [173, 3, 79, 153].
IL21: The cytokine Interleukin-21 (IL21) is produced by activated CD4+ T cells and
natural killer (NK) cells [36, 30, 71]. IL21 signals via the IL21R and mediates STAT1
and STAT3 activity. The IL21R receptor can trigger the activation of MAPK and
PI3K/AKT signaling [202, 59]. IL21 is a potent B cell activator and it induces plasma
cells to differentiate [36, 47]. The effect of IL21 stimulation on BLs and DLBCLs has
not been described so far; but it has been shown that follicular lymphoma (FL) highly
express IL21R and that the activation of these cells via IL21 induces apoptosis [1].
BAFF: The B cell activating factor of the TNF family (BAFF also called TNFSF13b or
CD257) is essential for homeostasis of mature B cells. BAFF is expressed by T cells and
macrophages. It can activate distinct TNF receptors which trigger non-canonical NF-
κB and MAPK signaling. (BAFF signaling reviewed by Bossen and Schneider [17].)
An over-expression of BAFF can lead to severe B cell hyperplasia and autoimmune
diseases [129, 100].
In lymphoma sections BAFF and BAFF receptors were detected [166] and seem to be
associated with a bad prognosis for DLBCL patients [145]. Autocrine BAFF signaling
has already been shown for chronic lymphoid leukemia, multiple myeloma, DLBCL and
BL cells [77, 166, 74, 145, 144].
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3.2.3 The effect of stromal signals on BL2 cells
Human transformed germinal center B cells (GC B cells) were used to identify patterns
of gene expression changes in response to B cell specific stromal stimuli. To achieve
in vitro perturbations, BL2 cells were stimulated in triplicates using CD40L, BAFF,
IL21, αIgM F (ab)2 fragments and lipopolysaccharide (LPS). The aim was to assess
ligand specific signal transduction. At the same time the signal had to be strong
enough to be monitored as gene expression change at the whole genome level. Probes of
three independent biological experiments were hybridized to U133 plus 2.0 microarrays.
Gene expression values were obtained by correcting for background and normalizing on
probe level using the variance stabilization method by Huber and colleagues [80]. The
normalized probe intensities were summarized into gene expression levels by using an
additive model [84] fitted by the median polish procedure [187].
3.2.4 Gene expression patterns induced by stromal effects in BL2 indicate
high pathway activation in DLBCL
Identifying global gene expression changes in response to stromal signals in BL2
cells
In order to identify pathway activities differing among aggressive NHL, we stimulated
human transformed GC B cells with five stimuli: αIgM (BCR activation), LPS, CD40L,
IL21 and BAFF. Using linear models implemented in the Bioconductor [64] package
limma [176], I searched for genes showing the highest differential expression in response
to each stimulus. The linear model was defined such that E[yj ] = Xαj , where yj is the
expression data for gene j, X is the design matrix and αj is the vector of coefficients
for each gene j to be estimated .
The design matrix determines how the 8 coefficients are to be estimated. The model
included the different stimulations and two of the three batches (pairs: B1,B2). The
third batch B3 was implicitly modeled, such that B3 is defined by not being B1 or B2.
The contrast βj were computed:
βj = C
T ∗ αj ,
where αj is a vector containing the 8 estimated coefficients and C is the contrast matrix.
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The following design matrix X and contrast matrix C were used:
X =

Crtl CD40 LPS BAFF BCR IL21 B1 B2
Crtl B1 1 0 0 0 0 0 1 0
CD40 B1 0 1 0 0 0 0 1 0
LPS B1 0 0 1 0 0 0 1 0
BAFF B1 0 0 0 1 0 0 1 0
BCR B1 0 0 0 0 1 0 1 0
IL21 B1 0 0 0 0 0 1 1 0
Crtl B2 1 0 0 0 0 0 0 1
CD40 B2 0 1 0 0 0 0 0 1
LPS B2 0 0 1 0 0 0 0 1
BAFF B2 0 0 0 1 0 0 0 1
BCR B2 0 0 0 0 1 0 0 1
IL21 B2 0 0 0 0 0 1 0 1
Crtl B3 1 0 0 0 0 0 0 0
CD40 B3 0 1 0 0 0 0 0 0
LPS B3 0 0 1 0 0 0 0 0
BAFF B3 0 0 0 1 0 0 0 0
BCR B3 0 0 0 0 1 0 0 0
IL21 B3 0 0 0 0 0 1 0 0

C =

CD40 LPS BAFF BCR IL21
Crtl −1 −1 −1 −1 −1
CD40 1 0 0 0 0
LPS 0 1 0 0 0
BAFF 0 0 1 0 0
BCR 0 0 0 1 0
IL21 0 0 0 0 1
B1 0 0 0 0 0
B2 0 0 0 0 0

The analysis resulted in five genelists (for each stimulation one) including significantly
differentially expressed genes. A gene was included in a list if the corresponding co-
efficient βj was significantly different from zero, thus if the p-value (adjusted after
Benjamini Hochberg [12]) was smaller than 0.05.
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Treatment with αIgM F (ab)2 fragments led to differential expression of 6596 genes.
CD40 activation changed the expression of 1194 genes. IL21 stimulation affected 902
genes. LPS stimulation lead to a significant expression change in 283 genes. BAFF
stimulation affected the expression of 129 genes significantly. Expression values of the
top 100 genes with the highest fold change between control samples and stimulations
are shown in the heatmap in Figure 3.1.
Figure 3.1: The top 100 genes showing the highest fold change per stimulation are shown in
the heatmap. The gene expression value are color coded, where yellow is high and blue is low
expression (Rows = BL2 Samples, Columns = Genes)
A gene ontology (GO) analysis of each genelists affected by the in vitro interventions
was performed. Full results can be found in the Appendix (tables A2).
αIgM up-regulated genes are associated with MAP kinase, tyrosine/serine/threonine
phosphatase activity and transmembrane transporter activity. We can summarize the
corresponding biological processes that were affected as regulation of immune responses,
MAP kinase activity, programmed cell death, regulation of metabolic processes or cell
cycle and stress responses.
IL21 activated genes that are enriched in genesets associated with responses to viruses
and cytokine production including type I interferon biosynthetic processes. IL21 up-
regulated genes are enriched in genesets associated with regulation of programmed cell
death, same as αIgM up-regulated genes are. The involvement of IL21 activated genes
on cytokine signaling could explain its relation to IκB kinase/NF-κB cascade and NF-
κB import into nucleus. Furthermore, IL21 affected genes are enriched in genesets
associated with Toll-like receptor pathways, JakSTAT and chemokine signaling path-
ways.
Genes down-regulated by IL21 are enriched in genesets associated with nucleotidyl-
transferase activity, cytoskeletal protein or phospholipid binding and with cell shape,
morphogenesis or chemotaxis.
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Genes activated by BAFF are enriched in genesets associated with metabolic processes
of amino acids and chromatin remodeling. Genes down-regulated by BAFF are en-
riched in genesets associated with lipoprotein metabolic process and protein amino
acid acylation.
The genes up-regulated by CD40L are enriched in genesets associated with the major
histocompatibility complex (MHC) class I receptor activity and hence antigen process-
ing and presentation of peptide antigen, the regulation of membrane potential, small
GTPase mediated signal transduction as well as metabolic processes. In contrast, genes
down-regulated after CD40L intervention are enriched in genesets associated with phos-
pholipase activity and negative regulation of transcription.
Lists of affected genes overlap significantly across stromal stimuli
To investigate whether the stimuli regulate the same genes, I analyzed the global re-
sponses of the stimuli in a pairwise manner using the method compareLists implemented
in the Bioconductor package OrderedList [122].
The genelists for each stimulation were ranked according to the log fold change after
treatment. Pairwise comparisons of the top and bottom ranks of the genelists regulated
by IL21, CD40L, αIgM, BAFF and LPS were plotted (Figure 3.2). It was possible to
observe high similarities between the genelists. The significant overlap can be observed
by the difference between the blue lines, representing the number of overlapping genes
at the respective position of the genelists, and the orange area giving the expected size
of a random overlap. The genelists are additionally compared in reversed order repre-
sented by the green line. When the lists were compared pairwise and in not reversed
order, they all showed a high similarity. Thus, all stimulations regulate the same genes
in the same direction.
The strongest overlap can be seen between the genelists regulated by LPS, BAFF and
CD40L, perhaps reflecting the NF-κB driven gene expression. But this could not be
validated with the GO enrichment results, where only the genelist regulated by IL21
was associated to NF-κB signaling.
A strong overlap for the genelists regulated by IL21 and αIgM can be seen and is re-
flected in the results of the GO analyses. There IL21 and αIgM affected genes enriched
for positive regulation of RNA metabolic processes or immune system processes and
DNA-repair.
83
Chapter 3 Lymphoma
The shared functions of CD40L and αIgM affected genes were for example characterized
by immune response, antigen processing and presentation or positive regulation of B cell
activation, the BMP signaling pathway and phosphate metabolic processes. Thus, the
stimulations of BL2 cells with αIgM, LPS, CD40, IL21 and BAFF all lead to changes in
gene expression. Additionally, it was possible to show that the distinct stimuli influence
common genes.
Next we addressed the question whether the stimulation data leads to a different strat-
ification of patients, revealing that different pathway combinations are active in some
patients and remain inactive in others. We used a dataset published by Hummel and
colleagues [81] including 219 gene expression profiles from different lymphomas. The
authors introduced an index of Burkitt-likeness for mature aggressive B cell lymphomas.
This index reflects how Burkitt-like a sample is and allows classification into molecular
BL (mostly sporadic BL), intermediate lymphoma and non-mBL (mostly diffuse large
B cell lymphoma (DLBCL)).
The top 100 differentially expressed genes per stromal stimulation were transfered to
the hgu133a chip (if possible) and plotted in the heatmap shown in Figure 3.3. The
samples are clustered, using complete linkage. Most mBLs show compared to DLBCLs
a low expression of genes stimulated by the stromal stimuli. Regarding the assignment
of the patients to the ABC-like or the GCB-like subgroup, I could not observe a con-
nection to the shown genesets. The DLBCLs show a continuous pattern but there is no
further stratification possible using these genesets. Thus, it would be better to focus on
genes that are not only regulated by one of the stromal stimuli, but that additionally
stratify DLBCL samples.
x
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Figure 3.2: Pairwise Compare List results: Pairs indicated by the header of the single pictures.
The blue lines represent the number of overlapping genes at the respective position of the
genelists and the orange area gives the expected size of a random overlap. The genelists are
additionally compared in reversed order represented by the green line.
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Figure 3.3: Heatmap of gene expression values of the top 100 regulated genes, after stimulation
with the 5 distinct stimuli, in the 219 lymphoma samples published by Hummel and colleagues
[81]. Samples in each heatmap are ordered differently, by the gene expression of the shown
effected genes. Relative gene expression is encoded with yellow (high expression) and blue
(low expression).
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3.2.5 Identification of activation indices in DLBCL patients that are
unique for a specific stromal stimulus
I used the guided clustering method [131] to identify genes that are specific for one of
the five stromal stimuli and additionally stratify the DLBCLs in the dataset of Hummel
and colleagues [81].
Guided clustering searches for clusters of genes that are highly correlated with a binary
vector within the guided data and that show a high correlation structure within the
patient data. I used this method five times, once for each stimulation (CD40L, BCR
(αIgM), IL21, LPS and BAFF). As guiding data I used the stimulated BL2 cellline
data, which was correlated to a binary vector that changed per guided clustering run.
Within that binary vector, the samples belonging to one of the stimuli were labeled
with 1, and the other stimulations, as well as the controls, were labeled with 0, making
sure that index genes were only regulated by one of the five stimuli.
To find genesets that show differences within the DLBCL samples and not only between
the DLBCL samples and the mBL samples, the patient data was reduced to the Myc
negative DLBCL cases, thus, excluding all mBLs and all the samples that showed a
Myc break of some kind.
For each stimulation I extracted up to three clusters depending on their direction and
the amount of genes included, ensuring to get at least two clusters which were regulated
in different directions. For example the IL21.1 cluster genes are down-regulated after
IL21 stimulation, whereas the IL21.2 cluster genes are up-regulated upon stimulation.
But there is a trade-off between uniqueness (correlation on the guided data) and the
correlation structure on the patient data. Hence there are some genes included that are
not uniquely and/or not so strongly regulated by one of the stromal stimuli but show
higher correlations on the patient data. The genelists of the different clusters can be
found in the appendix (tables A3).
The retrieved gene clusters are shown in the heatmap plotted in Figure 3.5. All iden-
tified clusters are of different size and are only regulated by one of the specific stromal
stimuli.
To visualize and to interpret the expression of the different genesets across patients,
guided clustering [131] returns an index reflecting the activity of the pathway activated
by the corresponding stromal stimulus. I recalculated the index on all 219 lymphoma
samples, including mBL samples and all samples with Myc translocation previously
excluded. To calculate the indices I used the method described in Section 1.1.
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Thus, I received one index vector per gene cluster. These indices represent the activity
of the corresponding pathway.
Next I compared the activity of the pathways, activated by the different stromal stimuli
across patients by plotting a pairwise scatter plot of the indices (Figure 3.4). There
are many indices highly correlated within the patients. This implies that the genes are
similarly regulated within the patients and yield the same stratification. Looking at
the scatter plot in Figure 3.4 there are two main groups of highly correlated indices.
Group 1 includes the indices belonging to cluster IL21.1, BCR.1, BCR.2, CD40.1 and
BAFF.1 (Text color green in Figure 3.4). The second group includes CD40.2, CD40.3,
LPS.1, LPS.2 and BAFF.2 (text color blue in Figure 3.4). An exception is the index
of IL21.2 (text color black in Figure 3.4) which is not correlated to any of the other
indices. Thus, two different main effects within the patients driven by the five stimuli
can be observed.
x
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Figure 3.4: Pairwise scatter plot of indices calculated on unique gene clusters. Text color
shows correlated groups of indices. The arrow within the first box in each row indicates if
these cluster genes were up or down-regulated after stimulation with the respective stimuli.
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Figure 3.5: Gene expression of the different cluster genes found by guided clustering. The data
shown was used as guiding data. Genes are ordered according to their belonging cluster which
was found by guided clustering. Samples are ordered according to stimulation. Relative gene
expression is encoded with yellow (high expression) and blue (low expression).
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Indices hold independent prognostic information in DLBCLs
I asked the question, whether the indices hold prognostic information. I used multi-
variate linear Cox regression to model survival of DLBCL patients. For a subset of 104
DLBCL patients, the complete clinical data was available. Other prognostic factors,
already known, were taken into account as confounding factors and were included in
the Cox model. These confounding factors were the age of the patients (AGE), the
stage of the disease (Ann Arbor stage, AAS) and the lymphoma definition as ABC- or
GCB-like (GCB). For each index one Cox model was computed, including the corre-
sponding index as continuous variable.
The Cox models were defined as follows:
h(t) = h0(t)× exp(b1 GCB + b2 AAS + b3 AGE + b4 INDEX),
where the hazard function h(t) is determined by the baseline hazard h0 and a set of 4
covariates: GCB,AAS,AGE, INDEX.
The aim of the analysis was to estimate the 4 coefficients bi (i = 1, . . . , 4) for the 4
covariates (GCB,AAS, . . . , INDEX). The 4 covariates act as factors on the hazard h(t)
at any time point t. Thus the hazard of the event in any group was a constant multiple
of the hazard in any other group. This proportionality implies that the quantities
exp(bi) can be called hazard ratios [20]. I used the coxph function provided by the
R-package survival, which fits the Cox proportional hazards regression model.
The fitted Cox model including the BAFF.2 index is returned by the coxph function in
the following way:
Call:
coxph(formula = surv.obj ~ as.factor(AAS) + GCB + AGE + IndexBAFF2)
coef exp(coef) se(coef) z Pr(>|z|)
AASII 1.20827 3.34768 0.60507 1.997 0.0458 *
AASIII 1.49588 4.46325 0.58270 2.567 0.0103 *
AASIV 1.14474 3.14163 0.66990 1.709 0.0875 .
GCB -0.29737 0.74277 0.36923 -0.805 0.4206
AGE 0.05533 1.05689 0.01421 3.894 9.88e-05 ***
IndexBAFF2 -3.58501 0.02774 1.69722 -2.112 0.0347 *
---
Signif. codes: 0 ’***’ 0.001 ’**’ 0.01 ’*’ 0.05 ’.’ 0.1 ’ ’ 1
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The coef column includes the estimated coefficients bi (i = 1, . . . , 4). The exp(coef)
column, where coef are the bi (i = 1, . . . , 4), includes the estimated hazard ratios. We
can see, that the Ann Arbor stages (AAS) and AGE have coefficients greater than zero,
thus if the AAS is higher, or if the AGE increases, the event hazard increases and thus
the length of survival decreases.
In contrast to that, the estimated coefficients for GCB and IndexBAFF2 are smaller
than zero, thus, a GCB expression type or a low IndexBAFF2 value is associated
with a better prognosis. The z column includes values that were calculated by dividing
the estimated coefficients (coef) by their corresponding standard error se(coef). It is
tested if these z values are significantly different from zero, yielding the p-values given
in the column PR(> |z|).
The fitted cox models using the function coxph including the BCR.2 index can be seen
here:
Call:
coxph(formula = surv.obj ~ as.factor(AAS) + GCB + AGE + IndexBCR2)
coef exp(coef) se(coef) z Pr(>|z|)
AASII 1.43033 4.18010 0.62227 2.299 0.02153 *
AASIII 1.59093 4.90830 0.58511 2.719 0.00655 **
AASIV 1.38878 4.00996 0.65252 2.128 0.03331 *
GCB -0.26716 0.76555 0.37214 -0.718 0.47282
AGE 0.05504 1.05658 0.01377 3.998 6.39e-05 ***
IndexBCR2 -2.41835 0.08907 0.95973 -2.520 0.01174 *
---
Signif. codes: 0 ’***’ 0.001 ’**’ 0.01 ’*’ 0.05 ’.’ 0.1 ’ ’ 1
As expected, the influence of the covariate AAS, GCB and AGE on survival did not
change. The estimated coefficient for IndexBCR2 is smaller than zero, thus a lower
IndexBCR2 value is associated with a better prognosis. The two indices BAFF.2 and
BCR.2 hold significant prognostic information, with p values (PR(> |z|)) smaller than
0.05.
In Figure 3.6 Kaplan-Meier curves for the two prognostic indices are shown. For the
Kaplan-Meier curves the patients were grouped by index value into two groups. The
first group comprised all patients with an index, smaller than the median index over
all patients, and the second group, comprised all patients showing a higher index.
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(a) (b)
Figure 3.6: Kaplan-Meier estimates of survival using the (a) BAFF.2 Index and (b) BCR.2
Index. DLBCL patients are grouped by index value. (Sample-index smaller than the median
or bigger than that).
Thus, the indices BAFF.2 and BCR.2 are of prognostic relevance for DLBCL patients.
GCB-like lymphomas are characterized by unbalanced BCR and CD40 signaling
Alizadeh and colleagues [2] sub-stratified DLBCLs depending on their similarity with
normal cells in different differentiation stages of B cells into ABC-like and GCB-like
DLBCLs. The ABC-like DLBCLs show a high aberrant activity of NF-κB and have a
worse prognosis compared to GCB-like DLBCLs. I checked if it is possible to associate
my indices with the two types of DLBCLs. The expression of the different target
genes does not seem to characterize ABC-like or GCB-like lymphomas on their own.
However, the difference of the two indices BCR.2 and CD40.1 (BCR.2-CD40.1) does
(Figure 3.7).
To investigate whether the difference seen in the scatter plot (Figure 3.7 (a)) is a
significant result, I combined the information given by the indices BCR.2 and CD40.1
by substracting the CD40.1 index from the BCR.2 index yielding a new combined
index.
By analyzing the “joint” activity of these genesets in DLBCL patient samples, I found
that there is a significant (t-test: p value leq0.05) difference between ABC-like DLBCL
and GCB-like DLBCL. Thus, GCB-like lymphomas are associated with unbalanced
BCR/CD40 signaling.
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(a) (b)
Figure 3.7: (a) Scatterplot of BCR.2 index plotted against the CD40.1 index. The orange circles
are ABC-like lyphomas the blue ones are GCB-like lymphomas and the grey ones were not
classified as such (b) Boxplot of the combined index, calculated by substracting the CD40.1
index from the BCR.2 index (BCR.2 − CD40.1). A t-test was used to test if the difference
between the two groups is significant yielding a p value of 1.385e− 08.
High c-Myc activity is associated with a low BCR.1 index
In Burkitt lymphoma (BL) aberrant c-Myc activity results from IG-MYC translocations
[109]. However, MYC aberrations also occur in DLBCLs and have a negative prognostic
impact [170]. Schrader and colleagues developed a “c-Myc index” which reflects the
expression of c-Myc responsive genes and thereby the activity of c-Myc [170]. As
expected, the “c-Myc index” is high in mBLs [170].
To see if we can link the c-Myc activity to one of our previously identified unique gene
indices and thus to respective pathways, we compared the c-Myc index to our indices
using 219 aNHL cases [81]. I found that the BCR.1 index is negatively correlated to
the c-Myc index, with a Pearson correlation coefficient of −0.76 (Figure 3.8).
Lymphomas that exhibit high c-Myc activity are associated with a high expression
of the genes included in the BCR.1 geneset, which are down-regulated upon BCR ac-
tivation. The mBL cases show a high c-Myc index, as expected, and a low BCR.1 index.
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However, this correlation can also be seen in the DLBCL cases. DLBCL cases that
show a low c-Myc index have a high BCR.1 index and vice versa.
The results indicate a connection between c-Myc activity and the expression of the
BCR.1 geneset. One possible explanation for the strong negative correlation could be
that BCR.1 genes are regulated directly or indirectly through c-Myc. To get an idea of
the function of these genes, a gene ontology (GO) analysis of the BCR.1 genelist was
done.
The BCR.1 genes were enriched in genesets associated with cell cycle. The genes down
regulated after BCR activation were enriched in genesets associated with ”M phase of
mitotic cell cycle” (GO:0000087), ”cell cycle” (GO:0007049) , ”M phase” (GO:0000279)
and ”cell cycle process” (GO:0022402). Thus, the differences of BCR.1 index in aNHL
could explain the differences of growth behavior differences in aNHL.
Figure 3.8: Scatterplot of the BCR.1 index plotted against the c-Myc index of 119 aNHL cases
[81]. Circle colors represent molecular diagnosis: Red= mBL, green= non-mBL and yellow=
intermediate
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Discussion
We identified patterns of gene expression changes in response to LPS, IL21, BAFF,
CD40L stimulation and αIgM crosslink and mapped them to expression profiles of
lymphoma samples. It was possible to show that the distinct stimuli influence common
genes and DLBCLs show a continuous pattern of gene module activity, whereas the
mBLs show in general a lower pathway activation than DLBCLs. The identification of
gene clusters regulated by the stromal stimuli offers new opportunities for the analysis
of aberrant signaling in lymphomas.
We used guided clustering to identify genesets uniquely regulated by one of the five
stimuli. From these regulated genesets we built indices on aNHL patients to summarize
the corresponding pathway activity across patients. We revealed two different effects
within the aNHL that hold prognostic information.
Furthermore, we found that the c-Myc index is negatively correlated to the newly iden-
tified BCR regulated gene cluster (BCR.1). One explanation for that could be that
BCR.1 genes are regulated directly or indirectly via c-Myc. Furthermore, the expres-
sion of the BCR.1 geneset could be linked to differences in aNHL and to genesets mainly
associated with the cell cycle. Further experiments are necessary to clarify the influence
of BCR signalling on the growth of aNHLs.
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3.3 Aberrant Lymphocyte enhancer binding factor 1
expression is characteristic for sporadic Burkitt lymphoma
compared to Diffuse Large B cell Lymphomas
This project was done in cooperation with the group of Dieter Kube from the depart-
ment of Haematology and Oncology, University Medical Center Go¨ttingen. Most exper-
iments were done by Antje Ulrich. I performed the statistical analysis and evaluation of
the microarray data. Parts of the work are already published: “Aberrant Lymphocyte
Enhancer-binding Factor 1 expression is characteristic for sporadic Burkitt lymphoma”
by A. Ulrich, N. Walther, F. von Bonin, W. Klapper, K. Meyer, A. Schrader, M.
Vockerodt, R. Spang, T. Pukrop, P. Murray,L. Trmper, D. Kube in The American
Journal of Pathology [190].
BL is a highly malignant aNHL consisting of rapidly proliferating B cells [81, 102]. A
characteristic feature of BL is a translocation of the MYC gene locus to one of the three
IG gene loci [81, 102]. A recent large-scale gene expression profiling study introduced
an index of Burkitt-likeness for mature aggressive B cell lymphomas [81]. Lymphocyte
enhancer-binding factor 1 (LEF1) is one of 58 genes defining the Burkitt index.
LEF1 was first identified in T-lymphocytes. It is a member of the LEF/TCF fam-
ily of transcription factors [185, 194]. LEF1-deficient mice exhibit defects in Wnt3a
dependent pro-B cell proliferation and survival [164]. LEF1 is a central mediator of
Wnt signaling. The Wnt pathway is important in cell development and differentiation
(reviewed in [120, 28]). In immune cells the canonical Wnt signaling pathway regulates
not only early steps of B cell development but also self renewal of hematopoietic stem
cells [177].
The classical view is that upon binding of canonical Wnt ligands to corresponding re-
ceptors cytoplasmic β-catenin gets stabilized. It translocates into the nucleus and there
it binds LEF/TCFs acting as a matrix for transcriptional coregulators of Wnt target
genes. It is thought that LEF/TCF proteins do not independently activate target genes
[65]. However, in BL and DLBCL no β-catenin was observed in the nucleus [67, 136].
LEF1 may not function in BLs in the classical way. This hypothesis is in line with
growing evidence that LEF1 can also functionally interact with other proteins in the
absence of β-catenin [34, 23].
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In a number of hematopoietic neoplasia the activity of the Wnt pathway or its com-
ponents, including LEF1, are dysregulated. This is supported by observations in B
cell chronic or acute lymphatic leukemia (CLL/ALL) or in subsets of mantle cell lym-
phoma (MCL) and T cell leukemias as well as in certain celllines and mouse models
[67, 150, 162, 200, 191, 167, 118, 46, 63, 139, 70, 126].
Nevertheless, detailed mechanisms are unclear. Studies on Wnt signaling in immune
cells support the notion that the canonical Wnt signaling pathway regulates early B cell
development [177] and not only self renewal of hematopoetic stem cells. LEF1-deficient
mice exhibit defects in Wnt3a dependent pro-B cell proliferation and survival [164]. It
is proposed that LEF1 expression is lost in peripheral B lineage cells. Nevertheless,
a deregulation of LEF1 in mature B cells is supported by the observation of aberrant
LEF1 expression in CLL.
Additionally, Qiang and colleagues found LEF1 expression in BL celllines [162, 67, 126,
70, 69].
Furthermore, in murine hematopoetic stem cells retrovirally transduced with a consti-
tutive active LEF1 variant (fusion of β-catenin with LEF1) B-ALL and acute myeloid
leukemia (AML) were observed [150]. LEF1-induced AMLs were characterized by im-
munoglobulin DH-JH rearrangements and expression of lymphoid and myeloid regu-
latory factors. The IG-gene rearrangements shown suggest that LEF1 induced AML
was propagated by a leukemic stem cell with lymphoid characteristics. Thus LEF1
can be involved in defining leukocyte plasticity supporting the hypothesis that lym-
phomas of B cell origin may be characterized by reexpression of early markers in B cell
differentiation providing B cell plasiticity during transformation [132].
We show that LEF1 expression is characteristic for BL in comparison to DLBCL.
Aberrant LEF1 expression is involved in proliferation of BL cells. Using whole genome
expression analysis new LEF1 target genes in lymphoma cells are identified. The joint
expression of newly identified LEF1 target genes is a surrogate for the regulatory ac-
tivity of LEF1 in individual lymphomas.
3.3.1 Data
127 B cell lymphoma specimens were obtained from the files of the Lymph Node Reg-
istry Kiel according to ethical approval. All lymphomas were classified according to
the WHO classification using standard histological, immunohistochemical and molecu-
lar criteria [181].
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In addition, 20 specimens obtained within the framework of the network project Molec-
ular Mechanisms in malignant Lymphoma (MMML) were analysed. The latter cohort
was diagnosed and classified based on molecular signatures [81]. All five lymphomas
were analysed using tissue-micro-arrays (TMA) containing two cores of 1 mm or 0.6
mm (for the MMML specimen) for each case (ethical approval Ref. Nr. 1/1/05).
For gene expression analysis, RNA from BL2 cells was isolated after LEF1 specific RNA
interference from three independent experiments. Fragmentation and hybridization of
labeled anti sense RNA on Human Genome U133A 2.0 plus Arrays (Affymetrix) was
performed according to manufacturers recommendations by the “Kompetenzzentrum
fu¨r Fluoreszente Bioanalytik, Regensburg”.
Gene expression values were obtained by first removing the background and normalizing
on probe level using the variance stabilization method by Huber and colleagues [80].
The normalized probe intensities were summarized into gene expression levels by using
an additive model [84] fitted by the median polish procedure [187].
3.3.2 LEF1 is aberrantly expressed in BL cells
In order to show aberrant expression of LEF1 in BL cells various experiments were
conducted. A representative panel of B cell derived tumours, primary normal GC B cells
and different celllines, were screened for LEF1 expression. Immunohistochemical (IHC)
analysis revealed that strong LEF1 expression found in interfollicular areas of reactive
lymph nodes, tonsils or spleen is restricted to CD3 positive T cells. A corresponding
example of LEF1 staining in normal reactive tonsillar tissue sections can be seen in
Figure 3.9 I and II. AB cells were devoid of detectable nuclear LEF1 expression.
The 127 lymphomas analysed by IHC were of B cell origin and 99 were classified as
NHL. These samples included 10 BL and 31 DLBCL cases. In total, 22 tumours were
found to show LEF1 expression. Due to insufficient staining (missing internal positive
controls) two of the ten BL samples were not evaluable. Five of the remaining eight
BL samples (63%) expressed nuclear LEF1 (Figure 3.9 III). Notably, LEF1 was found
frequently in BL, which are known to be devoid of nuclear β-catenin [67, 136]. Only 1
of the 31 DLBCL (3%) was found to be positive for LEF1 expression (Figure 3.9 IV).
All B-CLL (n = 6) and B-ALL (n = 6) showed nuclear LEF1 expression. No LEF1
expression was detected in mantle cell (MC), marginal zone or follicular lymphoma.
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LEF1 expression was investigated in different lymphoma celllines. Immunoblot analysis
revealed that 7/7 BL lines display increased LEF1 expression, while DLBCL and MCL
celllines show weak or no LEF1 expression. qRT-PCR confirmed stronger expression of
LEF1 in BLs compared to DLBCL cells. No mutations could be detected for LEF1 in
BL or HL cells analysed. A 3‘-RACE was performed to detect variations in the usage of
full length LEF1. Sequencing of cDNAs showed that in BL2 cells different 3‘-variations
can be detected: full length LEF1 with and without exon 6 and corresponding variants
with a truncation of exon 11.
Since in BL and DLBCL tissue no β-catenin was observed in the nucleus [67, 136], we
tested whether celllines express β-catenin. Immunoblot analysis showed weak to no
expression of β-catenin. Only DLBCL cells OCI-Ly3 were positive for β-catenin when
compared to SW480 cells.
Taken together, LEF1 is aberrantly expressed in BL cells.
Figure 3.9: Representative examples of lymphoma precursor cells and lymphomas stained for
LEF1. (I) Detection of LEF1 (brown) in the follical mantle of a germinal center in normal
reactive tonsillar tissue sections, (II) CD3 positive T cells (green) express LEF1 (red) obtained
from normal tonsil tissue (merged picture including DAPI for nuclear counterstain). (III) BL
(IV) DLBCL
3.3.3 Identifying LEF1 target genes in BL cells
Next, transient siRNA-mediated knockdown of LEF1 in BL2, BL30, BL70 and Ramos
cells was performed. Four independent siRNAs directed towards different exons were
used in a pooled assay. LEF1 knockdown was confirmed by qRT-PCR and immunoblot
(Figure 3.10 (A) and (B)).
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To identify LEF1 target genes, RNA from BL2 cells was isolated after LEF1 specific
RNA interference from three independent experiments and hybridized to U133 plus2.0
whole genome expression microarrays. I computed a list of differentially expressed
genes between the expression profiles of perturbed and control celllines by using linear
models implemented in the Bioconductor [64] package limma [176].
The linear model used was:
E[yj ] = Xαj ,
where yj is the expression data for gene j, X is the design matrix and αj is the vector
of coefficients for each gene j to be estimated.
The following design matrix X and contrast matrix C were used:
X =

Control LEF1 B1 B2
Scrb B1 1 0 1 0
LEF1 B1 0 1 1 0
Scrb B2 1 0 0 1
LEF1 B2 0 1 0 1
Scrb B3 1 0 0 0
LEF1 B3 0 1 0 0

C =

Control-LEF1
Control 1
LEF1 −1
B1 0
B2 0

The design matrix determines how the 4 coefficients are to be estimated. The model
took the treatment (LEF1 = siRNA-mediated knockdown of LEF1, controls)and the
different batches B1, B2 and B3 into account. The third batch B3 was implicitly
modeled, in a way that being batch B3 is determined by not being batch B1 or B2.
The contrasts βj were computed as follows:
βj = C
T ∗ αj ,
where αj is a vector containing the 4 estimated coefficients and C is the contrast ma-
trix. The result was a list of differentially expressed genes between control samples and
samples with siRNA-mediated knockdown of LEF1. In the list 1453 genes were found
to be significantly differentially expressed having a p value (adjusted after Benjamini
and Hochberg [12]) smaller than 0.01. The top 100 genes were plotted in a heatmap
shown in Figure 3.10.
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These LEF1 targets genes are involved in gene regulation (HIST1H2BK, H2AFV,
STAT2, ID1), cell signaling (BMPR2, CCDC88C, PRKAR1A, ITGB1), cell prolifera-
tion (CDC27, UBE2H, PSAT1, SATB1), regulation of metabolism (CTSH, ATP2B4,
MAN1A1) and antigen presentation (HLADMB, FcRL3). Others are involved in B cell
interaction with T cells (CD86), tumour progression (ARL6IP5, PSAT1, CTDSPL),
and B cell differentiation (PBXIP1).
Genes down-regulated in cells with reduced LEF1 levels are LEF1 activated (positive
regulated), whereas genes, that are up-regulated upon LEF1 knockdown are inhibited
(negative regulated) by LEF1. Thus, for example, the expression of the genes for
ARL6IP5, SATB1, STAT2, CCDC88C or CD86 is increased, whereas the expression of
the genes CDC27, CTDSPL or PSAT1 is lower, when LEF1 expression is reduced by
RNAi.
A set of LEF1 regulated genes was validated by qRT-PCR in BL2 and Ramos celllines,
and showed a good agreement with the microarray data. In Ramos cells the effect was
not obvious for STAT2 and CTDSPL. CD86 was not detectable in control siRNA
transfected BL2 cells, but was expressed at low levels after LEF1 knockdown. Simi-
larly, SATB1 is absent in Ramos cells, but appears after LEF1 silencing. Interestingly,
expression of TCF1 or c-Myc was not affected.
Figure 3.10: (A) Immunoblot analysis of LEF1 expression in Ramos, BL30, BL70 and BL2
lymphoma celllines after RNAi mediated knockdown of LEF1 (B) qRT-PCR analysis of the
expression of LEF1 in lymphoma cells after RNAi mediated knockdown of LEF1. (C) Heatmap
of LEF1 top 100 affected genes from RNAi mediated knockdown of LEF1 in BL2 cells. Each
row in the heatmaps represents a microarray sample and each column represents a gene. Yellow
and blue indicate high and low expression.
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I ranked the list of differentially expressed genes by fold change and used geneset
enrichment analysis (GSEA) [180] to detect functionally characterized genesets that
are enriched at either end of the LEF1 target genelist.
Six genesets associated with cell cycle regulation were significantly enriched among
LEF1 inducible genes, for one of the six genesets the enrichment plot is shown in Figure
3.11 (a). Most importantly, among LEF1 inducible genes a significant enrichment of
genes that are up-regulated in tumour cells relative to matching normal tissue cells
across many tumour entities [165] was observed.
Enrichment plots are shown in Figure 3.11. The results suggest that LEF1 target genes
represent essential transcriptional features of neoplastic transformation.
(a) (b)
Figure 3.11: Example from geneset enrichment analysis of LEF1 affected genes. Enrichment
plot from SERUM FIBROBLAST CELLCYCLE (a) and CANCER UNDIFFERENTIATED
META UP (b) including the profile of the running ES Score and positions of geneset members
on the rank ordered list.
3.3.4 LEF1 knockdown affects BL cell proliferation
Based on the enrichment of cell cycle regulators among LEF1 target genes, the effects
of LEF1 silencing were assessed by cell cycle analysis, DNA synthesis experiments for
proliferation and MTT assays for cell viability. DNA synthesis of cultured BL cells was
monitored by 3H-thymidine.
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Transient LEF1 knockdown in BL2 cells resulted in a marked inhibition of cell prolif-
eration of about 40% when compared to control while cell viability was affected only
by about 10%. Similar effects (10− 20% reduction) were observed for Ramos, BL30 or
BL70 cells in the absence of cell viability changes.
Additionally, the reduced expression of LEF1 in BL cells induces arrest at the G1 phase
of the cell cycle. Increased numbers of cells in G1 phase were consistently observed in
BL2, BL70, BL30 and Ramos cells, but were more pronounced in BL2 cells than in
Ramos, BL70 and BL30 cells.
3.3.5 LEF1 target genes are affected by β-catenin and Wnt signaling
I evaluated the effect of canonical Wnt-signaling onto the newly identified LEF1 target
genes. BL2 cells were transfected with a plasmid expressing constitutive β-catenin (β-
cateninS32A) or an empty vector as control. Additionally, BL2 cells were stimulated
by Wnt3a. Using linear models implemented in the Bioconductor [64] package limma
[176], I searched for genes that are differentially expressed.
The linear model used was:
E[yj ] = Xαj ,
where yj is the expression data for gene j, X is the design matrix and αj is the vector
of coefficients for each gene j to be estimated.
The following design matrix X and contrast matrix C were used:
X =

Control Wnt3a BetaCat B1 B2
Scrb B1 1 0 0 1 0
Wnt3a B1 0 1 0 1 0
BetaCat B1 0 0 1 1 0
Scrb B2 1 0 0 0 1
Wnt3a B2 0 1 0 0 1
BetaCat B2 0 0 1 0 1
Scrb B3 1 0 0 0 0
Wnt3a B3 0 1 0 0 0
BetaCat B3 0 0 1 0 0

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C =

Control-Wnt3a Control-BetaCat
Control −1 −1
Wnt3a 1 0
BetaCat 0 1
B1 0 0
B2 0 0

The design matrix determines how the 5 coefficients are to be estimated. The model
took the treatments (Wnt3a =stimulation with Wnt3a, BetaCat = ectopic expression
of β-catenin, controls) and the batches B1, B2 and B3 into account. The third batch
B3 was implicitly modeled, in a way that being batch B3 is determined by not being
batch B1 or B2.
The contrast βj were computed as follows:
βj = C
T ∗ αj ,
where αj is a vector containing the estimated coefficients and C is the given contrast
matrix. Two lists of differentially expressed genes were generated: One after stimulation
with Wnt3a and one after ectopic expression of β-catenin.
I ranked the two lists by fold change between controls and interventions. Next I used
the method compareLists implemented in the Bioconductor package OrderedList [122]
to quantify the similarity between the LEF1 target genelist (sorted in the same way)
and the two newly generated genelists.
Comparisons of the top and bottom ranks of the genelists regulated by LEF1, Wnt3a
and β-catenin were plotted (Figure 3.12). Genes up-regulated by LEF1 knockdown
showed a significant overlap with genes down-regulated by β-cateninS32A and vice
versa (Figure 3.12 a). A similar relation was observed for the Wnt3a stimulation
(Figure 3.12 b).
The significant overlap can be observed by the difference between the green lines, rep-
resenting the number of overlapping genes at the respective position of the genelists
and the orange area giving the expected size of a random overlap. Thus, on global level
LEF1 target genes are also affected by Wnt3a and β-catenin signals in the respective
direction.
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(a) (b)
Figure 3.12: CompareLists Results: Comparison of the ranked genelist of the LEF1 knockdown
experiment, (a) to the genelist affected by ectopic β-cateninS32A expression and (b) to the
genelist resulting of a Wnt3a stimulation. The genelist after LEF1 knockdown was reversed
to match the over-expression / stimulation contexts. The y-axis gives the number of genes
included in the top n-genes (x-axis) of both genelists. The green line gives the overlap of the
two genelists at each rank, where the order of one genelists was reversed. The orange line gives
the expected size of a random overlap, and the vertical orange lines indicate 95% probability
intervals of random overlaps.
3.3.6 LEF1 activity is higher in mBLs compared to DLBCLs
To further prove the functional relevance of LEF1 target genes identified in vitro, we
investigated if the top 100 LEF1 target genes are also expressed preferentially in pri-
mary BL samples. Furthermore, we wanted to know if this LEF1 activity defines a
group of genes of diagnostic relevance and can be used to discriminate subgroups of
aggressive NHL. The expression of the top ranking LEF1 targets were combined to an
index of LEF1 activity. From the top 100 LEF1 target genes, 68 genes were present on
the Affymetrix HG-U133A gene chip and were used for the index. The gene expression
values of theses 68 genes were condensed into an index of LEF1 target expression using
the method getIndex explained in Section 1.1. This index quantitatively assesses to
which degree an individual lymphoma expresses LEF1 target genes.
Lymphomas with a high LEF1 index showed more evidence of aberrant LEF1 activity
than those with a low index. Genes activated by LEF1 were highest in mBL cases, low
in non-mBLs and in between in those defined as intermediate lymphoma (Figure 3.13).
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For those LEF1 target genes identified as suppressed by LEF1 an inverse correlation was
observed (Figure 3.13). The expression of LEF1 target genes used to build the LEF1
index can be seen in Figure 3.14 showing the 219 lymphomas in a heatmap. Genes are
split into activated or suppressed target genes of LEF1. Samples are sorted according
to the LEF1 index. Thus, the combination of LEF1 target genes with large scale gene
expression data from lymphoma patients enables us to measure the LEF1 activity in
lymphoma subtypes. LEF1 activity is higher in BLs compared to DLBCLs.
Figure 3.13: Boxplots of the LEF1 target gene expression index across mBL, intermediate and
non-mBL lymphomas (Patient numbers: mBL=44, intermediates=48, non-mBLs=127). The
index is once calculated for the target genes activated by LEF and once for the genes inhibited
by LEF.
Figure 3.14: The heatmap shows the expression of LEF1 targets (rows) across 219 lymphoma
samples (columns). Target genes are grouped into LEF1 activated (blue bar above) and LEF1
inhibited (yellow bar above) genes. Lymphoma samples are sorted by the LEF1 index. The
color bar on top of the heatmap marks mBL in red, non-mBL in green and intermediate
lymphoma in grey. Colors of the heatmap indicate strength of expression: Yellow high and
blue low expression.
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3.3.7 Discussion
The distinction of subgroups of mature aggressive B cell lymphomas and the under-
standing of the molecular events leading to different subgroups is an important prereq-
uisite to further improve personalized treatment and to detoxify current chemotherapy
strategies. LEF1 could be one new candidate for treatment in BL. In contrast to DLB-
CLs, nuclear LEF1 expression is detectable in the majority (63%) of analysed BL. Since
normal GC B cells are negative for LEF1 the expression of LEF1 in BLs is aberrant. By
combining LEF1 target genes identified in BL celllines with large scale gene expression
data from lymphoma patients, it was possible to establish a LEF1 expression index that
reflects LEF1 activity. These observations further support the importance of molecular
stratifications of lymphomas.
LEF1 expression is involved in cell proliferation and cell cycle control of BL celllines.
The joint expression of LEF1 target genes as a surrogate for the regulatory activity
of LEF1 in primary BLs supports its role in cell proliferation and cell cycle. GSEA
revealed an enrichment of cell cycle regulators affected by LEF1 knockdown in BL cel-
llines. Thus, it is tempting to speculate that LEF1 is involved in a higher proliferative
rate observed in BLs compared to DLBCLs. Thus LEF1 contributes to the biology of
BLs but not DLBCLs [81, 101, 35].
Whether LEF1 acts as a cofactor for c-Myc affecting cell proliferation and cell cycle
progression is not yet clear. Under our experimental conditions, LEF1 affects c-Myc
expression only at low levels.
In addition, the LEF1 index can now be used to compare LEF1 activity in ALL or CLL
patients. The aberrant expression of LEF1 in ALL or CLL is stronger compared to BLs
and most probably depends on β-catenin [126, 97, 146, 178]. Interestingly the modern
therapeutic concepts to treat BLs are closer to that of ALLs as that for DLBCLs [95].
It should be discussed if the application of LEF1 specific inhibitors should be integrated
into respective protocols. However, so far small molecule inhibitors often lack precise
specificity and those published so far still need approval [62, 125].
The comparison of LEF1 target genes with those from β-cateninS32A/Wnt3a inter-
vened BL cells showed a significant target gene overlap (Figure 3.12). This suggests
that canonical Wnt signals further enhance pre-existing transcriptional activities of
LEF1 in BL cells.
Nevertheless, in BL and DLBCL tissue no β-catenin was observed in the nucleus sug-
gesting β-catenin independent LEF1 activity [67, 136].
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This is supported to some extend by immunoblot analysis that showed weak to no
expression of β-catenin in BL and most DLBCL celllines (data not shown). Whether
this weak β-catenin expression could be involved in aberrant LEF1 activity needs to
be further evaluated.
Furthermore, it would be interesting to analyse other potential binding partners of
LEF1 and the effect of Epstein-Barr virus in endemic BLs onto LEF1 and Wnt signaling
[136, 34, 23, 89].
In conclusion, the findings demonstrate aberrant LEF1 expression in sporadic BL.
Thus, the current study has potential clinical implications for patients with aggressive
lymphoma by describing new LEF1 target genes, which now should be investigated
further and evaluated as potentially therapeutic targets.
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Table A1: Sample-Name information
Overview of tumor samples used for microarray experiments. Tumors developed upon
transplantation of p53-deficient postnatal neural stem/progenitor cells over-expressing
different gene combinations.
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Figure A1: TGFβ induced SMAD2 phosphorylation
SMAD2 phosphorylation after incubation with TGFβ 1 and 2 (10 ng/ml) for 0, 10,
30, and 60 min was analyzed by immunoblotting. Beta-actin was included as loading
control. (Figure taken from publication by Beier et al [9].)
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CSC subtypes and TGFβ
Figure A2: Responsiveness to TGFβ in proneural- and
mesenchymal-like CSC lines
(a,c) TGFβ 1 and 2 expression in GBM (n=19). The amount of TGFβ expressing cells
was scored as described in the Material and Methods section. There was no significant
difference of TGFβ expression between proneural and mesenchymal GBM. (b) Relative
TGFβR2 mRNA expression normalized to 18S RNA is given in CSC lines with and
without SMAD phosphorylation. (d) Clonogenicity of the CSC line R11 after treatment
with TGF-beta in the medium supplemented or not with LIF. The number of clones is
indicated relative to the untreated control. (Figures taken from publication by Beier
et al [9].)
(a) (b)
(c) (d)
Figure 3.15
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Tables A2: Results GO-Analyses
In order to identify pathway activities differing among aggressive NHL, human trans-
formed GC B cells were stimulated with five distinct stimuli: αIgM (BCR activation),
LPS, CD40L, IL21 and BAFF.
Using linear models implemented in the Bioconductor [64] package limma [176] I
searched for genes showing the highest differential expression in response to each stim-
ulus and a significant regulation (adjusted p value ≤ 0.05). The experimental batches
were considered in the linear model.
A gene ontology (GO) analysis of each gene lists affected by the different in vitro in-
terventions was performed using the different GO gene lists of molecular functions,
biological processes and cellular components. Results are shown in the tables on the
following pages.
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O
:0008634
negative regulation of survival gene product expression
0,0002
G
O
:0008443
0,007
G
O
:0050789
regulation of biological process
0,0003
G
O
:0008092
0,009
G
O
:0030097
0,0003
G
O
:0019864
0,01
G
O
:0048523
negative regulation of cellular process
0,0004
G
O
:0002696
positive regulation of leukocyte activation
0,0004
G
O
:0050864
regulation of B cell activation
0,0005
G
O
 ID
G
O
 Term
p-value
G
O
:0010629
negative regulation of gene expression
0,0005
G
O
:0044464
cell part
0,003
G
O
:0050867
positive regulation of cell activation
0,0005
G
O
:0005623
cell
0,003
G
O
:0050871
positive regulation of B cell activation
0,0005
G
O
:0048519
negative regulation of biological process
0,0005
G
O
:0030890
positive regulation of B cell proliferation
0,0005
G
O
:0042100
B cell proliferation
0,0006
G
O
:0048534
0,0007
G
O
:0001775
cell activation
0,0008
G
O
:0045628
regulation of T-helper 2 cell differentiation
0,001
G
O
:0002520
im
m
une system
 developm
ent
0,001
G
O
:0065007
biological regulation
0,002
G
O
:0009607
response to biotic stim
ulus
0,002
G
O
:0009892
negative regulation of m
etabolic process
0,002
G
O
:0002252
im
m
une effector process
0,002
G
O
:0002902
0,002
G
O
:0045064
T-helper 2 cell differentiation
0,002
G
O
:0055091
0,002
M
olecular 
Function
B
iological 
Process
6-phosphofructo-2-kinase activity
glycolipid transporter activity
glycolipid binding
calm
odulin binding
lam
in binding
translation repressor activity
phospholipid binding
fructose-2,6-bisphosphate 2-phosphatase activity
phosphofructokinase activity
cytoskeletal protein binding
hem
opoiesis
IgG
 binding
C
ellular 
C
om
ponent
hem
opoietic or lym
phoid organ developm
ent
regulation of B cell apoptosis
phospholipid hom
eostasis
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C
D
40_D
ow
n
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
:0032395
M
H
C
 class II receptor activity
0,0000
G
O
:0019882
antigen processing and presentation
0,0000
G
O
:0042611
M
H
C
 protein com
plex
0,0000
G
O
:0032393
M
H
C
 class I receptor activity
0,0000
G
O
:0002504
0,0000
G
O
:0042613
M
H
C
 class II protein com
plex
0,0000
G
O
:0005515
protein binding
0,0000
G
O
:0048002
antigen processing and presentation of peptide antigen
0,0000
G
O
:0005737
cytoplasm
0,0000
G
O
:0004718
Janus kinase activity
0,0001
G
O
:0006955
im
m
une response
0,0000
G
O
:0042612
M
H
C
 class I protein com
plex
0,0000
G
O
:0046978
TAP1 binding
0,0008
G
O
:0002474
antigen processing and presentation of peptide antigen via M
H
C
 class I
0,0000
G
O
:0042824
0,0000
G
O
:0015197
peptide transporter activity
0,0020
G
O
:0002376
im
m
une system
 process
0,0000
G
O
:0042825
TAP com
plex
0,0002
G
O
:0015433
0,0020
G
O
:0002250
adaptive im
m
une response
0,0001
G
O
:0044464
cell part
0,0005
G
O
:0015440
0,0020
G
O
:0002460
0,0003
G
O
:0005623
cell
0,0005
G
O
:0046977
TAP binding
0,0020
G
O
:0002483
antigen processing and presentation of endogenous peptide antigen
0,0004
G
O
:0005788
0,0006
G
O
:0046979
TAP2 binding
0,0020
G
O
:0019885
0,0004
G
O
:0044424
intracellular part
0,0007
G
O
:0004716
0,0040
G
O
:0006694
0,0007
G
O
:0005622
intracellular
0,0010
G
O
:0030695
0,0040
G
O
:0016126
0,0007
G
O
:0005886
plasm
a m
em
brane
0,0020
G
O
:0042288
M
H
C
 class I protein binding
0,0050
G
O
:0019883
antigen processing and presentation of endogenous antigen
0,0010
G
O
:0042405
nuclear inclusion body
0,0020
G
O
:0005085
0,0070
G
O
:0009966
regulation of signal transduction
0,0010
G
O
:0005901
0,0020
G
O
:0005131
grow
th horm
one receptor binding
0,0070
G
O
:0006695
0,0010
G
O
:0043229
intracellular organelle
0,0040
G
O
:0015923
0,0080
G
O
:0016125
0,0020
G
O
:0043226
organelle
0,0040
G
O
:0007242
intracellular signaling cascade
0,0020
G
O
:0001725
stress fiber
0,0060
G
O
:0051056
0,0020
G
O
:0032432
0,0060
G
O
:0051249
regulation of lym
phocyte activation
0,0020
G
O
:0000323
0,0070
G
O
:0051168
nuclear export
0,0020
G
O
:0005764
0,0070
G
O
:0007264
0,0030
G
O
:0044459
plasm
a m
em
brane part
0,0070
G
O
:0010627
regulation of protein kinase cascade
0,0030
G
O
:0005783
0,0070
G
O
:0008203
cholesterol m
etabolic process
0,0030
G
O
:0005773
vacuole
0,0070
G
O
:0002286
T cell activation during im
m
une response
0,0040
G
O
:0012505
0,0080
G
O
:0046649
lym
phocyte activation
0,0040
G
O
:0043231
0,0080
G
O
:0006916
0,0050
G
O
:0043227
m
em
brane-bounded organelle
0,0090
G
O
:0007042
0,0050
G
O
:0031967
organelle envelope
0,0090
G
O
:0031119
0,0050
G
O
:0005643
nuclear pore
0,0090
G
O
:0042110
T cell activation
0,0050
G
O
:0031975
envelope
0,0090
G
O
:0002694
regulation of leukocyte activation
0,0050
G
O
:0006400
0,0050
G
O
:0016311
0,0060
G
O
:0006664
0,0060
G
O
:0002443
leukocyte m
ediated im
m
unity
0,0070
G
O
:0010646
regulation of cell com
m
unication
0,0070
G
O
:0050865
regulation of cell activation
0,0070
M
olecular 
Function
B
iological 
Process
C
ellular 
C
om
ponent
antigen processing and presentation of peptide or polysaccharide antigen via 
M
H
C
 class II
M
H
C
 class I peptide loading 
com
plex
peptide antigen-transporting 
ATPase activity
peptide-transporting ATP
ase 
activity
adaptive im
m
une response based on som
atic recom
bination of im
m
une 
receptors built from
 im
m
unoglobulin superfam
ily dom
ains
endoplasm
ic reticulum
 lum
en
antigen processing and presentation of endogenous peptide antigen via M
H
C
 
class I
receptor signaling protein tyrosine 
kinase activity
steroid biosynthetic process
G
TPase regulator activity
sterol biosynthetic process
guanyl-nucleotide exchange factor 
activity
caveola
cholesterol biosynthetic process
m
annosidase activity
sterol m
etabolic process
regulation of sm
all G
TPase m
ediated signal transduction
actin filam
ent bundle
lytic vacuole
lysosom
e
sm
all G
TPase m
ediated signal transduction
endoplasm
ic reticulum
endom
em
brane system
intracellular m
em
brane-
bounded organelle
anti-apoptosis
lysosom
al lum
en acidification
tR
N
A pseudouridine synthesis
tR
N
A m
odification
dephosphorylation
glycolipid m
etabolic process
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IL21_U
p
IL21_D
ow
n
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
:0003714
0,0000
G
O
:0009968
negative regulation of signal transduction
0,0000
G
O
:0030528
transcription regulator activity
0,0000
G
O
:0002376
im
m
une system
 process
0,0000
G
O
:0016564
0,0000
G
O
:0010648
negative regulation of cell com
m
unication
0,0000
G
O
:0003700
transcription factor activity
0,0000
G
O
:0006955
im
m
une response
0,0000
G
O
:0003684
dam
aged D
N
A binding
0,0007
G
O
:0000122
0,0001
G
O
:0003950
0,0001
G
O
:0009615
response to virus
0,0000
G
O
:0003696
satellite D
N
A binding
0,0020
G
O
:0048523
negative regulation of cellular process
0,0001
G
O
:0003676
nucleic acid binding
0,0001
G
O
:0006915
0,0000
G
O
:0043028
0,0040
G
O
:0048519
negative regulation of biological process
0,0002
G
O
:0016763
0,0002
G
O
:0051704
m
ulti-organism
 process
0,0000
G
O
:0003712
0,0050
G
O
:0006974
response to D
N
A dam
age stim
ulus
0,0002
G
O
:0005487
0,0003
G
O
:0012501
program
m
ed cell death
0,0000
G
O
:0032451
0,0050
G
O
:0010646
regulation of cell com
m
unication
0,0005
G
O
:0008134
transcription factor binding
0,0004
G
O
:0008219
cell death
0,0000
G
O
:0001530
0,0090
G
O
:0009966
regulation of signal transduction
0,0005
G
O
:0016564
0,0004
G
O
:0001775
cell activation
0,0000
G
O
:0005095
0,0090
G
O
:0010629
negative regulation of gene expression
0,0006
G
O
:0003677
D
N
A binding
0,0004
G
O
:0016265
death
0,0000
G
O
:0005515
protein binding
0,0090
G
O
:0006281
D
N
A repair
0,0006
G
O
:0017017
0,0007
G
O
:0046649
lym
phocyte activation
0,0000
G
O
:0030165
PD
Z dom
ain binding
0,0100
G
O
:0034984
cellular response to D
N
A dam
age stim
ulus
0,0006
G
O
:0033549
M
AP kinase phosphatase activity
0,0007
G
O
:0045321
leukocyte activation
0,0000
G
O
:0016481
negative regulation of transcription
0,0009
G
O
:0019955
cytokine binding
0,0007
G
O
:0007249
0,0000
G
O
:0045934
0,0010
G
O
:0005062
0,0020
G
O
:0009607
response to biotic stim
ulus
0,0000
G
O
 ID
G
O
 Term
p-value
G
O
:0033554
cellular response to stress
0,0010
G
O
:0032393
M
H
C
 class I receptor activity
0,0020
G
O
:0050794
regulation of cellular process
0,0000
G
O
:0044464
cell part
0,0020
G
O
:0044249
0,0010
G
O
:0046914
transition m
etal ion binding
0,0030
G
O
:0050789
regulation of biological process
0,0000
G
O
:0005623
cell
0,0020
G
O
:0045892
negative regulation of transcription
0,0020
G
O
:0005515
protein binding
0,0030
G
O
:0007243
protein kinase cascade
0,0000
G
O
:0005634
nucleus
0,0080
G
O
:0044260
cellular m
acrom
olecule m
etabolic process
0,0020
G
O
:0008270
zinc ion binding
0,0040
G
O
:0051707
response to other organism
0,0000
G
O
:0010558
0,0020
G
O
:0005488
binding
0,0040
G
O
:0001773
0,0000
G
O
:0006950
response to stress
0,0020
G
O
:0003712
transcription cofactor activity
0,0050
G
O
:0010556
0,0000
G
O
:0034960
0,0020
G
O
:0016757
0,0060
G
O
:0048519
negative regulation of biological process
0,0000
G
O
:0051253
0,0020
G
O
:0016563
transcription activator activity
0,0100
G
O
:0042110
T cell activation
0,0000
G
O
:0043170
m
acrom
olecule m
etabolic process
0,0020
G
O
:0060255
0,0000
G
O
:0051716
cellular response to stim
ulus
0,0020
G
O
 ID
G
O
 Term
p-value
G
O
:0048534
0,0000
G
O
:0031327
0,0020
G
O
:0005622
intracellular
0,0000
G
O
:0010468
regulation of gene expression
0,0000
G
O
:0043283
0,0020
G
O
:0044424
intracellular part
0,0000
G
O
:0002263
cell activation during im
m
une response
0,0000
G
O
:0009890
0,0020
G
O
:0005634
nucleus
0,0000
G
O
:0002366
0,0000
G
O
:0009058
0,0020
G
O
:0043231
intracellular m
em
brane-bounded organelle
0,0000
G
O
:0008632
0,0000
G
O
:0050794
regulation of cellular process
0,0020
G
O
:0043227
m
em
brane-bounded organelle
0,0000
G
O
:0002520
im
m
une system
 developm
ent
0,0000
G
O
:0044237
cellular m
etabolic process
0,0030
G
O
:0033256
0,0000
G
O
:0065007
biological regulation
0,0000
G
O
:0042110
T cell activation
0,0030
G
O
:0043229
intracellular organelle
0,0001
G
O
:0031326
0,0000
G
O
:0008152
m
etabolic process
0,0030
G
O
:0043226
organelle
0,0001
G
O
:0048523
negative regulation of cellular process
0,0000
G
O
:0006366
0,0030
G
O
:0033257
Bcl3/N
F-kappaB2 com
plex
0,0003
G
O
:0045449
regulation of transcription
0,0000
G
O
:0006357
0,0030
G
O
:0009897
external side of plasm
a m
em
brane
0,0003
G
O
:0009889
0,0000
G
O
:0006350
transcription
0,0040
G
O
:0031965
nuclear m
em
brane
0,0030
G
O
:0046632
alpha-beta T cell differentiation
0,0000
G
O
:0044238
prim
ary m
etabolic process
0,0040
G
O
:0042612
M
H
C
 class I protein com
plex
0,0050
G
O
:0019219
0,0000
G
O
:0010605
0,0040
G
O
:0044464
cell part
0,0060
G
O
:0042981
0,0000
G
O
:0005737
cytoplasm
0,0060
G
O
:0005623
cell
0,0060
M
olecular 
Function
B
iological 
Process
M
olecular 
Function
B
iological 
Process
transcription 
corepressor activity
transcription repressor 
activity
negative regulation of transcription from
 R
N
A 
polym
erase II prom
oter
N
AD
+ AD
P
-ribosyltransferase activity
apoptosis
caspase regulator 
activity
transferase activity, transferring pentosyl 
groups
transcription cofactor 
activity
nucleocytoplasm
ic transporter activity
dem
ethylase activity
lipopolysaccharide 
binding
transcription repressor activity
G
TPase inhibitor 
activity
M
AP kinase tyrosine/serine/threonine 
phosphatase activity
I-kappaB kinase/N
F-kappaB cascade
C
ellular 
C
om
ponent
negative regulation of nucleobase, 
nucleoside, nucleotide 
hem
atopoietin/interferon-class cytokine 
receptor signal transducer activity
cellular biosynthetic process
negative regulation of m
acrom
olecule 
biosynthetic process
m
yeloid dendritic cell activation
regulation of m
acrom
olecule biosynthetic 
process
cellular biopolym
er m
etabolic process
transferase activity, transferring glycosyl 
groups
negative regulation of R
N
A
 m
etabolic 
process
C
ellular 
C
om
ponent
regulation of m
acrom
olecule m
etabolic 
process
hem
opoietic or lym
phoid organ 
developm
ent
negative regulation of cellular biosynthetic 
process
biopolym
er m
etabolic process
negative regulation of biosynthetic process
leukocyte activation during im
m
une 
response
biosynthetic process
apoptotic program
I-kappaB/N
F-kappaB com
plex
regulation of cellular biosynthetic process
transcription from
 R
N
A polym
erase II 
prom
oter
regulation of transcription from
 R
N
A 
polym
erase II prom
oter
regulation of biosynthetic process
regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid m
etabolic 
process
negative regulation of m
acrom
olecule 
m
etabolic process
regulation of apoptosis
Appendix
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IL21_D
ow
n
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
:0030528
transcription regulator activity
0,0000
G
O
:0002376
im
m
une system
 process
0,0000
G
O
:0003700
transcription factor activity
0,0000
G
O
:0006955
im
m
une response
0,0000
G
O
:0003950
0,0001
G
O
:0009615
response to virus
0,0000
G
O
:0003676
nucleic acid binding
0,0001
G
O
:0006915
0,0000
G
O
:0016763
0,0002
G
O
:0051704
m
ulti-organism
 process
0,0000
G
O
:0005487
0,0003
G
O
:0012501
program
m
ed cell death
0,0000
G
O
:0008134
transcription factor binding
0,0004
G
O
:0008219
cell death
0,0000
G
O
:0016564
0,0004
G
O
:0001775
cell activation
0,0000
G
O
:0003677
D
N
A binding
0,0004
G
O
:0016265
death
0,0000
G
O
:0017017
0,0007
G
O
:0046649
lym
phocyte activation
0,0000
G
O
:0033549
M
AP kinase phosphatase activity
0,0007
G
O
:0045321
leukocyte activation
0,0000
G
O
:0019955
cytokine binding
0,0007
G
O
:0007249
0,0000
G
O
:0005062
0,0020
G
O
:0009607
response to biotic stim
ulus
0,0000
G
O
:0032393
M
H
C
 class I receptor activity
0,0020
G
O
:0050794
regulation of cellular process
0,0000
G
O
:0046914
transition m
etal ion binding
0,0030
G
O
:0050789
regulation of biological process
0,0000
G
O
:0005515
protein binding
0,0030
G
O
:0007243
protein kinase cascade
0,0000
G
O
:0008270
zinc ion binding
0,0040
G
O
:0051707
response to other organism
0,0000
G
O
:0005488
binding
0,0040
G
O
:0001773
0,0000
G
O
:0003712
transcription cofactor activity
0,0050
G
O
:0010556
0,0000
G
O
:0016757
0,0060
G
O
:0048519
negative regulation of biological process
0,0000
G
O
:0016563
transcription activator activity
0,0100
G
O
:0042110
T cell activation
0,0000
G
O
:0060255
regulation of m
acrom
olecule m
etabolic process
0,0000
G
O
:0048534
0,0000
G
O
 ID
G
O
 Term
p-value
G
O
:0010468
regulation of gene expression
0,0000
G
O
:0005622
intracellular
0,0000
G
O
:0002263
cell activation during im
m
une response
0,0000
G
O
:0044424
intracellular part
0,0000
G
O
:0002366
leukocyte activation during im
m
une response
0,0000
G
O
:0005634
nucleus
0,0000
G
O
:0008632
0,0000
G
O
:0043231
intracellular m
em
brane-bounded organelle
0,0000
G
O
:0002520
im
m
une system
 developm
ent
0,0000
G
O
:0043227
m
em
brane-bounded organelle
0,0000
G
O
:0065007
biological regulation
0,0000
G
O
:0033256
0,0000
G
O
:0031326
0,0000
G
O
:0043229
intracellular organelle
0,0001
G
O
:0048523
negative regulation of cellular process
0,0000
G
O
:0043226
organelle
0,0001
G
O
:0045449
regulation of transcription
0,0000
G
O
:0033257
Bcl3/N
F-kappaB2 com
plex
0,0003
G
O
:0009889
0,0000
G
O
:0009897
external side of plasm
a m
em
brane
0,0003
G
O
:0046632
alpha-beta T cell differentiation
0,0000
G
O
:0031965
nuclear m
em
brane
0,0030
G
O
:0019219
0,0000
G
O
:0042612
M
H
C
 class I protein com
plex
0,0050
G
O
:0042981
0,0000
G
O
:0044464
cell part
0,0060
G
O
:0005737
cytoplasm
0,0060
G
O
:0005623
cell
0,0060
M
olecular 
Function
B
iological 
Process
N
AD
+ AD
P-ribosyltransferase activity
apoptosis
transferase activity, transferring pentosyl groups
nucleocytoplasm
ic transporter activity
transcription repressor activity
M
AP kinase tyrosine/serine/threonine phosphatase activity
I-kappaB kinase/N
F-kappaB cascade
hem
atopoietin/interferon-class (D
200-dom
ain) cytokine receptor signal 
transducer activity
m
yeloid dendritic cell activation
regulation of m
acrom
olecule biosynthetic process
transferase activity, transferring glycosyl groups
C
ellular 
C
om
ponent
hem
opoietic or lym
phoid organ developm
ent
apoptotic program
I-kappaB/N
F-kappaB com
plex
regulation of cellular biosynthetic process
regulation of biosynthetic process
regulation of nucleobase, nucleoside, nucleotide and nucleic acid m
etabolic process
regulation of apoptosis
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LPS_U
p
LPS_D
ow
n
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
 ID
G
O
 Term
p-value
G
O
:0003873
0,0003
G
O
:0010629
negative regulation of gene expression
0,0001
G
O
:0032393
M
H
C
 class I receptor activity
0,0000
G
O
:0019882
antigen processing and presentation
0,0000
G
O
:0005521
0,0004
G
O
:0048523
negative regulation of cellular process
0,0006
G
O
:0032395
M
H
C
 class II receptor activity
0,0000
G
O
:0048002
0,0000
G
O
:0016564
0,0009
G
O
:0010605
0,0006
G
O
:0004888
0,0001
G
O
:0002474
0,0000
G
O
:0004331
0,0009
G
O
:0008634
0,0009
G
O
:0004872
receptor activity
0,0010
G
O
:0006955
im
m
une response
0,0000
G
O
:0008443
0,0009
G
O
:0009892
negative regulation of m
etabolic process
0,001
G
O
:0004871
signal transducer activity
0,0010
G
O
:0002376
im
m
une system
 process
0,0000
G
O
:0003714
0,0010
G
O
:0050896
response to stim
ulus
0,001
G
O
:0060089
m
olecular transducer activity
0,0010
G
O
:0002504
0,0000
G
O
:0016303
0,0020
G
O
:0048519
negative regulation of biological process
0,001
G
O
:0016866
0,0060
G
O
:0050896
response to stim
ulus
0,0008
G
O
:0019203
0,0020
G
O
:0001938
0,002
G
O
:0042517
0,0010
G
O
:0035004
0,0020
G
O
:0009607
response to biotic stim
ulus
0,004
G
O
:0002286
T cell activation during im
m
une response
0,0010
G
O
:0019200
carbohydrate kinase activity
0,0070
G
O
:0007165
signal transduction
0,004
G
O
 ID
G
O
 Term
p-value
G
O
:0006400
0,0020
G
O
:0002285
0,005
G
O
:0042611
M
H
C
 protein com
plex
0,0000
G
O
:0002285
0,0020
G
O
:0010558
0,005
G
O
:0042612
M
H
C
 class I protein com
plex
0,0000
G
O
:0042516
0,0020
G
O
 ID
G
O
 Term
p-value
G
O
:0043534
blood vessel endothelial cell m
igration
0,005
G
O
:0042613
M
H
C
 class II protein com
plex
0,0000
G
O
:0042503
0,0020
G
O
:0044464
cell part
0,0060
G
O
:0009615
response to virus
0,005
G
O
:0005886
plasm
a m
em
brane
0,0002
G
O
:0002263
cell activation during im
m
une response
0,0030
G
O
:0005623
cell
0,0060
G
O
:0002263
cell activation during im
m
une response
0,006
G
O
:0016020
m
em
brane
0,0030
G
O
:0002366
0,0030
G
O
:0002366
0,006
G
O
:0044459
plasm
a m
em
brane part
0,0030
G
O
:0042531
0,0030
G
O
:0045884
0,006
G
O
:0042110
T cell activation
0,0030
G
O
:0031327
0,006
G
O
:0010740
0,0040
G
O
:0009890
0,006
G
O
:0046427
positive regulation of JAK-STAT cascade
0,0040
G
O
:0002376
im
m
une system
 process
0,006
G
O
:0050776
regulation of im
m
une response
0,0050
G
O
:0016481
negative regulation of transcription
0,008
G
O
:0042509
0,0050
G
O
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phosphatase activity
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1-phosphatidylinositol-3-kinase 
activity
intram
olecular transferase activity
carbohydrate phosphatase 
activity
positive regulation of endothelial cell 
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positive regulation of tyrosine 
phosphorylation of Stat3 protein
phosphoinositide 3-kinase 
activity
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ponent
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odification
lym
phocyte activation during im
m
une 
response
lym
phocyte activation during im
m
une 
response
C
ellular 
C
om
ponent
negative regulation of m
acrom
olecule 
biosynthetic process
regulation of tyrosine phosphorylation of 
Stat3 protein
tyrosine phosphorylation of Stat3 protein
leukocyte activation during im
m
une 
response
leukocyte activation during im
m
une 
response
positive regulation of tyrosine 
phosphorylation of STAT protein
regulation of survival gene product 
expression
negative regulation of cellular 
biosynthetic process
positive regulation of protein kinase 
cascade
negative regulation of biosynthetic 
process
regulation of tyrosine phosphorylation of 
STAT protein
steroid biosynthetic process
tyrosine phosphorylation of STAT protein
cholesterol biosynthetic process
sterol m
etabolic process
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Unique gene clusters
x
Tables A3: Unique gene clusters
The method guided clustering [131] was used to identify genes that are specific for
one of the five stimuli and additionally stratify the DLBCLs in the dataset of Hummel
and colleagues [81]. As guiding data I used the stimulated BL2 cell line data, which
was correlated to a binary vector that changed per guided clustering run. Within that
binary vector the samples belonging to one of the stimuli were labeled with 1, and the
other stimulations as well as the controls were labeled with 0, making sure that genes
were only regulated by one of the five stimulations. To find gene sets that showed
differences within the DLBCL samples and not only between the DLBCL samples and
the mBL samples, the patient data was reduced to the Myc negative DLBCL cases.
Thus, excluding all mBLs and in addition all the samples that showed a Myc break of
some kind. For each stimulation I extracted up to three clusters depending on their
direction and the amount of genes included, making sure to get at least two clusters
which are regulated in different directions. The genes included in the different clusters
can be found on the following pages.
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BCR.1 BCR.2 IL21.1 IL21.2
XPO1 PEX14 RAD1 MAPKSP1 RBMX RAB7A SEC24B RIOK2 STAT1
PMS1 TOMM70A GCDH ATF1 DUSP11 THAP1 RSRC2 QTRTD1 IRF1
RNASEN TSN CPOX CCDC59 ATP6V1H RNMT DYNC1LI1 DDX50 IFIT3
LBR SFRS4 CLPX RSL24D1 MAP1LC3B SAT1 USP8 NMD3 CXCL10
CETN3 HSPH1 MORC2 BZW1 IDI1 CMTM6 RABGGTB SUCLA2 APOL6
DCK FOSL1 RFC5 BNIP2 NTAN1 WDR26 FAM178A DENR OASL
GPN3 KIAA0406 RAD51C ETF1 DCTN5 PYROXD1 NOC3L TCERG1 IFI44L
SLBP DSN1 RCN2 TAF9 CENPN PIKFYVE MTERFD1 DNAJA1 IFIT1
RHOT1 PRPF4B PIGF POMP HNRNPC NIPA2 ANKRD27 SEPHS2 RSAD2
CAND1 C13orf34 ACTR6 GNAI3 MARS RHOA ZDHHC6 DNAJC7 MX1
RACGAP1 BAG2 CDC73 ARF6 YARS DAZAP2 METAP1 CDC42EP3 IFI44
KIF20A ZNHIT3 MDM1 YWHAZ EDEM1 TBC1D15 C2orf49 REV1 IFITM1
AURKA PDHB KIAA0528 GABPB1 DDX18 C12orf35 TRA2B TIMM9 IFITM3
HMMR CCDC56 PARG CEBPG BUD31 WIPF1 SFRS1 XPOT NA
NDC80 CUTC THAP11 MAPK6 RCHY1 C10orf26 KRR1 HIRA
CDC20 C14orf104 C12orf52 RBM22 PRKD3 SKP1 RBM25 TXNL1
CENPA COX11 PTCD3 C6orf62 SWAP70 KIAA0232 NUP50 ABHD3
PLK1 CDK8 CASP6 ERBB2IP LY75 CHIC2 ZNHIT6 HSPA8
NEK2 C8orf41 CTR9 UBE2B CHD1 ARL8B GNL2 C3orf64
CCNA2 AURKAIP1 MRPL46 CSNK1A1 EIF1 PPP2R2A CCT6A PNN
KIF18A IMP3 GPSM2 NFE2L2 IMPA1 RNF111 POLR3E CSTF3
RMI1 MINA NDUFC1 PLEKHB2 CHMP2B AURKB RPL23AP7 EXOSC4
PBK PUM2 UBE2G1 MTMR6 OSBP TOP2B APIP NUDC
PRC1 DHX29 PRPSAP1 TRIP12 RAB5A BCL2L13 PSMC6 DICER1
BUB1B COASY NCAPD3 TM9SF3 LZTS1 ATP6V1E1 ZC3H15 KIAA1012
PLK4 THAP7 DPF2 DDX5 NCRNA00081 RAB1A SART3 C11orf58
CDCA8 MRPS34 HEATR3 YIPF4 RAB21 CD164 CHORDC1 KIF23
NCAPH CCDC51 SHCBP1 CEP57 UGCG PLEKHF2 C14orf104 FBXL4
TMEM48 MRPL17 C4orf41 MIS12 GABARAPL2 HECA WDR3 HAUS3
OIP5 COIL SKP2 ZNF330 FBXO28 ITSN2 FUBP3 YEATS2
CEP55 ATMIN MTX2 LARP7 HSD17B12 PPP2R3C TAF2 KIAA0753
KIF14 SMARCAL1 MUDENG NUP88 YTHDF3 RNF11 ZMYM4 HNRNPD
ESPL1 COQ9 C15orf44 WAPAL ECD ARF4 ZBTB11 FASTKD3
POLA2 COBRA1 GINS1 VPS26A ABCF1 SLC3A2 PRPF38B ATF2
FEN1 MED20 ZWILCH UBE2D3 C15orf24 SGPL1 BTAF1 PUS1
BRCA1 CCDC99 MRPL18 RBM15 TSPYL1 MORF4L1 TNFAIP8 JRKL
TUBG1 SIP1 C5orf22 PITPNB ZEB2 PIP4K2A KIAA0406 HSPA4
MRPL16 FANCG TTC33 TARS CD63 CHSY1 TM9SF3 RPAP3
TACC3 MCM2 PSME4 MAK16 BACH1 FAF2 PPWD1 TBK1
SAC3D1 CRIPT PPM1B MTHFD2 PRNP GOLT1B UBXN2B EIF4E
ASPM GAPVD1 PIAS4 SNX5 HEXB CYP20A1 LUC7L3 UTP11L
WDHD1 CNP WBP4 PDXDC1 PTTG1IP GOT1 GTF2H1 SUV39H2
BIRC5 RAB11A ACAP2 DHX15 CEBPB ADO PCNP TMEM165
CCNB1 MRPS31 GRSF1 DENR CTSB PSEN1 ANAPC10 HNRNPU
ASF1B MRPL34 GADD45GIP1 ZNF410 M6PR VAMP3 RECQL YME1L1
ORC1L PHB MSH2 DERL2 LAMP1 AGA KLHL2 ETFA
KIF2C POP4 DTYMK HNRNPK IFI30 CNIH4 TIMM17A NUP54
CDCA3 AGGF1 FRAT2 C5orf28 RIN2 HNMT CEP170 LIN37
FOXM1 KIF22 STAMBP DIMT1L TFEC ARL4C RRS1
RFC3 POP7 C17orf75 CDK7 GPX4 C3AR1 LARP4
ECT2 DDX23 FANCL RAP2C TLR1 SIRPA DNAJB14
DSCC1 ZBED5 SFRS2B SSFA2 TNFRSF14 EMP3 SERBP1
C12orf48 BBS10 HMBS JMJD1C GPR137B MKLN1 RBM28
WRAP53 ZNF638 PAAF1 EIF1B LY96 ITM2B SSB
PARP2 SRBD1 NAA40 ZC3H15 IFNGR1 CCPG1 MPHOSPH10
TRIP13 GTF2E1 NDUFS3 SAR1A SRGN CDC42 C1orf109
KIF11 MEN1 DUT BCAS2 CRIM1 KIAA0430 NOL7
AASDHPPT LSM2 STRA13 ETFDH CLEC2B TNPO1 TCEB1
FARSA SRPK1 HADH MMADHC CD97 TXNDC9 MAGOH
CTCF TTRAP SEPHS1 MRPS30 GPR65 EIF2S2 RCHY1
RNASEH2A ZNF184 ABHD10 MRPL39 CYFIP1 WARS C9orf82
NEIL3 MICB SLC4A1AP GMFB IFNGR2 CCL4 FBXW2
STIL TUBD1 STRADA TSG101 ATP6V0E1 NINJ1 ENOPH1
TARDBP NFYB CBX1 CSNK1D OSTM1 LGALS8 RARS
ARMC1 KIF18B MRPS27 GDI2 ACSL1 RRAGD TAF1A
MRPL35 PRDM10 WRB LASP1 WSB2 ACP5 VEZF1
WDR67 HMGN4 DERA CSGALNACT2 SGK1 C6orf145 CEBPZ
NUP37 RAD54B SAR1B ZBTB1 CSTB IL32 AGPAT5
MRPL12 DTWD1 MAP3K4 SLC2A3P1 UPP1 MARCH7 EIF3J
RAD54L BRD8 KIAA1279 ZNF217 LRP10 KLF10 ZCCHC8
C16orf53 TRMT61B PPCS CAPZA1 SERINC1 SMURF2 CNIH
ALG6 RNF34 C5orf15 HMGCR RAB22A SFT2D2 UNC50
TROAP CDC27 RIOK2 ATP2C1 AP2B1 FAM18B SGMS1
CDC7 EXOC1 CKAP2 HSPA5 C1orf54 UBL3 MLX
RFC4 SACM1L NARS2 PPP6C DENND4A MAFF AHCTF1
UNG VPS33B CEP76 TOR1A USP12 TMEM30A CEP57
PPAT SUCLA2 CACYBP JOSD1 STK17B TMBIM6 PIBF1
FASTKD1 MRS2 TMEM97 PTBP1 GHITM MON1B PSMD12
KIF15 C6orf211 POLE2 YBX1 EIF2S1 DOCK2 SDHAF1
ANP32A HMGB3 USP13 EPRS TOR1B NR3C1 C12orf44
SRRD GEMIN6 RTF1 SDCBP HSPA13 GCH1 MFSD1
LRRC47 MRPS16 MRPL49 RNF4 CD86 SAP30BP NPTN
PREB MCM10 CSE1L CAB39 FRG1 MATR3 SOAT1
ZC3H14 AP1AR PLA2G12A YAF2 PSMD12 GCC2 SLC35A1
TTK C4orf27 ELP4 TMEM123 TMEM66 PLXNC1 MTO1
EFTUD1 FASTKD3 UBTF TMEM222 ATF4 HEXA GSPT1
OSBPL11 CLCN3 GTF3C1 TFAM POLR2D UTP6
MYCBP PRMT5 BCOR CDK17 SHMT2 ANKRD40
DYNLL1 TDP1 USP16 SFPQ BANP
NIF3L1 LARS2 GARS USP15 TMEM33
MRFAP1L1 BARD1 CNIH OSBPL8 TMED5
NARG2 MSH3 RAN LPXN SLC30A5
SPAST MPHOSPH6 C11orf57 MAP2K3 SNW1
ZW10 MTIF2 LYRM1 ZHX2 C14orf135
ELF2 ATR SARS RHOG POP1
ADH5 PPP2R5E CLIC1 CYTSA ZDHHC13
ORC4L PSMC6 MAPRE1 H3F3B KIAA1704
ORC2L ZNF107 SLC25A32 PDXK RSC1A1
CLINT1 EIF2B4 ADIPOR2 RAB8B ATP11B
DLAT C9orf40 E2F6 NFYA CUL4A
Appendix
124
BAFF.1 BAFF.2 LPS.1 LPS.2 CD40.1 CD40.2 CD40.3
KPNB1 PDCD5 BPTF EPHB4 C1orf183 LAMA1 GRIN2B SFRS2 TFCP2 MGAT2 CCDC134 PICK1
SLTM ACOT7 NKTR AGRN SOX14 VNN3 POU2AF1 MRPL46 PSME3 ATMIN AMN SOX15
REV1 MCM10 SART3 VCX2 SLC14A2 ELAVL3 NRD1 MUS81 MAP2K4 UMPS DOK4 HP
EIF3A DDX52 MED24 TBKBP1 BBOX1 TSHZ2 FAF1 TOE1 EFR3A MRPL17 HABP4 TRIM17
LSM14A NCAPD3 FAM98A DNAJC28 CNTNAP2 MEGF8 TRBV10-2 FARSA EPS15 ELAC2 CST2 CYP2A13
CKAP5 LIG1 CCDC99 GPR110 FBXL12 FOXO4 PDGFB EIF4A3 TCTN3 ZNF706 TUT1 SLC9A3R2
CENPE RAD51AP1 MRPS15 ALDOAP2 NFASC GRK1 SLC34A1 MCM3 EIF4ENIF1 PRKRA SYNPO SDK2
ORC6L MRFAP1L1 ANKRD17 SLC18A3 PMS2L4 ADAMTSL2 NR2E3 NOC3L ANKRD40 CDC5L CRYBB2 APOC4
KIF18B TPR UBE2K MLXIPL CCR3 TMEM179B CRTAC1 ANKRD27 HPS6 TUBG1 OTOR DCLK2
ATAD2 PRPF3 CSTF3 DLG4 TAS2R9 DOHH GABRD DNAJA2 SART3 SAMM50 ANP32C CELA2B
TOP2A WHSC2 LSM6 OSGIN1 RGS12 PSD PDIA2 GPN2 ANAPC10 FBXL15 OR1F2P CNPY4
ASPM HAT1 POLR2E ENPP3 CPLX2 SNAPC2 ZNF205 C16orf80 MRS2 ERCC3 SOX14 LTB4R2
WHSC1 DNAJC13 EED ALPI C14orf79 NIN POU4F3 VRK1 KPNA3 SAE1 KCNG1 GPATCH2
SMC2 ATXN2 MTERFD1 SOX15 C19orf42 FOXE1 ADORA1 NDUFV2 APIP CDC25A HUNK KCNQ1
MSH2 MTDH TAF5 CADM4 GRIN2A ZNF646 KCNJ5 COX4NB BCL10 UCHL3 KCNQ1DN SULT4A1
CACYBP TCERG1 SS18L1 STBD1 C6orf54 C1orf183 IGF2AS SHQ1 CTSH ACD MAP1A IGF2AS
WBP4 RAD50 LRDD SCNN1A UTP14C GJA8 ABO MCAT TBK1 PSMB2 TACR2 IGFBP5
ZC3H13 YY1AP1 NCAPG2 PFKFB4 DUSP26 SIX5 TRGV5 PRPF4 RRP1B NAT10 NGB STMN3
SFRS1 DLX2 SPC25 MATN4 SLC9A3R2 PTPRS STMN3 LCMT1 NUFIP1 C21orf59 APOBEC3F PYY2
NASP DUOX2 NCOA6 PCYT1B AGER TEX11 PKLR RFC2 GRPEL1 RNF115 GRTP1 SLC9A3
ACYP1 NDUFS1 PSPC1 LRAT GNG7 FOXC2 WFDC8 RAD51C CHMP6 ELOVL1 SPINT3 ADRA2C
SDCCAG1 CEBPZ LIN37 OPRD1 MUC6 SLC2A4 NRXN2 FEN1 YIF1A NECAP2 KCNF1 NRXN2
LUC7L3 NDUFB8 HAUS6 NBR2 C2orf72 SPTB TRIP13 NSMCE4A NBN BRD7P3 AKAP4
KIF20B EXOSC7 EXOSC10 NPTXR NFKBIL2 OPRL1 TRA2B UBE3B GCNT4 NYX FAM179B
SUCLA2 HSPE1 IMMT KRT16 EPO CEMP1 SFRS1 PPCS SEMA3B TM6SF2 PLCH2
SPAG5 C14orf104 NAA16 TNXB GPR32 SLC9A3R2 HNRNPR ZBTB11 CLCN1 SLC12A4 ANKRD2
MKI67 ATR USP48 TUBB4Q PRDM8 TLX2 PEF1 NPL GFM1 NFKBIL2 UCP3
PLK4 PNN SPEN SH2D4A PLEKHA4 SYT5 C2orf47 NOTCH2 PNLIP MATK ALOX12B
NCAPH PHIP PIAS4 TGFB2 CYP11B2 NFIX DLD LAMP2 RCN2 GHSR HIST1H2AK
PRDX3 ZFC3H1 ABHD3 WIF1 BARX1 MMP16 SFRS3 RDX NPAS1 MYCN
ADK NUP43 CCDC91 MYH15 KRT3 SNCA DDX19A TMEM165 DNAJA1 SCN2B
PAICS NCOR1 PSMD1 HOXD10 CEBPE MAP1LC3C CIAPIN1 PIK3CB SF3B2 ZNF205
EIF2B3 TRIM24 RECQL4 GDF2 CDKN2B APCS CYC1 HLA-J MRPL39 EPB41L1
NUDC PSMC6 MTHFD1 CCL27 ZCCHC4 PSPN PEX14 HLA-F DDA1 SLC34A1
KIN POLR2B PPP2R5E MAPT MTHFR GCDH HLA-B WBP11 NHEJ1
C12orf48 NCL SEC24A CRYBB2 LRIT1 EXOSC4 HLA-G CMAS HDAC11
SSB RECQL SAR1B TPPP3 PUF60 HLA-C CCT6A FKBP6
SMC3 SYNCRIP CEP63 FGF20 REEP4 HCP5 TARDBP PCYT1B
KIF14 MCCC2 UCHL5 PCDHB17 SF4 HLA-A IMP3 SNCG
POLD1 HSPA4 RANGAP1 ADAMTS7 UBTF BTN2A2 RIOK2 OR3A2
SCRIB PSMD14 WDHD1 CABP2 ABCF3 PLEKHO1 MED22 PTCRA
REXO4 C1orf109 DNA2 PRB3 RRP9 CSF2RB FTSJ3 ROM1
MSH3 SLC4A1AP C11orf48 UBTD1 STX4 HLA-DPB1 ZFR NPHS1
MPHOSPH10 MED4 C10orf2 HSPB2 CTCF ZNF672 PWP1 SIRT5
FASTKD3 WDR61 CACNA1S PDGFB SMARCAL1 RFX5 MINA CATSPERB
ARL6IP4 AHCTF1 SAP30L NR2E3 NOC4L NUBP1 RARS TCL6
SAFB2 MAGOH CTNNBL1 CRTAC1 WDR18 TRIP4 HNRNPA0 HGFAC
CHERP BRD7 DHX30 C14orf115 PDCD5 RAB27A PRLR CCNJL
SRRM1 NSMCE4A C14orf166 GPR37L1 MAT2A BID HSPA4 HOXC13
ZNF146 PHF3 DHFR LCN1 AIMP2 ARIH1 SIX3 ADCY10
SUPT16H PPP1R12A ACD NDST1 MTIF2 CD59 ADRA1D ACAP2
KIAA0406 MAVS GPN3 TRPV6 HEATR3 SLC31A2 WDR41 HTR5A
UPF2 ST13 PDHB HOXA3 DDRGK1 FLVCR2 ALCAM TBL2
LUC7L2 SNX1 PIBF1 TP53TG5 THOC1 CTSC PALB2 SLC38A3
BMS1 CBX1 E4F1 TSKS MTHFS LGALS9 SYNGR2 ATP6V1B1
CHAF1A HNRNPH3 KRT19P2 TBL3 RAC2 PSMC4 PAX3
TCOF1 RNASEN RNLS PPP3CA HNRNPF RAP2B RBP3
SAFB PRR11 XPNPEP3 RPS6KA1 PSMC6 TAF1B C8orf30A
TOPBP1 HNRNPD DDX25 TYMS SLURP1 NUDT21 PBOV1
SSRP1 PRPF19 HSD3B2 RASSF2 TIMM17A YARS2 GNG7
SFRS12 DDX49 ACCN2 MRPL12 MINPP1 DCLRE1B NPPA
BAZ1A ESPL1 RGS7 HSPA14 UBAC1 CINP CLCN7
DAZAP1 EDF1 TACR2 BRMS1 C1orf35 IFRD2 PDGFRA
RPAP3 CSF3 PSG3 COPS7B DCC SERBP1 TASP1
HSPH1 NIPBL OR7C1 PIK3CD MTMR4 TTC4 EXOSC1
RSF1 ASCC3 BICC1 ACOX3 RPS6KB1 C16orf88 WNT8B
TOP1 NUP133 SYN2 IMPDH1 UBE3C PSMA7 ADORA1
PPWD1 TECR CAMKV SARS2 TMEM70 MCCC2 DHX29
KTN1 CCNE1 AMBN SPIB KIAA0947 TESC TLX2
CENPF KIAA0101 EPB41L1 SH3BP5 LARS2 LMNB2 DUSP9
IARS2 AK2 AP3D1 DOCK10 C12orf43 THAP11 KCNJ5
BRAP EXOSC9 SPAG9 ARHGAP17 STAM2 FNBP1
ACTR6 CHCHD3 OR11A1 RAB7L1 ISOC1 EIF4H
FABP5 RPIA PKLR EIF2B5 METAP1 CD160
POLR2F KIAA0562 SHB MICALL1 API5 TRAPPC3
ITGB1BP1 STK39 ADCY10 POP4 SRPK1 FASTKD3
GNB1 LRRC40 TGFBRAP1 TTC35 MFN2 CTR9
NUP107 HNRNPH1 TRIM49 UAP1 SEC23IP HCK
TCP1 C14orf156 PCDH1 ICT1 CAPRIN1 C3orf37
CCT6A PPIH ATP2B3 TACO1 SEC24B PHF16
PRPF38B RIOK2 RAX MRPL34 ARFGEF1 TRIM44
CPSF6 RCBTB1 CDHR5 C8orf33 CLPX KCNJ1
AHSA1 PRPF4B WNT8B UCK2 UBE2L3 NOL11
ERCC3 SMS RHO TOMM70A PDHX CPSF4
YY1 ACIN1 KRT15 AGFG1 C14orf104 C7orf23
CHD8 BRCA1 CACNA1E LSM12 BRD7 RSRC2
PPIG EBNA1BP2 LMAN1L G3BP1 METTL1 WDR1
DUT POLR3K GUCA1B ANXA7 C9orf114 WDR3
CHORDC1 GRPEL1 DNAH9 EXOC1 SLC35B1
DDX23 CISD1 NGFR SLC25A46 SNX4
RUVBL1 SNRNP25 GJA3 TRPM3 DCTD
EXO1 MELK MYL10 DDX50 PHB
EIF5B TACC3 NR0B1 EIF4E FAM35A
PABPN1 SNRPF GRAP2 ZC3H14 CNPY3
NDUFS8 PFAS IFT140 HEATR2 ABCB11
TAF2 USP24 LOC645961 GTF3C2 KEAP1
BUB1B CMAS PTPRU TIMM23 DDX42
DNM1L ROCK1 KRT83 POLR3E CCDC51
FIP1L1 WDR18 S100A14 DHX30 BRIX1
SMARCA4 IK NLGN3 DPH2 RRS1
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